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Abstract 
 
Introduction: Many people with long-term physical health conditions (LTCs) are non-adherent to 
prescribed medications and therefore have an increased risk of morbidity and mortality. Several 
psychological models have attempted to understand why people with LTCs do not adhere, but all have 
limited explanatory power and interventions stemming from them show modest effects. Few studies 
have explored the utility of the psychological flexibility model (PF), the transdiagnostic theory 
underlying Acceptance and Commitment Therapy (ACT), in this context. A small number of 
preliminary trials for ACT show promising efficacy but have been conducted in specific LTC groups 
with small samples. Ecological momentary assessment methods (EMA) may build on these studies 
because they could examine temporal relationships and account for within-individual variability across 
different contexts and are less prone to recall biases. However, few momentary PF measures have been 
validated in LTCs samples.   
Method: The primary aim of this online longitudinal study (n=701) was to examine relationships 
between validated measures of PF and self-reported intentional and unintentional non-adherence and 
appointment attendance in people with LTCs at baseline and three months follow-up using binomial 
regressions. The second aim (not reported in the current thesis) was to preliminarily validate new 
momentary measures of PF, adherence and mood for future EMA studies to better understand within-
individual and group-level variability. 
Results: PF variables explained a significant, albeit modest, amount of the variance in intentional 
and unintentional non-adherence and appointment attendance. However, confirmatory factor, internal 
consistency and test-re-test analyses indicated MARS-5 items failed to meet established criteria for 
construct validity and demonstrated poor stability over time. This was supported by the instrument’s 
poor convergence with new appointment attendance scales. PF shared medium to strong relationships 
with mood and general functioning in expected directions.  
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Discussion: This project has improved our understanding of the potential applicability of the PF 
model and ACT in understanding and treating intentional and unintentional non-adherence and 
appointment non-attendance. However, further clarification of the utility of PF in understanding 
treatment non-adherence is warranted using prospective or experimental designs in conjunction with 
more objective valid and reliable adherence measures. 
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Chapter 1: Providing a context: Understanding non-adherence to 
medication, its psychosocial impact and current evidence for psychological 
approaches: A review of the literature 
 
This first chapter begins with a narrative literature review (search terms presented in Appendix A), 
introducing definitions of medication adherence, the extent of non-adherence and its impact in the 
context of LTCs, and how it is currently operationalised. This section will also include an overview of 
predominant psychological theories and associated interventions attempting to understand and treat 
medication non-adherence in people with LTCs. A newer organising framework, the psychological 
flexibility (PF) model, will also be introduced as a potentially helpful alternative approach. The need to 
develop novel ultra-brief measures for ecological momentary assessment (EMA) methods to more 
accurately capture temporal patterns of medication non-adherence in individuals with LTCs will also 
be discussed. Finally, the chapter will conclude with a context and rationale for the programme of 
empirical research undertaken in this thesis. 
 
1.1. Adherence in long-term health conditions 
 
Adherence has been defined as “the extent to which the patient's action – taking medication, 
following a diet, and/or executing lifestyle changes – corresponds with agreed recommendations from 
a health care provider” (World Health Organisation (WHO), 2003, p.3). Conversely, “non-adherence” 
has either been broadly defined as “an absence in the actions required by the person receiving treatment” 
(Harrison, Graham, & McCracken, 2017, p.8), or more specifically, “where doses are missed, extra 
doses are taken, or doses are taken in the wrong quantity or at the wrong time’’ (Verbrugghe, 
Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013, p.610). Historically, the terms “adherence” and 
“compliance” have been used interchangeably within the research literature (Horne et al., 2005). 
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However, it has been argued that adherence implies individuals are free to choose whether to execute a 
treatment behaviour, whilst compliance assumes a person passively follows a treatment plan (Osterberg 
& Blaschke, 2005). The term “concordance” also refers to the process within health consultations where 
the patient’s perceptions/beliefs and preferences are elicited and taken into account by the clinician 
rather than ignored (Horne et al., 2005), and an “exchange of information, negotiation, and a spirit of 
cooperation” where setting collaborative treatment goals forms the key focus (Mullen, 1997, p.691). 
Consistent with concordance and the role of one’s motivation and freedom to choose inherent in most 
psychological approaches (Brawley & Culos-Reed, 2000; Munro, Lewin, Swart, & Volmink, 2007), 
the term “adherence” will be used throughout the remaining thesis. 
 
Several reviews show rates of non-adherence to prescribed treatments for people with a variety of 
LTCs range from 25% to 50%, depending on the method of measurement used and type and frequency 
of treatments recommended (Coleman et al., 2012; DiMatteo, 2004b; DiMatteo, Giordani, Lepper, & 
Croghan, 2002; Haynes, 2001; Osterberg & Blaschke, 2005). Two of these reviews conducted meta-
analyses, which estimate non-adherence rates are around 25% (DiMatteo, 2004b; DiMatteo et al., 2002). 
Overall, these findings appear consistent with reviews for specific LTCs (e.g., Albert, 2008; Bosworth 
et al., 2011; Broekmans, Dobbels, Milisen, Morlion, & Vanderschueren, 2009; Harrold & Andrade, 
2009; Ho, Bryson, & Rumsfeld, 2009; Restrepo et al., 2008; Wu, Moser, Lennie, & Burkhart, 2008), 
but evidence indicates rates of non-adherence are generally higher in children and adolescents, ranging 
from 50% to 88% (McGrady & Hommel, 2013).  
 
A review of several systematic reviews indicates that over seven-hundred potential factors have been 
studied in conjunction with treatment non-adherence (Kardas, Lewek, & Matyjaszczyk, 2013). Factors 
broadly range from patient characteristics, type of condition or treatment, psychological and other 
contextual or socio-economic variables, such as family environment, cost of treatment and low-social 
economic status, to the type of health system (WHO, 2003). The bewildering array of potentially 
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important factors highlights the complex and multifaceted nature of non-adherence. This poses the 
challenge of considering where one might begin in terms of targeting factors for intervention and 
understanding which may be most amenable to change (Harrison, Graham, & McCracken, 2017). 
 
While some frameworks suggest non-adherence is a ‘diagnosable medical condition’ (e.g., Marcum, 
Sevick, & Handler, 2013), pragmatic attempts to distil psychological explanations of non-adherence 
have resulted in the development of two broader sub-categories. These include “intentional non-
adherence”, defined as an informed and conscious choice to not take medications as prescribed, and 
“unintentional non-adherence”, arising from unconscious omissions or forgetting (Lehane & McCarthy, 
2007). Evidence shows that some patients exhibit non-adherence at the beginning of treatment (Vrijens, 
Vincze, Kristanto, Urquhart, & Burnier, 2008). Others indicate 25% of people become non-adherent a 
short time after starting a new treatment (Barber, Parsons, Clifford, Darracott, & Horne, 2004), and of 
these 45% report their non-adherence was intentional and 55% unintentional. A recent review also 
suggests unintentional non-adherence in particular tends to worsen with age (Hughes, 2004). However, 
a more recent correlational study shows that unintentional non-adherence is associated with medication 
beliefs, alongside socio-demographics and type of illness, suggesting it may be more difficult to 
disentangle intentional from unintentional non-adherence (Gadkari & McHorney, 2012). For instance, 
self-reported “forgetting” could either reflect a socially desirable response, or person’s reduced ability 
to engage in informed decision-making because of changes in mood, rather than simply just forgetting. 
 
1.2 The impact of non-adherence in long-term health conditions 
 
Advances in medical treatments have steadily improved the life expectancy of people with several 
LTCs over the last three to five decades (e.g. cystic fibrosis: McCormick, Green, Mehta, Culross, & 
Mehta, 2002; human immune-deficiency virus (HIV): Kelly, Otto-Salaj, Sikkema, Pinkerton, & Bloom, 
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1998; multiple sclerosis: Comi, 2013). However, poor adherence continues to pose an important 
challenge for clinicians and health care providers, because it affects treatment efficacy (e.g., Cramer, 
1998; Stephenson, 1999), attenuates optimum clinical benefit (Dunbar-Jacob & Mortimer-Stephens, 
2001), and undermines treatment evaluation (Unni, Shiyanbola, & Farris, 2013). Adherence has 
therefore been described as a “critical mediator between physician recommendations and patient 
outcomes” (Kravitz et al., 1993, p.1869), and the WHO have argued that “increasing the effectiveness 
of adherence interventions may have a far greater impact on the health of the population than any 
improvement in specific medical treatments.” (WHO, 2003, p.21)   
 
The burden of treatment regimens for people with LTCs and their families should not be 
underestimated. Some treatments need to be performed several times a day, are often complex, time-
consuming (e.g., Quittner, Opipari, Regoli, Jacobsen, & Eigen, 1992), have unpleasant side-effects 
(e.g., Kidder, Wolitski, Campsmith, & Nakamura, 2007; Verbrugghe et al., 2013) and can be associated 
with a reduction in a person’s quality of life (QoL) (e.g., Hodari, Nanton, Carroll, Feldman, & 
Balkrishnan, 2006; Mills et al., 2006). Furthermore, one meta-analytic review showed that adherence 
to treatment regimens that involve significant side-effects is also associated with increased mortality 
(Simpson et al., 2006). However, people with LTCs who regularly miss or change doses of potentially 
beneficial medications are more likely to experience delayed recovery (e.g., Grijalva et al., 2007), 
treatment complications (Hughes, Bagust, Haycox, & Walley, 2001), depression (DiMatteo, Lepper, & 
Croghan, 2000; Gonzalez, Batchelder, Psaros, & Safren, 2011), reduced QoL (Zwikker, van den Bemt, 
Vriezekolk, van den Ende, & van Dulmen, 2014), and increased risk of morbidity and mortality 
(DiMatteo et al., 2002; Simpson et al., 2006). A potential weakness of this body of evidence is that the 
causal direction of these relationships is not always clear and the reverse may also be true. 
 
Non-adherence has been argued to be a significant public health issue (Lam & Fresco, 2015). 
However, evidence for the socio-economic consequences of non-adherence in LTCs has historically 
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been described as “poor, disparate, variable and non-existent in many therapeutic areas and patient 
groups” (Horne et al., 2005, p.89). The negative consequences of non-adherence are likely to be 
significant, since unused medicines, worsening disease activity or progression, unnecessary escalation 
of treatment due to ‘ineffectiveness’, and increasing need for general practitioner appointments and 
hospital admissions (e.g., McDonnell & Jacobs, 2002; Miura et al., 2001), are likely to result in greater 
health service costs (DiMatteo, 1994; Higgins, Rubin, Kaulback, Schoenfield, & Kane, 2009; Hughes, 
Bagust, Haycox, & Walley, 2001).  
 
Few large-scale economic analyses of non-adherence across LTCs have been conducted (e.g., Senst 
et al., 2001), and adherence is not routinely included in pharmacoeconomic analyses (Hughes, Cowell, 
Koncz, & Cramer, 2007), presumably because combining different adherence and costing data for 
variable treatments is unfeasible and loses important distinctions between LTCs. However, the 
economic burden arising from the waste of non-adherence to medication is believed to range from $100 
to $300 billion per year (DiMatteo, 2004b; Osterberg & Blaschke, 2005). Some economic studies for 
specific LTCs and treatments report that non-adherence is associated with higher costs and poorer 
clinical outcomes (e.g., rheumatoid arthritis: Hughes, 2012, unpublished; oral bisphosphonates for 
people with osteoporosis: Hiligsmann, Rabenda, Bruyère, & Reginster, 2010), whilst others show non-
adherence has negligible consequences in terms of cost-effectiveness (e.g., immunosuppressive therapy 
after renal transplant: Cleemput, Kesteloot, Vanrenterghem, & De Geest, 2004) or show mixed findings 
(e.g., diabetes:(Asche, LaFleur, & Conner, 2011). Overall, evidence indicates supporting people with 
LTCs to achieve optimal adherence is likely to prevent morbidity, delay progression, improve survival 
and reduce costs. However, an important challenge in this growing economic literature is the variable 
operational definitions used to measure non-adherence (Cleemput, Kesteloot, & DeGeest, 2002). 
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1.3 Current challenges with operationalising medication non-adherence 
 
There is currently no ‘gold standard’ for measuring medication adherence in LTCs. Over the last 50 
years, non-adherence has been measured in a variety of ways, but each method has important limitations 
affecting its precision and accuracy. Examining concentrations of medications or their metabolite, 
usually in the blood or urine, has traditionally been viewed as a potentially useful biochemical marker 
of adherence (Osterberg & Blaschke, 2005). However, this method is usually costly and may not be 
possible for all medications. In addition, such measures can be influenced by diet, absorption and 
excretion rate, and use of other medications (Vitolins, Rand, Rapp, Ribisl, & Sevick, 2000). 
Furthermore, taking numerous blood and/or urine samples over time may be too invasive or impractical 
for the purposes of research or routine clinical practice (e.g. recording daily measures). 
 
Other less invasive measures include pill counts (i.e. number of pills remaining after a given time 
period compared to the recommended dose), prescription refill records, and medication vial caps 
(electronic Medication Event Monitoring System or eMEMS® caps), which electronically record time-
stamped data of bottle opening (Farmer, 1999). However, these methods can also be expensive and 
time-consuming, and whilst appearing objective have other important weaknesses. First, they assume 
all counted pills have been taken and omit key information about correct dosing or timing, making them 
less compatible with polypharmacy, which is more common in older people with LTCs (Elliott, Ross-
Degnan, Adams, Safran, & Soumerai, 2007; Marcum & Gellad, 2012; Payne, Abel, Avery, Mercer, & 
Roland, 2014). Second, there is no way of knowing whether people have discarded pills, referred to as 
“dose dumping”, or consumed them prior to health visits to appear more ‘compliant’ because they are 
aware they are being monitored (Osterberg & Blaschke, 2005). Finally, not all prescribed medications 
for LTCs comprise oral agents (e.g., insulin injections in diabetes), and therefore capturing non-
adherence using different forms of drug administration or polypharmacy becomes increasingly 
challenging. 
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The most common method of assessing medication adherence includes self-report questionnaires to 
assess a person’s intentions, attitudes or beliefs, behaviours and barriers (Nguyen, Caze, & Cottrell, 
2014). Compared to other methods, self-report measures are inexpensive, quick and easy to administer 
with opportunities for real-time clinician-patient feedback and can be used across LTCs (Lam & Fresco, 
2015). Carefully constructed scales can explore how and why a person is non-adherent and disentangle 
potentially different underlying causes (e.g., Horne & Weinman, 2002), which can inform the 
development of interventions that specifically target these. Several reviews show moderate levels of 
concordance between self-report instruments and other more objective measures of adherence, but it is 
unclear whether the latter are measuring adherence accurately (Choo et al., 1999; Garber, Nau, 
Erickson, Aikens, & Lawrence, 2004; Nguyen et al., 2014; Shi, Liu, Fonseca, et al., 2010; Shi, Liu, 
Koleva, et al., 2010). Therefore, using multiple measures to assess non-adherence is regarded as an 
optimal approach, if deemed useful and feasible (WHO, 2003). Self-report instruments too have 
important drawbacks. First, many adherence measures have been developed to date, but most have only 
been validated in a few LTC samples, varying in their focus of questioning and/or phrasing, showing 
inconsistent estimates of reliability, sensitivity and specificity (Lam & Fresco, 2015; Stirratt et al., 
2015). Health provider and patient self-reports typically overestimate adherence because people tend to 
either engage in socially desirable responding (Horne, 2006), or experience problems with retrospective 
memory bias when asked to rate their level of adherence over a given timeframe (Nguyen et al., 2014).  
 
In more recent years the LTC literature has seen the emergence of new technologies to measure 
adherence. For example, studies in cystic fibrosis now utilise nebuliser microchips, which measure 
dosing, frequency and quality of momentary nebuliser use for inhaled anti-biotics and mucolytics 
(Latchford, Duff, Quinn, Conway, & Conner, 2009). These methods currently form part of routine 
clinical practice, providing a potentially more objective and accurate estimate of adherence. Whilst 
these advances provide an exciting opportunity to measure adherence more objectively in conjunction 
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with other measures, Latchford et al.’s (2009) study has also demonstrated that calculating adherence 
using various indices of nebuliser data alone can result in remarkably different findings. In addition, 
there is no established cut-off for “poor” adherence in this context. Studies like these highlight the 
perennial issue of how adherence researchers might interpret these more accurate and objective indices 
of adherence and determine which holds the greatest utility in terms of measuring this complex 
construct. 
 
Another challenge with measurement is that most adherence studies report an average percentage of 
adherence or non-adherence within a given sample (see DiMatteo, 2004b; DiMatteo et al., 2002). 
However, group-level data and subsequent meta-analyses overlook potentially important individual 
differences, known as aggregation bias (Johnston & Johnston, 2013). For example, though estimates 
show 25% of samples of people with LTCs are “non-adherent” to medication, it is unclear whether 
every individual took 75% of their doses. Established clinical cut-offs or bandings of “non-adherence” 
and “adherence” (e.g. 80%, see Lam & Fresco, 2015) also have similar difficulties, and rather than 
being based on empirical evidence, cut-offs typically rely on arbitrary thresholds proposed by expert 
clinicians (WHO, 2003).  
 
In addition, it has been argued that developing a universal level of “adherence” or “non-adherence” 
either within or across LTCs is challenging for several reasons (Hughes, 2012, unpublished). First, some 
LTCs can be progressive and/or fluctuate over time (e.g. multiple sclerosis, rheumatoid arthritis), so 
treatment need and response may vary considerably between individuals. Second, solely establishing a 
level of adherence for a given drug via efficacy trials is also problematic, since adherence rates of self-
selecting participants may be higher than those recorded in routine clinical practice. Lastly, there is little 
evidence to indicate whether sporadic episodes of non-adherence, e.g. taking breaks from medications 
with adverse side-effects, known as “drug holidays” (Hughes, 2004), have a negative impact in the 
short- or long-term, which will likely vary across LTCs and treatments. For these reasons, establishing 
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levels of non-adherence for each LTC over the short- and long-term is one proposed strategy (Elliott, 
2008). However, one way to circumvent problems with group-level efficacy data and clinical 
heterogeneity in people with LTCs is to use idiosyncratic methods that include multiple measures of 
adherence. Such measures would be relatively easy to use and routinely administer in clinical practice 
(e.g. measuring momentary nebuliser use and ultra-brief self-report scales on an iPhone app) and could 
explore patterns and potential psychological determinants within and between individuals over time and 
across different contexts (see section 1.7 Need for validated momentary assessments). For this reason, 
self-report questionnaires will be used to measure adherence in the current thesis project.  
 
1.4 Existing psychological models to understand treatment non-adherence 
 
Given the large number of psychosocial factors evaluated to date (Kardas et al., 2013), and the high 
proportion of these with poor links to any coherent unifying conceptual models or set of guiding 
principles, the following section reviews the empirical support for existing theories applied to 
understand and treat non-adherence in people with LTCs. 
 
Since the 1960s “social cognitive” models have attempted to understand the role of planning and 
rational decision-making processes contributing to behaviour (including treatment non-adherence) 
resulting in the development of psychological interventions to improve self-management (Brawley & 
Culos-Reed, 2000; Munro et al., 2007). A unifying assumption of social cognitive models is that a 
person’s adherence to medical advice depends on their expectations surrounding the costs and benefits 
of executing a given behaviour (Edwards, 1954). Social cognitive models therefore centre on a person’s 
motivation and intentions. Later models also include a person’s perceived ability to perform a treatment 
behaviour or self-efficacy, building on Albert Bandura’s (1977) earlier theory. As such, these theories 
have been better placed to understand intentional rather than unintentional non-adherence. Several other 
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well-researched models of health behaviour have been applied to adherence more generally, but to date 
have not been studied as extensively in this area specifically1. 
   
The following section will first evaluate the evidence for the most prominent social cognitive 
theories, including the theory of planned behaviour, common-sense model of illness perceptions, and 
the necessity concerns framework. This will be followed by an outline of a more recent composite health 
behaviour change model that aims to provide a unifying framework to accommodate all other models, 
the capability, opportunity and motivation model of behaviour (COM-B) (Michie, van Stralen, & West, 
2011), motivational interviewing and third-wave approaches. The efficacy of treatments derived from 
these theories will also briefly be discussed. 
 
1.4.1 Theory of planned behaviour 
 
The theory of planned behaviour (TPB) (Ajzen, 1988; 2011) (Figure 1) extended Martin Fishbein 
and Icek Ajzen’s earlier work on the theory of reasoned action (TRA) (Fishbein & Ajzen, 1975) by 
incorporating four cognitive processes that are argued to influence a person’s (e.g. adherence) 
behaviour. The TPB works in a linear fashion, where the most proximal process and strongest predictor 
of behaviour (Ajzen, 1991) is one’s “intention” or motivation to undertake a behaviour. The theory 
                                            
1Other less prominent theories applied to adherence include: behavioural learning perspective (see van Dulmen 
et al., 2007), health belief model (Rosenstock, 1966) protection motivation theory (R. W. Rogers, 1975), self-
efficacy theory  (Bandura, 1977), theory of reasoned action (Fishbein & Ajzen, 1975), transtheoretical stages-
of-change model (DiClemente & Prochaska, 1983), traditional cognitive-behavioural model (Meichenbaum & 
Turk, 1987), cognitive analytic approaches (Fosbury, Bosley, Ryle, Sönksen, & Judd, 1997; Walsh, Hagan, & 
Gamsu, 2000), information-motivation-behavioural skills model (Fisher, Fisher, Amico, & Harman, 2006) and 
accident causation framework (Garfield, Clifford, Eliasson, Barber, & Willson, 2011).  
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suggests that if one’s intention is stronger, a behaviour is more likely to occur. Two other processes 
drawn from the TRA are assumed to influence behaviour indirectly via intentions: including (i) a 
person’s “attitudes”, beliefs or expectancies surrounding the behaviour, and its value in terms of 
perceived consequences; and (ii) ‘subjective norm’, reflecting the perceived social value of performing 
a given behaviour, including societal pressure, and the extent to which an individual conforms with 
these views. Finally, drawing on self-efficacy theory, ‘perceived behavioural control’ is the belief that 
the person has the necessary skills and resources required to successfully perform the behaviour, based 
on their previous personal experience or other social influences (e.g., the media). Perceived behavioural 
control has been shown to influence behaviour more directly compared to attitudes or social norms 
(Ajzen, 2007). This would suggest that even if a person’s intentions are strong, the likelihood of 
successfully performing an adherence behaviour will also depend on whether they perceive themselves 
as sufficiently competent to take their medications correctly.   
 
 
 
 
 
 
Figure 1: Theory of Planned Behaviour (Ajzen, 1991) 
 
A recent meta-analytic review of twenty-seven studies has examined the magnitude of relationships 
between TPB constructs and adherence outcomes for a range of treatments (medication, diet and 
exercise) across a variety of LTCs (e.g. epilepsy, HIV, and chronic obstructive pulmonary 
disease/COPD) (Rich, Brandes, Mullan, & Hagger, 2015). Consistent with reviews exploring other 
preventative health behaviours (Abraham, Sheeran, & Johnston, 1998; Albarracin, Johnson, Fishbein, 
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& Muellerleile, 2001; Armitage & Conner, 2001; DiMatteo, 2004b), findings show collectively 
attitudes, subjective norm and perceived behavioural control constructs accounted for 33% of the 
variance in intention, and 9% for adherence behaviour (r=.30). The finding that the TPB is superior in 
predicting intentions compared to behaviour is also consistent with previous reviews showing that 
intentions have a modest direct relationship with health behaviours (Sheeran, 2002; Webb & Sheeran, 
2006). Overall, these findings suggest the TPB has limited explanatory power to inform the 
development of interventions to improve adherence and it cannot sufficiently explain why people fail 
to act in accordance with their intentions, known as the “intention - behaviour gap” (Rich et al., 2015).  
 
Furthermore, the TPB is less likely to be accurate when predicting behaviours requiring certain 
skills, knowledge or resources that an individual may not have access to (e.g. how to administer certain 
medications or having appropriate transport to attend clinic appointments for treatment). In addition, it 
could be argued that several other potentially important factors do not feature in the TPB, including 
emotional and socio-contextual variables, such as social support (DiMatteo, 2004a) or access to 
treatment (Mills et al., 2006). This might explain why empirical support for the model is limited, having 
largely been applied to healthy populations (e.g. dietary patterns) (McDermott et al., 2015). 
 
1.4.2 The common-sense model of illness perceptions 
 
The common-sense or ‘self-regulatory’ model of illness perceptions (CSM) proposed by Howard 
Leventhal and colleagues in the 1980s (Leventhal, Meyer, & Nerenz, 1980) suggests people are active 
problem-solvers, who are motivated to make sense of and manage potential health threats associated 
with the prevention, adaption and maintenance of behaviours relating to their illness (Leventhal, 
Nerenz, & Steele, 1984). The CSM posits there are two partly interacting parallel processes, which 
become activated in response to internal or external cues about symptoms and health threats (see Figure 
2).  
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The first pathway is responsible for the development of a multi-dimensional framework of 
cognitions, called an ‘illness representation’ or schema, arising from this evaluative process, which are 
argued to directly influence coping strategies, including adherence behaviour. An illness representation 
incorporates five domains, including a person’s beliefs related to their overall understanding of their 
condition (“illness coherence”), symptoms attributed to illness (“identity”), duration (“timeline”), 
potential “causes”, “consequences” on physical, psychological and social functioning, and whether 
treatment or one’s own behaviour can “cure or control” the illness/symptoms. Illness representations 
are argued to continuously update as the person acquires new illness or health threat information, and 
the effectiveness of their coping behaviours are appraised for their efficacy. Based on this assessment, 
the person may persist with a particular coping behaviour or try alternatives. 
 
The second system is an emotional representation pathway, which is triggered by illness 
representations or external and internal cues (e.g. bodily sensations). Activation of this pathway can 
also result in the person using potentially successful or unsuccessful coping strategies aiming to 
attenuate or control negative emotions (e.g. suppression or expression of feelings or avoidance). 
Combining new and old information and direct experience of a health condition via these two pathways 
is argued to potentially result in erroneous beliefs about illness and unhelpful strategies for coping with 
associated emotions, which could lead to non-adherence. 
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Figure 2: Common Sense Model of Illness Perceptions (Leventhal, Brissette, & Leventhal, 2003) 
 
A relatively recent meta-analysis of twenty-three studies explored predictive relationships between 
CSM constructs and adherence to medication, diet and exercise recommendations (Brandes & Mullan, 
2014). Findings showed that overall illness representations only accounted for a small amount of the 
variance in adherence outcomes (r=.02 to 0.12), collectively reflecting a relatively weak predictor of 
adherence compared to constructs from the TPB. It has been argued that the inconsistent findings across 
studies examining illness perceptions and adherence in LTCs may partly reflect the different aetiology 
and treatment of conditions (e.g. being born with an illness, rather than developing one in later life) 
could result in the development of different illness representations (Hughes, 2012). However, others 
have argued that the narrow focus on a person’s disease self-management in the CSM ignores beliefs 
about medications or treatments themselves, the wider socio-economic context and other potentially 
important personal motivations, such as a person’s broader life values or goals (Graham, Gouick, Krahé, 
& Gillanders, 2016;. Harrison, Graham, & McCracken, 2017) 
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1.4.3 Necessity concerns framework 
 
An evolution in thinking about medication adherence in the late 1990s (Horne & Weinman, 1999) 
resulted in an extension of the health belief model (Rosenstock, 1966) and the notion that proximal 
beliefs about medications might be more potent predictors of adherence behaviour (Horne, Cooper, 
Gellaitry, Date, & Fisher, 2007). The necessity-concerns framework is underpinned by the same value-
expectancy principle as its predecessor, but instead argues that individuals will weigh-up perceived 
costs and benefits of treatment, resulting in an intentional decision to adhere or non-adhere to treatment 
recommendations. Constructs within the model were derived from the development of The Beliefs 
about Medications Questionnaire (BMQ) (Horne, Weinman, & Hankins, 1999), which explored the role 
of specific and general beliefs about medications and how they influence adherence behaviour. All scale 
items were based on the existing literature and interviews with patients. Results identified two 
categories of medication beliefs, including “general” and “specific”, which each comprise two further 
sub-categories: “general-overuse” (i.e. the patient’s perception that doctors over-prescribe medications) 
and “general-harm” (i.e. that medications are addictive, harmful, or poisonous and should not be 
continuously taken), but also “specific-necessity” (that medications are necessary and have benefit) and 
“specific-concern” (i.e. that medications come with actual or potential adverse consequences, including 
risk of long-term toxicity, dependence and disruption to one’s life). 
 
A recent meta-analytic review including ninety-four studies found that necessity (OR=1.74) and 
concern beliefs (OR=.50) only explain a modest relationship with adherence outcomes, and were similar 
after stratifying by LTC type, type of adherence measure, country, study design and sample size (Horne 
et al., 2013). As with other social cognitive models, an important weakness of the necessity concerns 
framework is the limited scope of the model, since it fails to consider the wider socio-economic context 
and patient factors, such as emotions and how (along with beliefs) people relate to them. In addition, 
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social cognitive models in general do not provide explanation of why unintentional non-adherence 
might occur and/or whether specific beliefs apply to specific medications/regimens. 
  
1.4.4 Interventions stemming from social cognitive models 
 
The wider adherence literature is now replete with trials evaluating interventions for people with 
LTCs and clinician/providers (see Conn, Ruppar, Enriquez, Cooper, & Chan, 2015) to improve 
adherence and other patient-centred outcomes, ranging from drug education, behavioural reminders 
(e.g. calendars/pill boxes) to cognitive-behavioural therapy and motivational interviewing (see reviews 
(Conn, Ruppar, & Cooper, 2016; Conn, Ruppar, Enriquez, & Cooper, 2016; Dean, Walters, & Hall, 
2010; Haynes, Ackloo, Sahota, McDonald, & Yao, 2008; Kripalani, Yao, & Haynes, 2007; McDonald, 
Garg, & Haynes, 2003; Nieuwlaat et al., 2014; Williams, Manias, & Walker, 2008). However, most of 
these treatments have either been ineffective or show only modest improvements in adherence. In 
addition, most are based on an unsatisfactory integration of the previous models or not based on any 
model at all, and those that were on models that are perhaps too narrow. However, whilst cognitive-
behavioural interventions stemming from social cognitive models are more effective than techniques 
used in current practice, they show small effect sizes overall (Hedges g=0.34) (Easthall, Song, & 
Bhattacharya, 2013). This finding might reflect the narrow focus and limited explanatory power of 
social cognitive models in understanding non-adherence. In addition, cognitive-behavioural 
interventions range from low- to high-intensity, where some are more resource-intensive than others. 
However, other than treatment setting (i.e. hospital being more effective than community), there is no 
clear differential pattern of effectiveness according to therapist experience or delivery methods used. 
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1.4.5 Motivational interviewing interventions 
 
Motivational interviewing (MI), initially developed to treat addictions (Miller, 1983) and now a 
well-researched intervention for broad range of behavioural problems and diseases (Rubak, Sandbæk, 
Lauritzen, & Christensen, 2005), is a commonly adopted treatment for non-adherence (Bisonó, Manuel, 
Forcehimes, OÕDonohue, & Levensky, 2006). Though distinct from social-cognitive models, which 
also addresses similar volitional processes. MI has four key principles: (i) drawing on earlier Rogerian 
principles (Rogers, 1957), the therapist is encouraged to actively listen to the person and understand 
their perspective (expressing empathy); (ii) reflect the person’s ambivalence about change, encourage 
them to provide reasons for change and make explicit the gap between their personal goals and current 
(i.e. adherence) behaviour (developing discrepancy); (iii) rather than opposing a person’s resistance to 
change the focus is on reflecting this resistance (rolling with resistance); (iv) promoting the person’s 
confidence in the idea that change is possible and conveying that any attempts to change will be meet 
with support from the therapist (supporting self-efficacy). Currently only a few trials have been 
reported, which show mixed success in enhancing adherence in only HIV and diabetes (Bisonó et al., 
2006), and therefore no robust meta-analysis of RCTs has been conducted to estimate efficacy and 
magnitude of improvement in adherence behaviours. However, current meta-analytic reviews of MI 
incorporating trials with adherence outcomes demonstrate modest effects overall, which persist over 
time (Lundahl & Burke, 2009; Lundahl et al., 2013).  
 
1.4.6 The Capability, Opportunity and Motivation Model of Behaviour (COM-B) 
 
Another recent theoretical development is the Capability, Opportunity and Motivation Model of 
Behaviour (COM-B) (Michie et al., 2011), which has emerged as a health behaviour change framework 
aiming to subsume all constructs from earlier models and address important gaps. The COM-B was not 
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specifically designed to understand and treat non-adherence, but rather takes its root in an extensive 
consultation process, which initially involved recruiting expert clinicians and researchers to a Delphi 
study to develop a “behaviour change technique taxonomy” comprising 93 techniques to improve 
reporting of health behaviour change interventions (Michie et al., 2013). For instance, it has been argued 
the COM-B may provide an account for both intentional and unintentional non-adherence (Jackson, 
Eliasson, Barber, & Weinman, 2014). The COM-B attempts to distil a range of factors that might 
influence an individual’s health behaviour, including non-adherence. These include (i) a person’s 
physical and psychological capacity to engage in (i.e. adherence) behaviour (“capacity”) – e.g. beliefs 
about illness, (ii) social or physical contextual factors that might prompt or enable their behaviour 
(“opportunity”) – e.g. treatment cost, and (iii) a person’s reflective (e.g. cognitive or evaluative) and 
automatic (e.g. impulses or affect) volitional processes underlying (“motivation”) – e.g. neurocognitive 
functioning. A key strength of the framework is that it could encourage clinicians to consider a range 
of potentially amenable factors that might influence adherence behaviour.  
 
The COM-B has several weaknesses. First, the broad range of factors and methods in the framework 
make it inclusive, but it attempts to combine an exhaustive number of models for health behaviours and 
associated treatments that have been shown to have modest explanatory power and efficacy. The COM-
B also fails to provide a coherent theoretical account of how variables interact to influence non-
adherence behaviour that focus on key principles and processes and tries to merge models with 
potentially distinct ontological and epistemological assumptions. Therefore, formulating why 
individuals are non-adherent with a framework or method of categorisation that is not underpinned by 
any particular underlying (and potentially conflictual) theory becomes increasingly challenging. 
 
One appeal of the COM-B is that a range of corresponding behaviour change techniques can be 
drawn on by clinicians and combined to “build” interventions to improve adherence. However, 
clinicians may also encounter problems with combining potentially contrary techniques stemming from 
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different theoretical perspectives. It also becomes difficult to imagine how a “built” intervention in a 
treatment trial might include a process evaluation without being guided by a coherent explanatory model 
with a clear set of guiding principles. Currently, there is limited research exploring the efficacy of 
behaviour change interventions arising from the framework. 
 
1.4.7 Third-wave mindfulness-based approaches 
 
More recently, there has been a growing interest in applying so-called “third-wave” approaches 
(Hayes, 2004) to improve people’s adherence to medical treatment, including Mindfulness-based Stress 
Reduction (MBSR) and Dialectical Behaviour Therapy (DBT). MBSR and DBT and their operational 
definitions of mindfulness have drawn mostly on teachings from Mayahana and Theravada Buddhist, 
as well as yogic, traditions (Kabat-Zinn, 1982).  
 
There are a small but growing number of studies that have examined the applicability of MBSR in 
addressing treatment non-adherence. Specifically, the 10-week MBSR programme comprising secular 
mindfulness meditation (seated meditations, body scan practice, mindful yoga/movement and walking 
meditation) based on Buddhist teachings is regarded as the earliest third-wave development, 
demonstrating significant reductions in pain severity and interference, negative body image and pain-
related drug utilisation and improvements in emotional functioning of patients with chronic pain in the 
early 1980s (Kabat-Zinn, 1982; Kabat-Zinn, Lipworth, & Burney, 1985). More recently, applications 
of MBSR for treatment adherence have mostly been confined to HIV. One systemic review, including 
three studies exploring the utility of MBSR in people with HIV prescribed antiretroviral therapy, shows 
that adherence-related outcomes (e.g. CD4+ lymphocyte counts and T cell activity) were inconsistent 
across studies, where some participants experienced improvements whilst others worsened at post-
intervention and long-term follow-up (Riley & Kalichman, 2015).  
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The inconsistent findings of MBSR on improving adherence outcomes suggests the approach may 
have some limitations. First, MBSR and subsequently Mindfulness-based Cognitive Therapy (MBCT) 
(Segal, Williams, & Teasdale, 2013) have not been guided initially by a coherent testable theoretical 
model or key set of guiding principles, but rather have attempted to recognise a range of traditional 
Eastern meditation methods and only later attempted to understand how they work  (Harrison, Scott, 
Johns, Morris, & McCracken, 2017). Second, aside from engaging a person in mindful practice, MBSR 
does not incorporate an explicit behavioural activation component (e.g. exposure, setting goals or 
making commitments), and therefore its limited success may echo previous dismantling studies of 
traditional cognitive behavioural therapies, which consistently show that behavioural activation exerts 
the greatest influence on treatment outcomes (Jacobson et al., 1996; Longmore & Worrell, 2007).  
 
A recent conceptual review has also promoted the adapted use of DBT, initially designed for people 
with Borderline Personality Disorders (Linehan, 1993) to improve medication adherence in adolescents 
with chronic medical illness (DBT-CMI) (Becky H Lois & Miller, 2018). The authors highlight three 
overarching goals of the eight individual session intervention, including: (i) increasing a young person’s 
awareness of the consequences of non-adherence, (ii) conceptualising non-adherence as a form of 
emotional avoidance or crisis-driven behaviour, and teaching mindfulness and emotion regulation 
strategies to help the person develop more skilful responses to difficult emotions, and (iii) increasing a 
person’s ‘radical acceptance’ of their illness to enhance distress tolerance, for example when they 
believe themselves to be “invincible”. In addition, three family sessions are aimed at resolving parent-
child relational conflicts around their illness and medication use. Primary treatment targets include 
decreasing non-adherence behaviours that interfere with treatment engagement and QoL, whilst 
increasing behavioural skills. Secondary targets include alleviating emotional avoidance, social 
pressures, shifting illness responsibility between parent and teen, and nonacceptance. Evidence for 
DBT-CMI is in its infancy, but one pilot study shows promising efficacy in terms of improving self-
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reported adherence and depression but not QoL in difficult-to-treat youth with end-stage renal disease 
(Hashim, Vadnais, & Miller, 2013). Another trial targeting non-adherence in adolescents with Type I 
diabetes is currently underway (Lois et al., 2017, unpublished). 
 
A strength of DBT-CMI is that it brings together a potentially useful combination of mindfulness-
based strategies in conjunction with behavioural elements. However, despite providing a more 
traditional cognitive-behavioural vicious cycle example in their review, Louis and Miller (Lois & 
Miller, 2018) focus mostly on a range of treatment techniques rather than presenting a coherent testable 
theory with a set of key processes. Similar to MBSR, the lack of theoretical clarity in DBT more 
generally is potentially problematic because it undermines attempts to conduct mediational process 
analyses to evaluate the role of a pre-defined set of independent variables (Harrison et al., 2017). This 
makes it difficult to disentangle which of the many components that make up DBT-CMI exert most 
influence on adherence and other key outcomes. Also, given the broader adherence outcomes used in 
these trials, it remains unclear whether DBT-CMI is better equipped to target intentional and/or 
unintentional forms of non-adherence. 
 
1.4.8 Summary 
 
Existing psychological theories have for some time argued that people with LTCs are non-adherent 
to their medications because they do not intend to take them, or because they hold certain unhelpful 
erroneous beliefs about their illness or treatment. Others suggest a person’s confidence in taking a 
medication determines whether they are adherent or not. Whilst a review of existing reviews published 
over a decade ago stated that, “interventions to improve patient adherence are unsuccessful and sound 
theoretical foundations are lacking” (van Dulmen et al., 2007, p.1), current empirical studies have 
shown these constructs do help to understand adherence and patient centred outcomes, accounting for 
some of the variance in medication taking behaviour (Conn, Enriquez, Ruppar, & Chan, 2016). 
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However, they are not strong predictors of adherence and are less theoretically equipped to explain 
unintentional non-adherence. In addition, psychological treatments aiming to directly enhance self-
efficacy and change potentially unhelpful beliefs about illness and medication have mostly shown 
mixed findings in terms of improving adherence, and effect sizes overall are modest. Furthermore, few 
have directly targeted potentially difficult emotions arising from being asked to adhere to long-term 
treatments, but those that have indicate some preliminary efficacy. There are also a vast number of 
attempts to tackle non-adherence by using information and advice-giving interventions, which show 
limited efficacy overall (Conn, Ruppar, Enriquez, et al., 2016; Nieuwlaat et al., 2014). Taken together, 
this suggests there may be other more potent predictors of adherence that could potentially be targeted 
in the context of psychological intervention. 
 
1.5 Utility of the psychological flexibility model to understand adherence to 
medical treatment 
 
Another third-wave approach, the Psychological Flexibility model (PF), which underlies Acceptance 
and Commitment Therapy (ACT) (Hayes, Strosahl, & Wilson, 1999), offers an alternative framework 
for understanding and treating intentional and unintentional non-adherence to medication in the context 
of LTCs. It is beyond the scope of this summary to describe PF and ACT’s underlying philosophical 
assumptions (functional-contextualism and its pragmatic truth criterion to scientific enquiry) 
(Vilardaga, Hayes, & Schelin, 2007) and basic level theory2 in great detail here (see Hayes et al., 2001). 
 
                                            
2Relational frame theory (RFT) is a post-Skinnerian account of human language and cognition rooted in operant 
principles (Hayes, Barnes-Holmes, & Roche, 2001), which focuses on generalised response classes, 
experiential avoidance and “relational responding” (for a more detailed summary see Torneke, 2010). 
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PF has been defined as, “the capacity for an individual to persist with, or change, behaviour in a 
manner that includes conscious and open contact with thoughts and feelings, appreciates what situations 
afford, and serves one’s goals and values” (Scott & McCracken, 2015, p.91). Conceived as a 
transdiagnostic theory of “normal” human behaviour (McCracken & Morley, 2014), PF incorporates 
six integrated processes: acceptance, cognitive defusion, self-as-context, present moment focus or 
awareness, values and committed action (Figure 3). The first four have been broadly categorised as 
‘acceptance and mindfulness’ processes, whilst the remaining two reflect more ‘commitment and 
behaviour change’ processes (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). Acceptance or willingness 
is the ability to openly engage in activities in the presence of unwanted experiences, without struggling 
with them, when doing so is guided by one’s goals (Scott & McCracken, 2015). Cognitive defusion is 
the ability to experience a distinction between thoughts and the things they describe and to contact 
experiences directly, without being dominated by the literal meaning and influences carried in thought 
content (Fletcher & Hayes, 2005). Self-as-context refers to perspective skills or one’s ability to 
experience a point of view distinct from thought content and arising feelings, where they are neither 
defined by nor harmed by them (Hayes et al., 1999). Present-focussed awareness, similar to other 
mindfulness definitions, is ongoing, non-judgmental awareness of one’s experience and the capacity to 
attend and flexibly, fluidly, and voluntarily switch focus between the immediate internal and external 
environment (Zhang et al., 2017). Values are freely chosen, verbally constructed qualities of purposive 
action that we define as important, which are never fully achieved and guide our goals (Hayes et al., 
2006). Committed action is flexibility persisting with goals or actions informed by values in a manner 
that incorporates discomfort and failure and still continue, or are abandoned if unworkable (McCracken, 
2013). 
 
In the context of adherence, PF suggests a person may not adhere due to three potentially unhelpful 
patterns of behaviour: i. Closed: Avoiding situations and related private emotional experiences, such as 
thoughts, mood states, or bodily sensations; ii. Unaware: Being overly influenced by, or entangled with, 
potentially unhelpful thoughts, including a pre-occupation with the past or future, or unable to take a 
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point of view separate from these thoughts and feelings; and iii. Disengaged: Failing to identify and 
pursue valued life directions and related goals and persisting inflexibly or impulsively in potentially 
“unworkable” behaviour.  
 
For example, a person with a LTC might believe that medication is helpful or necessary, but may 
still not adhere because they try to control or eliminate uncomfortable physiological sensations, 
thoughts and emotions related to their condition, treatment and/or wider life circumstances (e.g. shame, 
fear, anxiety taking antiretroviral therapy) (closed); and often dwell on the past or worry about the 
future to the extent they are not present in the here and now (e.g. worry, anxiety and fear after a breast 
cancer diagnosis and taking Tamoxifen) (unaware). Therefore, taking medication becomes an aversive 
experience, and though the person might believe treatment is effective (e.g. ACE inhibitors for 
hypertension), they cannot see if or how taking medication serves their long-term values or goals (e.g. 
being independent, healthy and continuing with work and/or being a good parent) (disengaged). The 
emphasis of experiential avoidance in PF could potentially either equate to (i) a person actively choosing 
not to follow their treatment regimen, or (ii) becoming so pre-occupied with their private aversive 
experiences (wittingly or unwittingly) and efforts to reduce or eliminate them, it reduces their present 
moment awareness and they forget to take their medications. Therefore, PF does obviously not 
distinguish between intentional and unintentional forms of non-adherence. 
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Figure 3: ACT’s six- and three-processes psychological flexibility model  
(reproduced from Harrison et al., 2016). 
 
 
ACT is a newer form of cognitive-behaviour therapy (CBT), which aims to modify the three 
psychological inflexibility processes described above. ACT focuses on how private events, such as 
thoughts, feelings and behaviours are experienced (i.e. contextual change), rather than what is 
experienced. The focus differs slightly to “second-wave” traditional cognitive behavioural approaches 
(Beck, 1979), which assume a more rational, refuting stance to align beliefs or thought content with 
essential ‘truths’. As such, ACT encourages the person to learn mindfulness and acceptance-based 
strategies to change their relationship with their private experience and clarify their values in the service 
of pursuing valued actions or goals. It has recently been argued that ACT and other mindfulness-based 
interventions may be more helpful when a person’s beliefs appear highly plausible in the context of 
LTCs and may be useful to improve adherence (Graham et al., 2016). 
Open Aware Engaged 
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The six PF processes have been further condensed into three broader sub-processes, including: (i.) 
Open: Being open and willing to have potentially unpleasant thoughts, feelings and bodily sensations 
without trying to change them; (ii.) Aware: Being in the present moment, able to recognise and 
disentangle oneself from the influence of potentially unhelpful thoughts and feelings, with the aim of 
being (iii.) Engaged: Persisting in or initiating behaviours that allow the person to work towards freely 
chosen valued life directions, and flexibly disengage from actions if they prove to be unhelpful to enable 
more effective patterns of behaviour (Hayes, Villatte, Levin, & Hildebrandt, 2011; Scott, McCracken, 
& Norton, 2016). 
 
ACT could improve medication non-adherence. For example, a person who demonstrates   PF may 
still experience negative emotions and worry about their LTC. However, they may also develop the 
ability to open-up to these difficult private experiences, enabling them to choose to follow (or not 
follow) their treatment regimen, and engage in meaningful actions or goals in a more effect way. ACT 
assumes that adherence behaviour can occur in the presence of contrary or disturbing thoughts or 
feelings, or a lack of confidence. It also brings into focus the pragmatic question of how effective or 
“workable” a person’s behaviour is by setting it against their values. This patient-centred focus on 
values and “workability” provides a useful framework to enhance the clarity of a person’s informed 
consent to treatment, which along with available medical advice, may help the individual and their 
families to more fully consider whether they adhere or non-adhere to their medications as prescribed. 
 
1.6 Evidence for the psychological flexibility model in treating non-adherence 
 
Review evidence for PF (Levin, Hildebrandt, Lillis, & Hayes, 2012; Ruiz, 2010) and the efficacy of 
ACT for a range of clinical problems is mounting but there are still few interventions and those that 
exist seem very limited in scope and quality (e.g., Graham et al., 2016; Hann & McCracken, 2014; 
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Swain, Hancock, Hainsworth, & Bowman, 2013). However, there is growing support for the idea that 
PF processes mediate improvements in treatment outcomes (Stockton et al., 2018).  
 
At least two correlational studies have shown that greater PF is significantly associated with better 
self-reported and more objective measures of adherence (i.e. HbA1c) in people with Type I diabetes 
mellitus (Kamody et al., 2017), and higher rates of influenza vaccination uptake in people with chronic 
respiratory diseases (Cheung & Mak, 2016). However, a more recent study found only small bivariate 
relationships between PF overall and three sub-processes (cognitive fusion, self-as-context and 
committed action) and self-reported most recent CD4+ counts and intentional and unintentional non-
adherence to antiretroviral treatment in people with HIV (Harrison, Scott, Graham, & Harrison, 2019, 
unpublished). However, associations for intentional and unintentional non-adherence were no longer 
significant after controlling for relevant demographic and disease variables. Cross-sectional studies 
have three important weaknesses. First, they are correlational in nature, so it cannot be assumed that the 
relationship between PF, mood and adherence is causal and there might be potential for reverse 
causality, or that PF reflects a marker for a different variable, such as distress (Wolgast, 2014). Second, 
group-based designs lose important within-individual change in context. Therefore, a more robust 
approach would be to conduct a sufficiently powered longitudinal study to estimate the temporal 
relationships between PF, mood and adherence over time. Third, given the limitations of group-level 
designs in understanding adherence, the longitudinal study could also preliminarily validate new 
momentary measures against established measures for use in future diary-based studies.   
 
Two conceptual reviews have highlighted the applicability of PF and ACT as a potentially useful 
intervention to support health behaviour change more generally (Kashdan & Rottenberg, 2010; Zhang 
et al., 2017). In addition, three conceptual and one systematic review have also suggested that PF and 
ACT may have some utility in terms of improving adherence to treatment recommendations in the 
context of chronic pain (Harrison, Graham, & McCracken, 2017), adolescents with Type I diabetes 
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(Hadlandsmyth, Nesin & Greco, 2013), LTCs more generally (Graham et al., 2016) and psychosis 
(Moitra & Gaudiano, 2016; Spidel, Lecomte, Kealy, & Daigneault, 2018). All four reviews indicate 
few trials have specifically investigated the efficacy of ACT in improving adherence to prescribed 
medications in LTCs, and even fewer in child or adolescent populations. Two preliminary evaluations 
show ACT may improve adherence in LTCs, including reducing viral load and increasing CD4+ 
lymphocyte counts to highly active antiretroviral therapy in adults with HIV (Moitra, Herbert, & 
Forman, 2011) and increasing men’s attendance to intracavernosal injection therapy as part of an 
erectile dysfunction programme after radical prostatectomy compared to enhanced monitoring (Nelson, 
Kenowitz, & Mulhall, 2014). However, neither study measured PF at pre- and post-treatment, nor 
examined its role as a potential mediator of treatment effect.  
 
1.7 Need for validated momentary assessments of PF, mood and adherence  
 
As mentioned previously, a key problem with most adherence research is that studies rely on group-
based designs, which lose important individual differences, and self-report scales can often result in 
retrospective memory biases (Moskowitz & Young, 2006). Ecological Momentary Assessment (EMA) 
is an established real-time idiographic diary-based method that attempts to capture an individual’s 
representation of experience as it occurs within the context of everyday life (Hektner, Schmidt, & 
Csikszentmihalyi, 2007; Stone & Shiffman, 1994).  
 
In recent years, the psychology literature has seen a resurgence of interest in EMA methods due 
largely to increased availability of advanced smartphone technologies (Heron & Smyth, 2010; 
Leventhal, Phillips, & Burns, 2016; Runyan & Steinke, 2015). In the health context, a few studies have 
used EMA methods to examine relationships between constructs from social cognitive models and 
adherence outcomes in LTCs, demonstrating mixed results (Basen-Engquist et al., 2013; Bond et al., 
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2013). However, currently no studies have used EMA methods to explore relationships between PF, 
mood and adherence in people with LTCs specifically, despite reflecting a potentially more reliable 
way to examine their dynamic interactions over time (Moitra & Gaudiano, 2016).  
 
A principle advantage of EMA is the potential to examine relationships between variables in 
conjunction with relevant situations or events, or sudden changes in routine, such as going on holiday 
(Hektner et al., 2007), which for example may result in higher rates of unintentional non-adherence (de 
Klerk et al., 2003). Specifically, EMA can explore temporal relationships between PF and adherence 
time-series data in conjunction with the presence or absence of a given contextual variable/s (e.g. being 
on holiday or not), or the different levels of a given contextual variable (e.g. a weekend break, fortnight 
trip or longer). Therefore, using EMA could for the first time allow for a more valid and reliable 
examination of an individual’s daily or momentary patterns of adherence behaviour in relation to mood 
and PF across different contexts. 
 
An important challenge is that established group-based measures of adherence, mood and PF are not 
validated for use in EMA and other idiographic methods generally, and due to the high number of items 
may be too burdensome (Boorsbom, Mellenbergh, & Van Heerden, 2002). Therefore, ultra-brief 
momentary measures need to be developed with experts by experience and statistically validated to 
ensure they measure constructs accurately. Currently, there is little established guidance on validating 
momentary measures, but existing cross-sectional and EMA studies with large samples in chronic pain, 
social anxiety and healthy university students have preliminarily investigated the reliability, concurrent 
and predictive validity of new momentary measures of experiential avoidance (e.g., Kashdan et al., 
2014; Machell, Goodman, & Kashdan, 2015; Scott, unpublished, 2017) and cognitive fusion 
(Bolderston, Gillanders, Turner, Taylor, & Coleman, 2018). EMA multilevel analyses are powered on 
repeated measures within individuals, which means the number of participants required may be 
relatively small (Nezlek, 2001; 2003; 2007; 2008; 2012). However, a large number of participants and 
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repeated measurement is needed to reliably validate momentary measures in conjunction with 
established group-level measures that relies on large samples, which may not always be possible for 
rare LTCs or hard-to-reach groups. One way to circumvent this problem is to conduct a large 
longitudinal study to preliminarily validate new momentary measures of adherence, mood and the 
transdiagnostic PF processes against existing group-level measures in people with a range of LTCs. 
 1.8 Aims 
 
Given the challenges outlined, the overarching project aims to conduct a large three month online 
longitudinal study to assess the utility of PF model processes to improve prediction and inform novel 
intervention development for medication non-adherence in LTCs. A secondary aim is to develop and 
evaluate ultra-brief momentary measures of adherence and appointment attendance, mood and PF for 
the purpose of future EMA designs to further examine the applicability of PF in this area.  
 
The project has two objectives: 
 
1. Examine the extent to which PF processes measured using validated trait/group-level scales 
predict self-reported adherence to medication and appointment attendance in people with LTCs 
after accounting for demographic, illness and other contextual variables (e.g. age, gender, type 
of LTC, country of residence). 
 
2. Design and statistically validate new ultra-brief momentary self-report scales of PF, mood and 
medication adherence in conjunction with established trait/group-level measures and general 
functioning in people with LTCs.  
 
Findings for the secondary aim and objective will not be reported in the current thesis due to shortage 
of space but will written up for peer-reviewed publication after thesis submission. The methods section 
 43 
 
will include information related to the secondary aim to contextualise decisions made regarding the 
primary aim.  
 
The current study is therefore the first to examine cross-sectional and longitudinal relationships 
between established and new momentary measures of PF and self-reported intentional and unintentional 
non-adherence and percentage of routine appointments for illness attended outcomes in people with 
LTCs. Overall, the current project contributes to a growing body of research evaluating the potential 
utility of PF and ACT to better understand and treat non-adherence in people with LTCs. 
 
1.8.1 Study Hypotheses 
 
Based on the primary aim and objective above, the current study has two specific hypotheses: 
 
Cross-sectional data: 
 
1. Greater psychological inflexibility will be associated with poorer adherence and appointment 
attendance, independent of demographic and illness characteristics. Specifically, higher levels of 
psychological inflexibility will predict higher rates of intentional and unintentional non-
adherence and fewer routine appointments attended in the last three and twelve months. Greater 
psychological inflexibility will also be correlated with poorer general functioning. 
 
Longitudinal data: 
 
2. Greater psychological inflexibility will predict poorer adherence and appointment attendance in 
previously expected directions in hypothesis one, independent of demographic and illness 
characteristics. Greater psychological inflexibility will also be related to poorer general 
functioning over time. 
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Chapter 2: Method 
 
The first chapter highlighted the modest predictive power of existing psychological models as 
applied to treatment non-adherence in people with LTCs. It also indicated the potentially novel 
applicability of the Psychological Flexibility (PF) model in this context. The current chapter will 
summarise the proposed methods used in the project, which aims to (i) explore cross-sectional and 
longitudinal relationships between PF processes, self-reported adherence, mood and general 
functioning, and (ii) preliminarily validate novel momentary measures of PF, mood and medication 
adherence in conjunction with established group-level measures. 
 
2.1 Design 
 
The current study was an online longitudinal survey. A full pre-registration summary of the project 
can be found at the Centre for Open Science: 
https://osf.io/aste7/?view_only=df6a676512344b71a7dd373ae144f8c2 
 
2.3 Ethical clearance 
 
The study was approved by the Faculty of Medicine and Health Research Office School of Medicine 
Research Ethics Committee (SoMREC) in June 2018 (MREC17-068) (Appendix B). Informed consent 
was obtained online.  
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2.4 Participants and procedure 
 
All participants were asked to complete a battery of baseline self-report questionnaires, including 
established trait/group-based measures of PF, mood and adherence, along with corresponding new ultra-
brief momentary scales. Participants were also asked to complete questions about demographic and 
illness characteristics and general functioning. At three months, all participants were invited via email 
to repeat the same questionnaire battery (minus the demographic questions) to explore temporal 
relationships. The decision to follow-up participants at three months reflected a compromise between 
the primary and secondary aims, providing an opportunity to preliminarily assess psychometric 
properties of new momentary and established group-based scales over time. Specifically, it was 
assumed this timeframe provided the minimum amount of time required to capture any significant 
changes in established group-based scales, whilst allowing for detection of any subtle fluctuations in 
momentary/state scales. 
 
2.4.1 Eligibility criteria and recruitment 
 
All participants were recruited via international online advertisements on 441 LTC organisation 
websites, registries or patient groups and forums, Twitter feeds and Facebook pages after approaching 
relevant gatekeepers. Efforts were made to contact a range of organisations to recruit people with 
different LTCs according to an alphabetical list. The eligibility criteria for the online survey were (i) 
people with any type of LTC who are (ii) 13 years of age or over, and (iii) prescribed medication to 
manage their LTC. All participants were required to read the corresponding participant information 
sheets (Appendix C.1 to C.3) and sign the consent form electronically, including parents of adolescents. 
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2.4.2 Sample size  
 
No published studies have reported on direct predictors or correlates between established group-
level measures of PF and self-reported adherence and general functioning in LTCs. However, other 
psychological constructs from social cognitive models range from small to medium effect sizes in the 
context of adherence (Brandes & Mullan, 2014; Horne et al., 2013; Rich et al., 2015). Consistent with 
established rules of thumb (Green, 1991) and according to G*Power version 3.1.9.2. (Faul, Erdfelder, 
Buchner, & Lang, 2009; Faul, Erdfelder, Lang, & Buchner, 2007), at least n=92 participants were 
required to detect a moderate effect size of 0.15 (and n=647 for a small effect size of 0.02) to achieve 
80% power at a two-tailed alpha level of 0.05 using a multiple linear regression fixed model with R2 
increase, including seven demographic and disease variables, and five PF predictors. The latter was also 
sufficient for exploratory factor analyses (EFA) for the new 9- and reduced 3-item momentary PF scale 
baseline data based on a three or single-factor solution (Tabachnick & Fidell, 1996). It was also 
recommended that confirmatory factor analysis (CFA) for the 9- and reduced 3-item momentary PF 
scales follow-up data were run with at least n=200 participants (Brown, 2015).  
 
 
Based on attrition rates in similar prospective studies, we expected a conservative estimate of 40% 
attrition over 3-months (e.g., Banning, 2012; Carrieri et al., 2006; Golin et al., 2002). Therefore, 
assuming a medium effect size, 80% power and a 0.05 level of significance, a baseline sample size of 
at least n=154 participants (or n=1078 to detect a small effect) was needed to achieve sufficient power 
for the longitudinal analysis. 
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2.5 Established measures 
 
Two versions of the online longitudinal survey were launched, one for adults (Appendix D) and for 
adolescents (Appendix E). Therefore, different versions of validated scales for mood and PF in these 
populations were included (see Table 1). All authors were asked for their permission to use or adapt a 
modified version of their measure unless it was freely available. The online survey asked participants 
to complete the battery of questionnaires twice: once at baseline (0 months) and following one reminder 
email at 3 months follow-up.  
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Table 1: List of established and new non-validated self-report measures used in both the adolescent 
and adult versions of the online survey 
 
Measure 
 
Construct Reference 
Adolescent version 
Modified Work and social 
adjustment (WSAS) 
Modified version  
 
General functioning (Mundt et al., 2002) 
Medication Adherence 
Rating Scale 5 items 
(MARS-5) 
 
Medication adherence (Horne et al., 2001) 
New single-item momentary 
numerical rating scales 
(NRS) for daily and hourly 
self-reported adherence 
Momentary measure of 
medication adherence 
 
NA 
New single-item numerical 
rating scales (NRS) for 
percentage of attendance to 
appointments for LTC in 
last 2-3 and 12 months 
Health care utilisation / 
attendance 
NA 
Avoidance and Fusion 
Questionnaire for Youth 8 
items (AFQ-Y8) 
PF 
 
 
(Greco et al., 2008) 
 
Child and Adolescent 
Mindfulness Measure 
(CAMM) 
 
Mindfulness (Greco et al., 2011) 
New 9-item momentary 
measure of PF: Open, 
Aware, Engaged 
 
Momentary measure of PF  NA 
New single-item numerical 
rating scales (NRS) for 
percentage of attendance to 
appointments for LTC in 
last 2-3 and 12 months 
Health care utilisation / 
attendance 
NA 
 
Generalised anxiety 
Disorder Scale 7 items 
(GAD-7) 
 
Anxiety 
 
(Mossman et al., 2017) 
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Patient Health 
Questionnaire 8-items 
adolescent version  
(PHQ-8-A)  
Depression (Johnson et al., 2002) 
Modified Generalised 
anxiety Disorder Scale 2 
items (GAD-2) 
Momentary self-report 
measure of anxiety 
(Skapinakis, 2007) 
Modified Patient Health 
Questionnaire 2-items 
(PHQ-2) 
Momentary self-report 
measure of depression 
(Kroenke et al., 2003) 
Adult version    
Work and social adjustment 
(WSAS) 
General functioning (Mundt et al., 2002) 
Medication Adherence 
Rating Scale 5 items 
(MARS-5) 
 
Medication adherence (Horne et al., 2001) 
New single-item momentary 
numerical rating scales 
(NRS) for daily and hourly 
self-reported adherence 
Momentary self-report 
measure of medication 
adherence 
 
NA 
   
Acceptance and Action 
Questionnaire II (AAQ-II) 
 
PF 
 
(Bond et al., 2011) 
Comprehensive assessment 
of Acceptance and 
Commitment Therapy 
processes (CompACT) 
Self-report measure of three 
facets of PF 
(Francis, Dawson, & 
Golijani-Moghaddam, 
2016) 
New 9-item momentary 
measure of PF: Open, 
Aware, Engaged 
 
Momentary measure of PF  NA 
Patient Health 
Questionnaire 8-items 
(PHQ-8)  
Group-based self-report 
measure of mood / 
emotional functioning 
(Kroenke et al., 2009) 
 
Generalised anxiety 
Disorder Scale 7 items 
(GAD-7) 
 
Group-based self-report 
measure of mood / 
emotional functioning 
 
 
 
(Spitzer et al., 2006) 
   
Modified Generalised 
anxiety Disorder Scale 2 
items (GAD-2) 
Momentary self-report 
measure of anxiety 
(Skapinakis, 2007) 
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Modified Patient Health 
Questionnaire 2-items 
(PHQ-2) 
Momentary measure of 
depression 
(Kroenke et al., 2003) 
 
 
2.5.1 Demographic and disease variables 
 
All participants were asked to report their age, ethnicity, gender, education level, and employment 
and relationship status, and time since diagnosis, which were entered as covariates if related to 
adherence outcomes at the bivariate level.  
 
 
2.5.2 Established psychological flexibility scales  
 
Two validated PF scales for adults were included: 
 
1. The Acceptance and Action Questionnaire (AAQ-II) (Bond et al., 2011) is a broad measure of 
PF based on the Acceptance and Action Questionnaire (AAQ) (Hayes et al., 2004).  Items 
include statements such as, “My painful experiences and memories make it difficult for me to 
live a life that I would value” or “Emotions cause problems in my life”, using a scale from 1 
(“never true”) to 7 (“always true”). The AAQ-II is scored as a total sum score of all 7-items. 
Bond et al. report the AAQ-II has improved validity and reliability=.84; test–retest reliability 
α=.81 and .79) compared to its predecessor and is the most widely used measure of PF. 
However, recent evidence suggests that the AAQ-II may be tapping a measure of generalised 
distress (Wolgast, 2014) and may not adequately assesses all six PF processes.  
 
Given these challenges, an additional PF scale was included to assess the previously defined “open, 
aware, and engaged” facets summarised in Chapter 1 (Hayes et al., 2011): 
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2. The Comprehensive assessment of Acceptance and Commitment Therapy processes 
(CompACT) Scale (Francis et al., 2016) is a relatively recent 23-item measure of PF, 
comprising Openness to Experience (OE), Behavioral Awareness (BA) and Valued Action 
(VA) subscales that map directly onto the new 9-item momentary PF scale of “Open, Aware, 
Engaged”. After reversing 12 items, scores are derived by summing responses for the Openness 
to Experience, Behavioral Awareness and Valued Action subscales, where higher scores 
represent greater PF. The three subscales can also be added together to derive the total 
CompACT score. Based on an email communication with the last author (Appendix F) both the 
summed and mean scores (accounting for 20% of missing items) were calculated. The scale 
demonstrated good internal consistency (α=.87 to .90), and convergent and divergent validity. 
However, currently there is no longitudinal data supporting the test-re-test reliability of the 
CompACT.  
 
 
Two validated PF scales for adolescents were included: 
 
1. The Avoidance and Fusion Questionnaire for Youth 8-items (AFQ-Y-8) (Greco, Lambert, & 
Baer, 2008) is a broad measure of PF based on the Acceptance and Action Questionnaire (AAQ) 
(Hayes et al., 2004). Items include statements such as, “My life won’t be good until I feel happy” 
or “I stop doing things that are important to me whenever I feel bad” using a 0 (“not true at 
all”) to 4 (“very true”) point scale. The AFQ-Y-8 is scored as a total sum score of all 17-items, 
where higher scores represent greater avoidance and cognitive fusion. Greco et al. (2008) show 
the AFQ-Y-8 has adequate validity and reliability (α=.89) when evaluated in a random sample 
of youths who on average were 12.6 years old.  
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2. The Child and Adolescent Mindfulness Measure (CAMM) (Greco, Baer, & Smith, 2011) was 
used to measure present-moment awareness and nonjudgmental, nonavoidant responses to 
thoughts and feelings, which reflects acceptance, present moment awareness, self-as-context 
and defusion processes within the PF model. The CAMM was designed for children of ages 9 
upwards, with items including “I get upset with myself for having feelings that don’t make 
sense” or “It’s hard for me to pay attention to only one thing at a time” on 0 (“never true”) to 
4 (“always true”) point scale. After reversing all scores, the CAMM  is scored as a total sum 
score of all 17-items, where higher scores correspond to greater levels of mindful awareness. 
The CAMM has adequate validity and reliability (α=.77).  
 
2.5.6 Established adherence scale 
 
A recent review shows several self-report instruments for adherence have been developed (Nguyen 
et al., 2014), but most assess beliefs or barriers rather than aspects of medication-taking behaviour per 
se, and even fewer provide information on their psychometric properties. The most well-validated 
adherence measure is the Morisky-8 (Morisky, Green, & Levine, 1986). However, unfortunately the 
developers of the Morisky-8 charge a fee to use this questionnaire, and the project had insufficient funds 
to purchase the rights to use the scale for the current online study. In addition, similar to most other 
self-report instruments, the Morisky-8 does not distinguish between intentional and unintentional non-
adherence. 
 
The Medication Adherence Report Scale 5-item scale (MARS-5) was therefore selected to assess 
self-reported intentional and unintentional non-adherence to medication (Horne, Hankins, & Jenkins, 
2001). The MARS-5 includes wording that attempts to reduce social pressure to avoid inflated reports 
of adherence with five statements that does not specify a timeframe, e.g. “I forget to take my 
medication” or “I adjust the dosage of my medication”, using a 5-point scale: 5 (“never”), 4 (“rarely”), 
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3 (“sometimes”), 2 (“often”), 1 (“very often”). Four items measure intentional and one unintentional 
non-adherence. Following a pragmatic approach used in previous studies with other LTCs (de Vries et 
al., 2014; Moon, Moss‐Morris, Hunter, & Hughes, 2017), the total score and intentional and 
unintentional subscale scores were dichotomised because the distribution was significantly negatively 
skewed. Specifically, adherence was conservatively defined as a total score of 25 (i.e. 100%). Based on 
previous studies (Daleboudt, Broadbent, McQueen, & Kaptein, 2011; de Vries et al., 2014; Moon et al., 
2017; Timmers et al., 2014), participants were categorised as unintentionally non-adherent if they 
scored <5 on the single-item subscale, and intentionally non-adherent if they scored <20 on the four-
item subscale. 
 
The MARS-5 is based on the original MARS and MARS-9 (Horne & Weinman, 2002), which were 
derived from the Drug Attitude Inventory (DAI) (Thompson, Kulkarni, & Sergejew, 2000), and have 
both been used with mixed success to assess adherence in a range of LTCs (Salt, Peden, & Horne, 
2012). The clinician administered version of the MARS-5 shows unacceptable levels of sensitivity with 
pharmacy records in people taking blood-pressure-lowering drugs in a primary care (Van De Steeg, 
Sielk, Pentzek, Bakx, & Altiner, 2009). However, the patient self-report version of the MARS-5 shows 
good internal reliability and test-retest reliability (α=0.83) (Horne et al., 2001). It has been used in a 
variety of LTCs, including patients with breast cancer (Boonstra et al., 2013; Grunfeld, Dhesy-Thind, 
Levine, Care, & Cancer, 2005), COPD (George, Kong, Thoman, & Stewart, 2005) and inflammatory 
bowel disease (Ediger et al., 2007). 
 
Few studies have evaluated the validity of the MARS-5, but those that have found moderate to strong 
convergent validity with other scales and adequate internal consistency (α=.77) (e.g., rheumatoid 
arthritis: Salt, Hall, Peden, & Home, 2012). Salt et al.’s (Salt, et al., 2012) review indicates there are 
mixed findings for correlations between the MARS-5 and more objective adherence measures. 
Specifically, the MARS-5 is significantly associated with continuous electronic adherence (r=.42, 
p=.001) in asthma patients. However, it has also been shown to have a small association with medication 
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refill adherence, with low sensitivity (13%) and specificity (94%), and positive predictive values (57%) 
in people with COPD (Tommelein, Mehuys, Van Tongelen, Brusselle, & Boussery, 2014). Beyond the 
LTC literature, the MARS-5 has demonstrated strong correlations with health care professional scores 
(r=.50) and serum concentration of prescribed medication (r=.52) in people diagnosed with 
schizophrenia or bipolar disorder (Jónsdóttir et al., 2010). When set against serum concentration the 
MARS-5’s sensitivity (98%) and negative predictive value (89%) were good, but specificity was poor 
(33%). Although the MARS-5 has not yet been validated in many LTC samples, established self-report 
adherence scales do not distinguish between intentional and unintentional non-adherence. 
 
2.5.8 Established mood scales 
 
The Patient Health Questionnaire 8-items (PHQ-8) (Kroenke, Strine, et al., 2009) and adolescent 
version (PHQ-8-A), taken from the previous 9-item PHQ-A (Johnson, Harris, Spitzer, & Williams, 
2002), assessed self-reported symptoms of depression. The PHQ-8 was used instead of the PHQ-9 to 
avoid causing distress from the PHQ-9’s item asking about thoughts about suicide. This was felt to be 
important in the context of an online survey, where it will not always be possible to fully address risk 
related to this disclosure, particularly if the person does not share identifiable information or is based 
outside of the UK. The PHQ-8 is scored as a total sum score of all 8-items, where higher scores 
correspond to higher levels of depression. The established cut-point of ≥10 on the PHQ-8 was applied, 
with sensitivity and specificity for major depressive disorder 100% and 95% respectively, whilst any 
depressive disorder was 70% and 98% respectively (Kroenke, Strine, et al., 2009). The PHQ-A 
sensitivity and specificity for major depression was 73% and 94% respectively, whilst for any mood 
disorder was 61% and 94% (Johnson et al., 2002). 
 
The Generalised Anxiety Disorder Scale 7-items (GAD-7) was used to estimate self-reported anxiety 
(Mossman et al., 2017; Spitzer, Kroenke, Williams, & Löwe, 2006). Both the PHQ-8 and GAD-7 use 
 55 
 
the same scale: 0 (“Not at all”), (1) “Several days”), 2 (“More than half the days”) and 3 (“Nearly every 
day”). The GAD-7 is scored as a total sum score of all 7-items, where higher scores correspond to higher 
levels of anxiety. The established cut-point of ≥10 on the GAD-7 was applied, showing good sensitivity 
(89%) and specificity (82%) (Spitzer et al., 2006). Similarly, the PHQ-8 and PHQ-8-A are also most 
optimal with a cut-point of ≥10, demonstrating satisfactory psychometric properties with sensitivity 
ranging from 70% and specificity 98%. 
 
2.5.10 Established and modified general functioning scales 
 
The Work and Social Adjustment Scale (WSAS) examined the extent to which a person’s LTC 
interferes with everyday life (Mundt, Marks, Shear, & Greist, 2002). Other scales of general functioning 
for adolescents were explored (e.g., Adams, Streisand, Zawacki, & Joseph, 2002; Varni, Burwinkle, 
Seid, & Skarr, 2003; Wardenaar et al., 2013), but were either too burdensome, costly or had subscales 
that did not obviously reflect items in the WSAS. The WSAS has not been validated in adolescent 
samples with LTCs, and therefore the language of items was modified to take this into account to reflect 
the WSAS for adolescents (WSAS-A), e.g. “Because of my illness my social leisure activities (with 
other people e.g. [parties, outings, visits, dating, having people over]) are [badly affected]” or “Because 
of my illness, my private leisure activities (done alone, such as [reading, playing, walking alone]) are 
[badly affected]” (Appendix E). This aimed to provide an estimate of whether PF predictor variables 
were significantly associated with self-reported adherence but also illness-related functioning. The 
WSAS is scored as a total sum score of all 4-items, where higher scores correspond to greater 
impairment of functioning 
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2.6 Development of new momentary measures 
 
New momentary measures of PF, adherence and mood were developed and included as part of the 
battery of questionnaires completed at baseline and three months. 
 
2.6.1 Experts by experience involvement   
 
The development of the novel PF measures in this study incorporated feedback from experts with 
lived experience of LTCs. To our knowledge, few existing PF measures have been developed 
incorporating feedback from expert service-users by experience and/or representatives.  Therefore, 
consistent with the available guidance for the development and use of patient-reported outcome 
measures (FDA, 2006; Snyder et al., 2012; Wild et al., 2005), three adults and two adolescents with 
different LTCs (inflammatory bowel disease, multiple sclerosis, chronic constipation, an endocrine 
disorder and a traumatic brain injury) provided feedback on the participant information sheet and battery 
of questionnaires overall. Gaining expert by experience feedback on the new hourly and daily 
momentary measures of PF initial item pool comprising 22 statements enabled the author to establish 
whether items on the questionnaire were interpreted as intended or had face validity. In addition, experts 
were asked to rank the 22-items to indicate which were the most important and understandable to them 
(Appendices G and H) and were paid £25 in gift vouchers to thank them for their time. 
 
Based on this feedback, the 22-item momentary measure of PF was reduced to an initial 9-item scale. 
The scale was further reduced to 3-items based on established exploratory and confirmatory factor 
analyses. All experts by experience felt that the wider survey and 22-item PF momentary scale had little 
potential for causing distress and participant burden of the overall questionnaire was minimal. 
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2.6.2 New momentary scales of psychological flexibility 
 
All participants completed the new hourly and daily momentary 9-item PF scales described above 
at baseline and 3-months follow-up, which aimed to capture psychological inflexibility and the inverse 
of the three ‘Open, Aware, Engaged’ sub-processes, namely ‘Closed, Unaware, Disengaged”. Some of 
the items were drawn from existing PF group-level and momentary scales with author’s permission 
(Greco et al., 2011; Kashdan et al., 2013; Kashdan et al., 2014; Machell et al., 2015). The scale was 
further reduced to 3-items based on the baseline EFA results, informing items selected for the CFA 
within the follow-up data analysis. The initial 9-item scale included items such as “Today / Within the 
last hour or so… I struggled to control my thoughts or feelings” (Closed), “I found it difficult to stay 
focused on what was happening in the present” (Unaware) or “I stopped doing things that were 
important to me when I felt bad.” (Disengaged) using a 0 (“not at all”) to 10 (“very much”) scale (see 
Appendices D and E).  
 
2.6.3 New momentary adherence scale  
 
 
A review of adherence measures suggests using multiple methods to assess adherence to medication 
due to limitations of self-report scales (Bond, 2016). In addition, treatment recommendations can extend 
beyond simply prescribing medication, and although more established scales are relatively short, few 
have been developed for use in EMA studies. Although several reviews summarise guidance or criteria 
on how to develop new adherence measures (Garfield et al., 2011; Lam & Fresco, 2015; Stirratt et al., 
2015), few provide guidance on developing ultra-brief momentary scales specifically. 
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Two novel single-item momentary numerical rating scales (NRS) for self-reported hourly and daily 
adherence to medication were developed: “In the past hour / Today, how good have you been at taking 
your medications for your illness on time and as prescribed?” ranging from 0 (“not good at all”) to 10 
(“extremely good”). The new scales do not separate intentional or unintentional non-adherence, since 
it is assumed PF has the potential to influence both. 
 
In addition, two new single-item NRS asking about the participant’s percentage of attendance to 
routine clinical appointments in the last 2 to 3 and 12 months were also included as a key outcome: “In 
the last two to three months / In the last year, what percentage of routine appointments for your illness 
have you attended?” on a 0 to 100% scale.  
 
2.6.4 New momentary mood scales 
 
In addition to PF and adherence, two new momentary NRS for self-reported mood and anxiety were 
also included (Appendices D and E). With permission of the authors, a modified version of the GAD-2 
(Skapinakis, 2007) and PHQ-2 (Kroenke, Spitzer, & Williams, 2003) for momentary assessment were 
preliminarily evaluated. Changes pertaining to timeframe include, “Today / over the last hour or so how 
often have you been bothered by the following problems?” ranging from 0 (“Not at all”) to 3 (“Very 
much”), both with a cut-point of ≥3. The GAD-2 demonstrates acceptable levels of sensitivity (92%) 
and specificity (76%) in the context of primary care, whilst the PHQ-2 performs less well at 62% and 
95%, respectively. 
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2.7 Analysis   
 
Four adolescents completed the online survey but only one provided consent, therefore only the adult 
sample were included in the following analyses to address the primary aim/objective. Analyses 
pertaining to the secondary aim, including exploratory and confirmatory factor analyses, internal 
consistency and test-re-test reliability statistics for the new 9- and 3-item PF scales are not reported 
here.  
 
Continuous variables from the baseline and follow-up data were checked for kurtosis and skewness 
parameters to identify violations of normality according to established guidance (George & Mallery, 
2010) and internal consistencies were assessed. Confirmatory Factor Analyses (CFA) were conducted 
using Mplus version 7 (Muthén & Muthén, 2006) to test previously identified or hypothesised factor 
structures of established PF, mood and adherence scales at baseline. Given the large sample size and 
ordinal nature of the data, the Diagonally Weighted Least Squares (WLSMV) estimator was used for 
normally distributed measures, whilst Maximum Likelihood estimation with Robust standard errors 
(MLR) was used for the non-normal MARS-5 (Li, 2016). There are various methods of assessing model 
or absolute fit. However, the Root Mean Square Error of Approximation (RMSEA), Tucker Lewis 
Index (TLI), Comparative Fit Index (CFI) and Standardized Root Mean Square Residual (SRMR) are 
recommended (Brown, 2015; Jackson, Gillaspy, & Purc-Stephenson, 2009). According to Hu and 
Bentler (Hu & Bentler, 1999), RMSEA values <0.06, TLI/CFI values of >0.95 and SRMR values of 
<.08 indicate acceptable model fit. For categorical data, the less commonly reported Weighted Root 
Mean Square Residual (WRMR) with a value of >1 indicate acceptable model fit (DiStefano, Liu, Jiang, 
& Shi, 2018). 
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Pearson’s r correlations, t-tests and Chi2 tests (or non-parametric equivalents, including Pearson’s 
biserial correlations pb for continuous variables) were used to examine:  (i) differences between 
validated continuous and dichotomous outcome variables in relation to participant demographics (e.g. 
age, gender, ethnicity) and illness characteristics (e.g. time since diagnosis); and (ii) PF measures in 
relation to adherence, routine appointment attendance, anxiety and depression and general functioning 
at baseline to assess criterion validity. Convergence between adherence and attendance measures at 
baseline was also assessed. Separate multiple binomial logistic regression analyses were conducted to 
assess baseline relationships between PF predictors and intentional and unintentional non-adherence 
and routine appointment attendance outcome variables. Baseline demographic and disease variables 
showing a significant bivariate relationship with non-adherence at baseline were entered in the first step 
of the regressions. Validated PF measures formed the predictors in the second step. Standard p<.05 
criteria were applied to all statistical analyses.  
 
Predictive validity was assessed by examining Pearson’s r or pb between validated PF, emotional 
and general functioning scales at baseline in relation to adherence outcomes at three months follow-up. 
Test-retest validity of all measures were calculated using Intra-class correlations (ICC) to determine if 
participants’ responses were consistent over time, assessing the reliability of the scales. ICC values vary 
between of 0 and 1, where the latter indicates perfect reliability. According to established guidance for 
95% confidence intervals values less than 0.5=poor, between 0.5 and 0.75=moderate, 0.75 and 
0.9=good, and greater than 0.90=excellent (Koo & Li, 2016). 
 
Finally, separate multiple binomial logistic regression analyses were conducted to assess baseline 
and longitudinal relationships between PF predictors and intentional and unintentional non-adherence 
and routine appointment attendance outcome variables. Baseline demographic and disease variables 
showing a significant bivariate relationship (p<.05) with non-adherence were entered in the first step. 
PF processes were entered in the following step to assess their association with adherence after 
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demographic and disease variables were accounted for. The proportion of explained variance in these 
models were assessed using Nagelkerke R2 (pseudo R2). The -2 Log Likelihood statistic (-2LL) assessed 
model fit. Specifically, lower -2LL values indicate superior model fit, such that if adding variables in 
each step reduces the -2LL value, they have improved the model fit as represented by a non-significant 
(p>.05) Hosmer and Lemeshow Chi2 Test value. Diagnostic checks, including checking residuals 
(Cook’s distance and Leverage hat values), outliers (standardised residuals and DFBeta), linearity of 
the logit (check predictor by In*(predictor interaction) and multicollinearity (linear regression 
collinearity VIF and tolerance values), were conducted to confirm the validity of all regression models 
following established guidelines (Field, 2013). All analyses were conducted using SPSS Version 24 
(IBM Corp., New York). 
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Chapter 3: Results 
 
Between June and December 2018 N=709 people with LTCs, including n=4 adolescents and n=705 
adults, currently prescribed medications for their illness completed the online baseline survey hosted 
by Online Surveys. Seven cases were excluded for the following reasons: not prescribed medication/s 
for their LTCs (n=2), LTC was mental health problem (n=2), adolescents who did not get parental 
consent (n=3). Therefore, given that only one adolescent had usable data, only the adult data (n=701) 
were analysed and reported in the following sections. 
3.1 Baseline analyses 
3.1.1 Demographic and disease characteristics of overall sample 
 
Participants (N=701) were predominantly white-Caucasian (97.0%) and female (73.0%), on average 
in their mid-fifties (M= 54.93, SD= 15.81), with most responders from the UK (92.7%). Thirty-eight 
percent were retired, 10.8% medically retired, 19.4% in full- and 12.6% part-time employment, 5.0% 
self-employed, 3.3% full/part-time students, 3.4% homemakers and 2.9% unemployed, whilst 4.5% 
selected “other” status. Fifty-nine percent were married or in a civil partnership, 10.4% cohabiting, 
3.1% widowed, 8.3% separated/divorced, 18.4% single, whilst 0.6% indicated “other” status. Forty-one 
percent of participants were diagnosed with Parkinson’s disease and 57.3% reported having more than 
one LTC. Participants on average reported they were diagnosed with their primary LTC for M=8.65 
(SD=10.08) years, experienced mild levels of anxiety and depression, and fell within the ‘normal 
subclinical populations’ range in terms of general functioning (Table 2).  
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3.1.2 Descriptive statistics of measures 
 
As shown in Table 2, The MARS-5 total sum score, MARS-5 total mean item score adjusted (with 
less than 20% missing items) and intentional non-adherence subscale were all significantly negatively 
skewed, but the unintentional sub-scale score distribution was normal. Therefore, established binary 
cut-offs for the MARS-5 total and subscale scores were used in all analyses. All measures showed 
Means/SDs that were largely consistent with the measure validation studies (Bond et al., 2011; Francis 
et al., 2016; Jónsdóttir et al., 2010; Kroenke, Spitzer, Williams, & Löwe, 2009; Mundt et al., 2002; 
Spitzer et al., 2006). 
  
Self-reports of attendance to routine clinical appointments in the last 2-3 months and 12 months 
using the single-item NRS were also significantly negatively skewed. Therefore, ‘near perfect’ binary 
cut-offs modelled on the MARS-5 were applied in all analyses (see adherence and attendance 
convergence rates in section 3.1.5). The number of participants completing the 2-3- and 12-month 
appointment attendance NRS were lower than the MARS-5 because many people indicated these 
timescales were not applicable. To preserve statistical power, all cases (including any with missing 
items) were used to calculate summed scores and variances for each of the psychological scales. As 
shown in Table 2, the variances were checked against those calculated with 20.0 to 25.0% of missing 
data, depending on the number of scale items to explore if there were any clear differences. Missing 
data was remarkably low, and few obvious differences were identified, therefore summed scores were 
used in all analyses. 
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Table 2: Baseline descriptive data for all measures in the adult sample  
Measure n Mean  
(SD) 
Skewness 
(SE) 
Kurtosis 
(SE) 
Reliability 
Cronbach α 
Adherence and attendance      
MARS-5 total sum score   697 21.01 (4.02) -1.93 (.09)* 4.89 (.18) .77 
MARS-5 total mean item 
score adjusted (<20% of 
missing items) 
683 4.27 (.66) -1.33 (.09)* 1.77 (.18)  
MARS-5 Intent sum score 693 17.29 (3.29) -1.70 (.09)* 3.39 (.18)  
MARS-5 Unintent sum 
score 
692 3.85 (.89) -.44 (.09) -.28 (.18)  
Single item appointment 
attendance in last 2-3 
months NRS (%) 
592 91.80 (24.70) -3.13 (.10)* 8.37 (.20) NA 
Single item appointment 
attendance in last 12 
months NRS (%) 
680 94.82 (16.72) -4.21 (.09)* 18.44 ( .18) NA 
Functioning  
  
  
WSAS total sum score 701 16.97 (10.99) .26 (.09) -.95 (.18) .93 
Mood      
PHQ-8 total sum score 699 8.94 (6.26) .58 (.09) -.58 (.18) .89 
PHQ-8 total mean item 
score adjusted (<25% of 
missing items) 
699 1.12 (.78) .57 (.09) -.60 (.185)  
GAD-7 total sum score 699 6.56 (5.86) .88 (.09) -.23 (.18) .92 
GAD-7 total mean item 
score adjusted (<25% of 
missing items) 
699 .93 (.83) .87 (.09) -.23 (.18)  
Psychological flexibility processes 
AAQ-II total sum score 700 20.61 (10.62) .54 (.09) -.56 (.18) .94 
AAQ-II total mean item 
score adjusted (<25% of 
missing items) 
700 2.94 (1.15) .54 (.09) -.56 (.18)  
CompACT total sum score 700 81.02 (21.38) -.18 (.09) -.61 (.18) .88 
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CompACT total mean item 
score adjusted (<25% of 
missing items) 
699 3.75 (1.01) -.11 (.09) -.59 (.18)  
OE subscale sum score 700 34.03 (11.90) .07 (.09) -.64 (.18) .82 
OE mean item score 
adjusted (<25% of missing 
items) 
693 3.44 (1.18) .06 (.09) -.66 (.18)  
BA subscale sum score 700 16.37 (6.15) -.37 (.09) -.39 (.18) .79 
BA mean item score 
adjusted (<25% of missing 
items) 
697 3.50 (1.43) -.15 (.09) -.66 (.18)  
VA subscale sum score 700 30.61 (7.63) -.72 (.09) .20 (.18) .85 
VA mean item score 
adjusted (<25% of missing 
items) 
698 4.38 (1.09) -.75 (.09) .27 (.18)  
*Non-normal distribution 
Adherence measures: MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and 
<25 ‘non-adherent’); MARS-5 Intent (Medication Adherence Rating Scale five items intentional non-adherence 
subscale score: 20=’adherent’ <20=’non-adherent’); MARS-5 Unintent (Medication Adherence Rating Scale five 
items unintentional non-adherence subscale score: 5=’adherent’, <5=’non-adherent’). 
Attendance measures: <100% appointment attendance in last 2-3/12 months NRS (%) (Single item appointment 
attendance in last 2-3/12 months Numerical Rating Scale percentage, binary cut-offs: 100%=adherent; 
<100%=non-adherent).  
Mood and functioning: PHQ-8 (Patient Health Questionnaire 8-items: 0-4 ‘No significant depressive 
symptoms’, 5-9 ‘mild depressive symptoms’, 10-14 ‘moderate depressive symptoms’, 15-19 ‘moderately severe 
depressive symptoms’, 20-24 ‘severe depressive symptoms’; GAD-7 (Generalised Anxiety Disorder 7-items: 0-
4 ‘Minimal’, 5- 9‘Mild’, 10-14 ‘Moderate’, 15-22 ‘Severe’; WSAS (Work and Social Adjustment Scale: 0-9 
‘Normal subclinical populations’, 10-19 ‘Normal subclinical populations’, 20-40 ‘moderately severe or worse 
psychopathology’). 
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT total 
(Comprehensive assessment of Acceptance and Commitment Therapy processes total sum score); CompACT 
total BA (CompACT Behavioral Awareness subscale) CompACT total OE (CompACT Openness to Experience 
subscale); CompACT total VA (CompACT Valued Action subscale). 
 
 
All confirmatory factor analyses of established measures are presented in Appendix I). In summary, 
most scales met at least two of the four absolute goodness of fit indices, indicating acceptable construct 
validity. However, the MARS-5 only met one of these indices, indicating the underlying single factor 
structure tested was not a good fit with the data overall. Additionally, the CompACT was tested for 
both three and single factor solutions, but also only met the WRMR goodness of fit criteria. Both 
measures showed a small proportion of items factor loadings ranged from .7 to .9, therefore underlying 
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constructs identified in previous validation studies did not extend to the current sample and therefore 
interpretations should be tempered with caution. 
 
3.1.3 Demographic and disease characteristics for adherent and non-adherent 
subgroups 
 
According to the MARS-5 cut-offs 88.6% of the sample were non-adherent. Of those, 74.8% were 
intentionally non-adherent, whilst 84.3% were unintentionally non-adherent (Table 3). As shown in 
Table 3, there was a significantly larger proportion of non-adherers from the UK compared to other 
countries. Non-adherers reported significantly more years living with their primary LTC and worse 
general functioning and depression compared to adherers. However, there were no differences in levels 
of anxiety and any other demographic and disease variables.  
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Table 3: Participant characteristics according to MARS-5 cut-offs (n=699) 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=80, 11.4%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=619, 88.6%) 
p value 
Mean age (SD) 57.08 (12.92) 54.57 (16.10) .181 
Gender (%) 
Female 
Male 
Other (“Non-binary”)  
 
53 (67.1) 
26 (32.9) 
0 
 
456 (74.1)  
158 (25.7) 
1 (0.9) 
.172 
Country (%) 
UK  
Non-UK 
 
69 (86.3)  
11 (13.8) 
 
579 (93.7) 
39 (6.3) 
.013 
White ethnicity (%)  77 (96.3) 598 (97.1) .694 
Mean education years (SD) 16.24 (3.28) 16.59 (3.59) .455 
Employment status (%) 
Full time  
Part time  
Self-employed 
Homemaker 
Retired 
Medically retired  
Unemployed 
Full/part-time student 
Other 
 
14 (17.5) 
11 (13.8) 
7 (8.8) 
1 (1.3) 
28 (35.0) 
8 (10.0) 
2 (2.5) 
3 (3.8) 
6 (7.5) 
 
121 (19.7) 
77 (12.5) 
29 (4.7) 
23 (3.7) 
234 (38.1) 
67 (10.9) 
18 (2.9) 
20 (3.3) 
25 (4.1) 
.406 
Relationship status (%) 
Single 
Married or civil 
partnership 
Separated or divorced 
Cohabiting 
Widowed  
Other 
 
9 (11.3) 
58 (72.5) 
 
9 (11.3) 
1 (1.3) 
2 (2.5) 
1 (0.1) 
 
119 (19.3) 
355 (57.4) 
 
49 (7.9) 
72 (11.7) 
20 (3.2) 
3 (0.4) 
.397 
Mean years since diagnosis 
(SD) 
6.60 (8.67) 8.84 (10.02) .058 
More than one LTC (%) 39 (48.8) 359 (58.5) .099 
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Mean Depression PHQ-8 
(SD) 
7.10 (6.26) 
 
9.18 (6.25) <.0110 
Mean Anxiety GAD-7 (SD) 5.87 (6.10) 6.65 (5.82) .2611 
Functioning WSAS 12.38 (11.04) 17.57 (10.83) <.0112 
Intentionally  
non-adherent MARS-5 (%) 
NA  460 (74.8) NA 
Unintentionally non-
adherent MARS-5 (%) 
NA 516 (84.3) NA 
<100% appointment 
attendance in last 2-3 
months NRS (%) 
6 (9.1) 84 (16.0) NA 
<100% item appointment 
attendance in last 12 
months NRS (%) 
7 (9.1) 105 (17.5) NA 
Adherence measures: MARS-5 (Medication Adherence Rating Scale five items total score: 
25=‘adherent’ and <25 ‘non-adherent’); MARS-5 Intent (Medication Adherence Rating Scale five items 
intentional non-adherence subscale score: 20=’adherent’ <20=’non-adherent’); MARS-5 Unintent 
(Medication Adherence Rating Scale five items unintentional non-adherence subscale score: 
5=’adherent’, <5=’non-adherent’). 
Attendance measures: <100% appointment attendance in last 2-3/12 months NRS (%) (Single item 
appointment attendance in last 2-3/12 months Numerical Rating Scale percentage, binary cut-offs: 
100%=adherent; <100%=non-adherent).  
Mood and functioning: PHQ-8 (Patient Health Questionnaire 8-items: 0-4 ‘No significant depressive 
symptoms’, 5-9 ‘mild depressive symptoms’, 10-14 ‘moderate depressive symptoms’, 15-19 
‘moderately severe depressive symptoms’, 20-24 ‘severe depressive symptoms’; GAD-7 (Generalised 
Anxiety Disorder 7-items: 0-4 ‘Minimal’, 5- 9‘Mild’, 10-14 ‘Moderate’, 15-22 ‘Severe’; WSAS (Work 
and Social Adjustment Scale: 0-9 ‘Normal subclinical populations’, 10-19 ‘Normal subclinical 
populations’, 20-40 ‘moderately severe or worse psychopathology’). 
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT 
total (Comprehensive assessment of Acceptance and Commitment Therapy processes total sum score); 
CompACT total BA (CompACT Behavioral Awareness subscale) CompACT total OE (CompACT 
Openness to Experience subscale); CompACT total VA (CompACT Valued Action subscale). 
Statistical analyses: 1t(697)=1.33, p=.18, 95% CI=-1.17,6.18 two-tailed; 2Male versus female as too few 
expected counts for “other”: 2(1, 693)=1.85, p=.17; 32(1, 698)=5.89, p<.01; 4White versus everything 
else (as too few expected counts for other groupings): Likelihood ratio(1, 696)=.15, p=.69); 5t(514)=-
.74, p=.45, 95% CI=-1.29,.58 two-tailed; 6’Working/in education’ versus ‘everything else’ (as too few 
expected counts for other): 2(1, 640)=.70, p=.40; 7‘In a relationship’ versus ‘not in a relationship’ (as 
too few expected counts for ‘other’): 2(1, 698)=.72, p=.39; 8t(689)=-1.91, p=.05, 95% CI=-4.55,.06 two-
tailed; 92 (1, 694)=2.73, p<.09; 10t(695)=-2.78, p=<.01, 95% CI=-3.55,-.61 two-tailed; 11t(695)=-1.11, 
p=.26, 95% CI=-2.15,.59 two-tailed; 12 t(697)=4.02, p=<.01, 95% CI= -7.72,-2.65 two-tailed. 
 
 
Table 4 provides a summary of primary LTCs reported by participants in the online sample (for a 
more detailed summary of LTCs see Appendix J). There was no significant association between the 
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proportion of people with Parkinson’s disease who were adherent and non-adherent compared with all 
other LTCs. 
 
Table 4: Primary LTC types of the sample across MARS-5 cut-offs (n=695) 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=80, 11.5%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=617, 88.5%) 
p value 
Parkinson’s Disease vs.  
All other LTCs (%) 
36 (45.0) 
44 (55.0) 
250 (40.6) 
366 (59.4) 
.451 
 
Type of LTC by ICD-11 disease category   
Allergies 1 (1.3) 3 (0.5)  
Autoimmune 20 (25.0) 157 (25.4)  
Birth defect  0 2 (0.3)  
Cancers (all types) 3 (3.8) 9 (1.5)  
Cardiovascular/Circulatory 7 (8.8) 39 (6.3)  
Endocrine 0 18 (2.9)  
Genitourinary 0 2 (.03)  
Hereditary 0 29 (4.7)  
Immunodeficiency 6 (7.5) 11 (1.8)  
Infectious 0 2 (.03)  
Inflammatory 1(1.3) 18 (2.9)  
Neurodegenerative 41 (51.3) 263 (42.6)  
Neurology other 0 1 (0.2)  
Trauma/injury 0 6 (0.9)  
Other conditions 1 (1.3) 55 (8.9)  
LTC not reported 0 2 (.3)  
Adherence measures: ICD-11 (WHO International Classification of Diseases, 11th Revision (ICD-11) 
MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and <25 ‘non-
adherent’). 
Statistical analyses: 12 (1, 696)=.57, p=.45 
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3.1.4 Attendance at routine clinical appointments 
 
Available data for the single-item percentage of appointments attended in last 2-3 months NRS 
(n=592) indicated that n=501 (84.6%) people reported they attended 100% of appointments related to 
their LTC, whilst n=91 (15.4%) reported attending <100%. Similarly, for the percentage of 
appointments attended in last 12 months NRS (n=701), five-hundred and sixty-seven (83.4%) attended 
100% of appointments, whilst one-hundred and thirteen (16.6%) attended <100%. 
 
3.1.5 Convergence between MARS-5 and attendance to routine clinical appointments 
 
As indicated in Table 5, n=590 people with LTCs completing the single-item percentage of 
appointments attended in last 2-3 months NRS (dichotomised as 100%= ‘adherent’, <100%=non-
adherent) and MARS-5, n=60 (10.2%) were identified as ‘adherent’ and n=84 (14.2%) ‘non-adherent’ 
on both measures, indicating 24.4% convergence and no significant association between cut-offs (2 
(1,590)=2.18, p=.13). Of the n=678 people completing both the single-item percentage of appointments 
attended in last 12 months NRS (dichotomised in the same way) and MARS-5, n=70 (10.3%) were 
identified as ‘adherent’ and n=105 (15.5%) ‘non-adherent’ on both measures, indicating 25.8% 
convergence and no significant association between cut-offs (2(1, 678)=3.47 p=<.06). 
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Table 5: Cross-tabulations of convergence between the MARS-5 and routine appointment attendance 
measures 
 
 
MARS-5 
Total Adherent Non-adherent 
Percentage of appts. 
attended in last 2-3 
months NRS 
Adherent 60 440 500 
Non-adherent 6 84 90 
Total 66 524 590 
 
 
Total Adherent Non-adherent 
Percentage of appts. 
attended in last 12 
months NRS 
Adherent 70 496 565 
Non-adherent 7 105 112 
Total 77 601 678 
 
3.1.6 Adherence and general functioning  
 
General functioning showed a small significant relationship with the dichotomised MARS-5 total 
and intentional and unintentional non-adherent subscale dichotomised scores (Table 6). Medium to 
large relationships between self-reported general functioning, PF processes and anxiety and depression 
were also identified, falling in expected directions. General functioning showed a small significant 
relationship with both appointment attendance measures, and medium relationships with mood and PF 
measures. 
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3.1.7 Bivariate analyses adherence, psychological flexibility, mood and general 
functioning 
 
Several demographic and clinical variables were associated with increased cases of intentional non-
adherence, including being female (69.0% vs. male 59.0%: 2(1, 689)=5.96, p=.01), younger (‘adherers’ 
M=57.35, SD=14.86); ‘non-adherers’ M=53.47, SD=16.10: t(693)=3.08, p<.01, 95% CI=1.41, 6.35, 
two-tailed) in a relationship (71.9% vs. 63.8% not in a relationship: 2(1, 694)=4.25, p=.03), having 
more years of education (‘adherers’ M=16.11, SD=3.41; ‘non-adherers’ M=16.79, SD=3.61: t(511)=-
2.04, p=.04, 95%CI=-1.33,-.02, two-tailed), an LTC that is not Parkinson’s Disease (72.4% vs. 56.9%: 
2(1, 692)=17.87, p<.01), more than one LTC (2(1, 690)=7.59, p<.01), more years since diagnosis 
(‘adherers’ M=6.95, SD=8.15; ‘non-adherers’ M=9.45, SD=10.61: t(685)=-3.14, p<.01, 95% CI=-4.06,-
.93, two-tailed) and higher levels of self-reported depression and anxiety (Table 6). 
 
Variables associated with unintentional non-adherence included not working (77.4% vs. 69.6%: 2 
(1)=4.78, p=.02), having Parkinson’s Disease as opposed to any other LTC (2 (1)=4.57, p=.03), more 
years since diagnosis (‘adherers’ M=7.26; ‘non-adherers’ M=9.06, t(682)=-2.07, p=.03, 95% CI=-3.49,-
.09, two-tailed), more than one LTC (2(1)=5.81, p=.01) higher levels of depression (Table 6) and 
residing in the UK  (75.7% vs. 61.2%:2(1)=5.04, p=.02). Therefore, these variables were entered in the 
first step of the regression models as covariates. 
 
Demographic and clinical variables associated with single-item percentage of appointments attended 
in last 2-3 months NRS binary cut-off include having more than one LTC (2 (1,587)=8.77, p<.01) and 
worse mood (Table 6). Variables associated with the single-item percentage of appointments attended 
in last 12 months NRS binary cut-off included being female (84.7% vs. male 54.3%: 2(1,586)=8.55, 
p<.01), being younger (‘adherers’ M=55.76; ‘non-adherers’ M=50.15, t(678)=3.48, p<.01, 95% 
CI=2.44, 8.77, two-tailed), having more than one LTC (2 (1)=29.85, p<.01), LTCs other than 
Parkinson’s disease (2 (1,677)=17.00, p<.01), having more years since diagnosis (‘adherers’ M=8.20; 
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‘non-adherers’ M=10.19, t(671)=-1.90, p=.05, 95% CI=-4.03, .05, two-tailed) and worse mood (Table 
6). Therefore, these variables were entered in the first step of corresponding regression models as 
covariates. 
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Table 6: Bivariate correlations (Bca 95% CIs) between adherence and appointment attendance, psychological flexibility, and mood and general 
functioning measures at baseline (sample sizes range from n=577 to n=700) 
   MARS-5 
Intent 
MARS-5 
Unintent 
<100% 
App. 2-3 
mo. 
<100% 
App. 12 
mo. 
WSAS PHQ-8 GAD-7 AAQ-II CompACT 
total 
CompACT 
total OE 
CompACT 
total BA 
CompACT 
total VA 
 MARS-total 
dich 
 .50** 
(.45,.56) 
.61** 
(.56,.69) 
.05 
(-.01,.12) 
.06 
(-<.01,.12) 
.15** 
(.07,.22) 
.11** 
(.03,.18) 
.04 
(-.03,.12) 
.09* 
(.02,.16) 
-.07* 
(-.14,<-.01) 
-.02 
(-.09,.04) 
-.08* 
(-.16,-<.01) 
-.09** 
(-.16,-.02) 
 MARS-5 
Intent 
  .14** 
(.06, .21) 
.07 
(<.01,.15) 
.12** 
(.04,.19) 
.22** 
(.14,.29) 
.15** 
(.07,.21) 
.10* 
(.03,.16) 
.16** 
(.08,.22) 
-.08* 
(-.15,<-.01) 
-.05 
(-.11,.02) 
-.07 
(-.14,<.01) 
-.10** 
(-.17,-.03) 
MARS-5 
Unintent  
   .10** 
(.02,.16) 
.09** 
(.02,.16) 
.11** 
(.04,.18) 
.12** 
(.04,.20) 
.05 
(.02,.13) 
.07 
(-<.01,.14) 
-.08* 
(-.16, <.01) 
-.06 
(-.13,.01) 
-.10** 
(-.17,-.02) 
.06 
(-.13,.01) 
<100% App. 
2-3 mo. 
    .61** 
(.51,.69) 
.18** 
(.10,.27) 
.22** 
(.1,3.30) 
.17** 
(.07,.25) 
.16** 
(.07,.25) 
-.16** 
(-.24,-.07) 
-.10** 
(-.18,-.01) 
-.12** 
(-.21,-.04) 
-.18** 
(-.26,-.09) 
<100% App. 
12 mo. 
     .23** 
(.14,.30) 
.25** 
(.17,.33) 
.24** 
(.16,.31) 
.19** 
(.11,.27) 
-.19** 
(-.27,-.12) 
-.15** 
(-.22,-.08) 
-.15** 
(-.24,-.09) 
-.18** 
(-.26,-.11) 
WSAS       .59** 
(.54,.64) 
.44** 
(.37,.49) 
.53** 
(.47,.59) 
-.36** 
(-.43,-.30) 
-.30** 
(-.37,-.23) 
-.29** 
(-.36,-.23) 
-.31** 
(-.37,-.23) 
PHQ-8        79** 
(.76,.82) 
.72** 
(.69,.76) 
-.66** 
(-.70,-.61) 
-.68** 
(-.64,-.54) 
-.53** 
(-.59,-.48) 
-.49** 
(-.54,-.42) 
GAD-7         .75** 
(.72,.78) 
-.68** 
(-.72,-.65) 
-.66* 
(-.70,-.63) 
-.51** 
(-.56,-.45) 
-.46** 
(-.53,-.40) 
AAQ-II          -.73** 
(-.77,-.70) 
-.71** 
(-.74,-.67) 
-.56** 
(-.60,-.50) 
-.50** 
(-.58,-.43) 
CompACT 
total 
          .92** 
(.91,.93) 
.74** 
(.70,.77) 
.76** 
(.73,.79) 
CompACT 
total OE 
           .59** 
(.54,.63) 
.55* 
(.49,.60) 
CompACT 
total BA 
            .34** 
(.27,.41) 
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 Italics=point biserial Pearson’s correlations; **Correlation is significant <.01 (2-tailed); *Correlation is significant <.05 (2-tailed); Bca 95% bootstrapped CI (bias corrected 
and accelerated r value 95% confidence intervals with 1000 samples).  
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT total (Comprehensive assessment of Acceptance and Commitment 
Therapy processes total sum score); CompACT total BA (CompACT Behavioral Awareness subscale); CompACT total OE (CompACT Openness to Experience subscale); 
CompACT total VA (CompACT Valued Action subscale). 
Adherence and appointment attendance measures: All measures were coded 0=’adherent’, 1=’non-adherent’. %App. 2-3 mo. (Single item percentage of appointment 
attendance in last 2-3 months numerical rating scale, 100%=adherent, <100%=non-adherent”); %App. 12 mo. (Single item percentage of appointment attendance in last 12 
months numerical rating scale, 100%=adherent, <100%=non-adherent”). MARS-5 (Medication Adherence Rating Scale five items total score), MARS-total dich (MARS-5 
total score dichotomised), MARS-5 Intent (Medication Adherence Rating Scale five items intentional non-adherence subscale score: 20 coded as 0=’adherent’, <20 1= ‘non-
adherent’); MARS-5 Unintent (Medication Adherence Rating Scale five items unintentional non-adherence subscale score: 5 coded as 0=’adherent’, <5 coded as 1=’non-
adherent),  
Mood and functioning: PHQ-8 total (Patient Health Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items); WSAS (Work and Social Adjustment 
Scale). 
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All biserial relationships between PF processes and the dichotomised adherence outcomes 
were in expected directions (Table 6). However, intentional non-adherence showed only small 
significant associations with PF and ‘valued action’, whilst ‘openness to experience’ and 
‘behavioural awareness’ subscales were unrelated. Bootstrapped 95% confidence intervals 
indicated the AAQ-II total score showed a stronger relationship with intentional non-adherence 
compared to the CompACT. Similarly, unintentional non-adherence showed small associations 
with PF as measured the CompACT but not the AAQ-II, and ‘openness to experience’ and ‘valued 
action’ subscales were unrelated. 
 
3.1.8 Binomial regressions intentional and unintentional non-adherence 
 
The first logistic regression satisfied all diagnostic assumptions (see file subfolder ‘Regression 
diagnostics’ in CD enclosed) and tested the components of the PF model in predicting intentional 
non-adherence, controlling for relevant demographic and disease variables (Table 7). 
Demographic and disease variables accounted for 9.7% (Nagelkerke R2=.097) of the variance in 
intentional non-adherence, significantly improving the model fit (2(6)=35.06, p<.01). 
Specifically, more years of education (OR=1.07, 95% CI=[1.01, 1.13]) and years since diagnosis 
(OR=1.03, 95% CI=[1.00, 1.05]) was associated with increased odds of intentional non-
adherence. Adding PF processes did not significantly improve the model fit (Δ2(2)=.86 (p=.64), 
only explaining a further 0.3% (Nagelkerke ΔR2=.003) of the variance.  
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Table 7 Multiple binomial logistic regression to predict intentional non-adherence (MARS-5) 
 
Step 1: Demographic and disease variables 
  
n=494  R2=.097 
2(9)=35.68, p<.01 
 
-2LL=586.51 (2(8)10.08., p=.25) 
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
 
  
 
 
Gender1 -.41 -.89, .11 .66 .41, 1.06 
Age <-.01 -.02, .01 .99 .97, 1.01 
Relationship status2 -.33 -.82, .10 .71 .45, 1.13 
Years of education .06* .01, .13* 1.07 1.01, 1.13 
LTC type3 <-.01 -.58, .62 .99 .56, 1.73 
More than one LTC .24 -.21, .68 1.27 .83, 1.93 
Years since diagnosis .03* <.01, .05* 1.03 1.00, 1.05 
Depression (PHQ-8) .03 -.01, .09 1.03 .98, 1.09 
Anxiety (GAD-7) .00 -.05, .06 1.00 .95, 1.06 
    
Step 2: Psychological flexibility processes  
  R2=.10 
 Δ2 (2)=.86 (p= .64)  
 
-2LL=585.65 (2(8) 9.11, p=.33)  
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
Psychological inflexibility (AAQ-II) -<.01 -.03, .03 1.00 .96, 1.03 
Valued Action (CompACT total VA) -.01 -.04, .01 .98 .95, 1.01 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2In a relationship=0; 3Parkinson’s 
disease =0;  2 Chi-squared goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% 
bootstrapped CI  (bias corrected and accelerated beta value 95% confidence intervals with 1000 
samples); *beta is significant <.05 (2-tailed); OR (standardized odds ratio); OR 95% CI (standardized 
odds ratio 95% confidence intervals); -2LL(-2 Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); 
AAQ-II (Acceptance and Action Questionnaire II); CompACT total VA (Comprehensive assessment of 
Acceptance and Commitment Therapy processes Valued Action subscale); PHQ-8 total (Patient Health 
Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items) 
 
 
The second logistic regression satisfied all diagnostic assumptions and tested the components 
of the PF model in predicting unintentional non-adherence, controlling for relevant demographic 
and disease variables (Table 8). Demographic and disease variables were entered in the first step 
and PF scores in the second step. Demographic and disease variables accounted for 8.3% 
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(Nagelkerke R2=.083) of the variance in unintentional non-adherence, significantly improving the 
model fit 2(5)=36.01 (p<.001). Having LTCs other than Parkinson’s disease (OR=.43, 95% 
CI=[.27,.69]) was associated with decreased odds of unintentional non-adherence. Conversely, 
more years since diagnosis (OR=1.02, 95% CI=[1.00,.1.05]), having more than one LTC 
(OR=1.74, 95% CI=[1.16,2.59]), and higher levels of depression (OR=1.05, 95% CI=[1.02, 1.09]) 
was associated with increased odds of unintentional non-adherence. Adding behavioural 
awareness (i.e. ‘Aware’ processes, incorporating present moment awareness and self-as-context) 
did not significantly improve the model fit (Δ2(1)=2.28, p=.13), 2LL=664.38, Nagelkerke 
ΔR2=.005). 
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Table 8: Multiple binomial logistic regression to predict unintentional non-adherence (MARS-
5) 
Step 1: Demographic and disease variables 
  
n=617  R2=.083 
2 (5)=36.01 (p<.001) 
 
-2LL=670.25 (2(8)8.23, p=.41) 
  
 
 
b Bca 95% CI OR OR 95% CI 
     
Occupational status1 .11 -.35, .57 1.12 .74, 1.69 
LTC type2* -.82* -1.3, -.34* .43 .27, .69 
Years since diagnosis .02* <.07, .05* 1.02 1.0, 1.05 
More than one LTC .55* .13, .99* 1.74 1.16, 2.59 
Depression (PHQ-8) .05* .02, .09* 1.05 1.02, 1.09 
    
Step 2: Psychological flexibility processes  
  R2=.088 
 Δ2 (1)=2.28, p=.13) 
 
-2LL=667.97 (2(8)5.33, p=.72)  
  
 
 
b Bca 95% CI OR OR 95% CI 
Behavioural awareness (CompACT 
total BA) 
-.02 -.07, .01 .97 .93, 1.0 
     
Adherent=0, Non-adherent=1; 1Working=0; 2Parkinson’s disease=0; 3UK=0; 2 Chi-squared goodness 
of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% bootstrapped CI  (bias corrected and 
accelerated beta value 95% confidence intervals with 1000 samples); *beta is significant <.05 (2-tailed); 
OR (standardized odds ratio); OR 95% CI (standardized odds ratio 95% confidence intervals); -2LL(-2 
Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II (Acceptance and Action 
Questionnaire II); CompACT total BA (Comprehensive assessment of Acceptance and Commitment 
Therapy processes Behavioural Awareness subscale); PHQ-8 total (Patient Health Questionnaire 8-
items). 
 
3.1.9 Binomial regressions routine appointment attendance 
 
The third logistic regression did not satisfy the linearity of the logit assumption for the AAQ-
II (p=.02) and standardized residuals were slightly exceeded (6% >1.96 SD), so should be 
interpreted with caution in testing components of the PF model in predicting nonattendance to 
related health care appointments in the last 2-3 months (i.e. anything less than 100%) controlling 
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for relevant demographic and disease variables (Table 9). Demographic and disease variables 
accounted for 9.3% (Nagelkerke R2=.093) of the variance in nonattendance, significantly 
improving the model fit (2(3)=32.29, p<.01). Being more depressed (OR=1.10, 95% CI=[1.04, 
1.17]) was associated with increased odds of nonattendance. Adding PF processes did not 
significantly improve the model fit (Δ2(4)=7.39, p=.11, 2LL=466.68), explaining a further 2% 
(Nagelkerke ΔR2=.02) of the variance. However, engaging in valued action (OR=.95, 95% 
CI=[.92,.98]) was associated with decreased odds of non-attendance. 
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Table 9: Multiple binomial logistic regression to predict appointment nonattendance in the last 
2-3 months 
Step 1: Demographic and disease variables 
  
n=587  R2=.093 
2 (3) = 32.29 (p<.01) 
 
-2LL = 474.08 (2(8)6.01, p=.64) 
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
More than one LTC .46 -.06,.97 1.59 .94, 2.67 
Depression (PHQ-8) .09* .04, .15* 1.10 1.04, 1.17 
Anxiety (GAD-7) -.01 -.07,.04 .98 .92,1.04 
    
Step 2: Psychological flexibility processes  
  R2=.113 
 Δ2 (4) = 7.39 (p=.11) 
 
-2LL = 466.68 (2(8)10.36, p=.24)  
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
Psychological inflexibility (AAQ-II) <.01 -.03,.045 1.00 .96,1.04 
Openness to Experience subscale 
(CompACT total OE) 
.02 <-.00,.06 1.02 .99,1.06 
Behavioural awareness (CompACT 
total BA) 
-.01 -.065,.02 .98 .93,1.02 
Valued Action (CompACT total VA) -.04* -.08,-.01* .95 .92,.98 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2White=0; 2 Chi-squared 
goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% bootstrapped CI  (bias 
corrected and accelerated beta value 95% confidence intervals with 1000 samples); *beta is significant 
<.05 (2-tailed); OR (standardized odds ratio); OR 95% CI (standardized odds ratio 95% confidence 
intervals); -2LL(-2 Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II (Acceptance and 
Action Questionnaire II); CompACT total BA (Comprehensive assessment of Acceptance and 
Commitment Therapy processes Behavioral Awareness subscale); CompACT total OE (CompACT 
Openness to Experience subscale); CompACT total VA (CompACT Valued Action subscale; PHQ-8 
total (Patient Health Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items) 
 
The final logistic regression satisfied all diagnostic assumptions and tested the components of 
the PF model in predicting nonattendance to related health care appointments in the last 12 months 
(i.e. anything less than 100%) controlling for relevant demographic and disease variables (Table 
10). Demographic and disease variables accounted for 16.1% (Nagelkerke R2=.161) of the 
variance in nonattendance, significantly improving the model fit (2(7)=65.53 (p<.01). Having 
more than one LTC (OR=1.10, 95% CI=[.55,2.20]) and higher levels of depression (OR=1.05, 
95% CI=[1.00,1.11]) was associated with increased odds of nonattendance. Adding PF processes 
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did not significantly improve the model fit (Δ2=3.42, p=.48, 2LL= 515.31), explaining a further 
0.8% (Nagelkerke ΔR2=.008) of the variance and none of the processes were related.  
 
Table 10: Multiple binomial logistic regression to predict appointment nonattendance in the last 
12 months 
Step 1: Demographic and disease variables 
  
n=658  R2=. 161 
2 (7) = 65.53 (p<.01) 
 
-2LL = 518.74 (2(8)4.65, p=.79) 
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
Age <-.01 -.02,.012 .99 .97,1.01 
Gender1 -.34 -1.12,.27 .70 .37,1.34 
More than one LTC .95* .44,1.62* 2.60 1.50,4.51 
LTC type2 .10 -.57,.85 1.10 .55,2.20 
Years since diagnosis .01 <-.01,.03 1.01 .99,1.03 
Depression (PHQ-8) .05* <-.01,.11* 1.05 1.00,1.11 
Anxiety (GAD-7) .03 -.02,.09 1.03 .97,1.09 
    
Step 2: Psychological flexibility processes  
  R2=.169 
 Δ2 (4) = 3.42 (p=.48) 
 
-2LL = 515.31 (2(8)6.68, p=.57)  
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
Psychological inflexibility (AAQ-II) -.01 -.05,.02 .98 .94,1.02 
Openness to Experience subscale 
(CompACT total OE) 
<.01 -.02,.04 1.00 .97,1.04 
Behavioural awareness (CompACT 
total BA) 
-.01 -.06,.02 .98 .93,1.02 
Valued Action (CompACT total VA) -.02 -.07,<.01 .97 .93,1.00 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2Parkinson’s Disease=0; 2 Chi-
squared goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% bootstrapped CI  
(bias corrected and accelerated beta value 95% confidence intervals with 1000 samples);; *beta is 
significant <.05 (2-tailed); OR (standardized odds ratio); OR 95% CI (standardized odds ratio 95% 
confidence intervals); -2LL(-2 Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II 
(Acceptance and Action Questionnaire II); CompACT total BA (CompACT Behavioral Awareness 
subscale); CompACT total OE (CompACT Openness to Experience subscale); CompACT total VA 
(CompACT Valued Action subscale; PHQ-8 total (Patient Health Questionnaire 8-items), GAD-7 
(Generalised Anxiety Disorder scale 7-items) 
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3.2 Longitudinal analyses 
3.2.1 Demographic and disease characteristics of the follow-up sample  
 
Of the n=701 adults who completed the baseline questionnaires n=341 completed the 3-month 
follow-up questionnaire. However, five were excluded, either not having provided an identifying 
email/name to link-up the data (3) or was a duplicate (2). On average, the n=336 participants 
(48.07%) completed the follow-up questionnaire M=94.63 (SD=5.66) days after baseline. 
 
Consistent with the baseline only sample (n=365), follow-up participants (n=336) were mostly 
white-Caucasian (97.33: 2(1,698)=.229, p=.63) and female (72.5%: 2(1,695)=.282, p=.59). 
However, the follow-up sample were on average significantly older (M=56.72, SD=15.20: 
t(699)=-2.893, p=<.01, 95% CI= -5.77, -1.10, two-tailed). Most resided in the UK (92.9%) 
compared to other countries (6.9%: 2(1,700)=.020, p=.88). Forty-two percent of participants were 
retired, 12.9% medically retired, 35.7% were in full- or part-time employment or education, 3.3% 
were homemakers and 1.8% were unemployed. There were significantly fewer participants 
working/in education in the follow-up sample (2(1,642)=7.19, p=<.01). Sixty-one percent of 
participants were married or in a civil partnership, 8.3% cohabiting, 17.9% single, 9.2% separated 
or divorced, 2.4% widowed and 0.6% described their relationship status as “other”, showing 
similar proportions of participants in relationships compared to the baseline sample 
(2(1,700)=0.42, p=.83).  
 
A larger proportion of participants in the follow-up sample were diagnosed with Parkinson’s 
disease (46.9% versus 36.1%: 2(1,698)=8.35, p<.01). Similar to the baseline only sample, 55.8% 
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reported more than one LTC (2(1,696)=.59, p<.43). Follow-up participants on average reported 
similar years of disease duration with their primary LTC (M=8.23, SD=9.82: t(691)=1.05, p=.29, 
95%CI=-.69,-2.31, two-tailed) and as shown in Table 11 mild levels of anxiety (t(697)=1.81, 
p=.06, 95%CI=-.06,1.67), but also reported significantly lower levels of depression (t(697)=1.98, 
p=.04, 95%CI=<.01,1.86).  Compared to the baseline only sample, the follow-up sample had a 
lower proportion of non-adherers according to the MARS-5 (85.0% versus 90.0%, 
2(1,698)=4.95, p=.02), but similar rates of intentional (64.8% versus 67.0%, 2(1, 693)=.39, 
p=.63) and unintentional non-adherence (73.5% versus 75.6% 2(1,692)=.38, p=.53). 
 
3.2.2 Descriptive statistics 
 
All measures showed Means/SDs that were largely consistent with measure validation samples 
and the baseline sample and missing data was minimal, therefore summed scores were used in all 
analyses (Table 11).  
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Table 11: Follow-up descriptive data for measures in the adult sample  
Measure n Mean  
(SD) 
Skewness 
(SE) 
Kurtosis 
(SE) 
Reliability 
Cronbach α 
Adherence and attendance      
MARS-5 total sum score   336 21.38 (13.40) -1.79 (.13)* 4.60 (.26) .77 
MARS-5 total mean item 
score adjusted (<20% of 
missing items) 
333 4.32 (.65) -1.34 (.13)* 1.97 (.26)  
MARS-5 Intent sum score 333 17.60 (2.81) -1.35 (.13) 1.88 (.26)  
MARS-5 Unintent sum score 336 3.94 (.87) -.48 (.13) -.34 (.26)  
Single item appointment 
attendance in last 2-3 months 
NRS (%) 
288 91.07 (25.49) -3.00 (.14)*    7.56 (.28) NA 
Single item appointment 
attendance in last 12 months 
NRS (%) 
332 94.71 (17.31) -4.28 (.13)* 18.70 (.26) NA 
Functioning      
WSAS total sum score 332 16.05 (10.76) .40 (.13) -.80 (.26) .93 
Mood      
PHQ-8 total sum score 336 8.27 (6.21) .74 (.13) -.32 (.26) .89 
PHQ-8 total mean item score 
adjusted (<25% of missing 
items) 
336 1.03 (.77) .73 (.13) -.33 (.26)  
GAD-7 total sum score 336 6.03 (5.84) 1.01 (.13)* .06 (.26) .93 
GAD-7 total mean item 
score adjusted (<25% of 
missing items) 
336 .86 (.83) .99 (.13) <.01 (.26)  
Psychological flexibility processes 
AAQ-II total sum score 335 19.69 (10.25) .69 (.13) -.29 (.26) .94 
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AAQ-II total mean item 
score adjusted (<25% of 
missing items) 
335 2.81 (1.46) .68 (.13) -.30 (.26)  
CompACT total score 336 89.66 (23.94) -.25 (.13) -.30 (.26) .91 
CompACT total mean item 
score adjusted (<25% of 
missing items) 
336 3.92 (1.04)  -.25 (.13) -.25 (.26)  
OE subscale sum score 336 35.22 (12.24) -.06 (.13) -.57 (.26) .85 
OE mean item score 
adjusted (<25% of missing 
items) 
333 3.55 (1.22) -.08 (.13) -.55 (.26)  
BA subscale sum score 336 17.91 (7.42) -.09 (.13) -.88 (.26) .85 
BA mean item score 
adjusted (<25% of missing 
items) 
336 3.59 (1.48) -.10 (.13) -.86 (.26)  
VA subscale sum score 336 36.46 (8.21) -.69 (.13) .33 (.26) .85 
VA mean item score 
adjusted (<25% of missing 
items) 
336 4.57 (1.02) -.68 (.13) .21 (.26)  
*Non-normal distributions 
Adherence measures: MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and 
<25 ‘non-adherent’); MARS-5 Intent (Medication Adherence Rating Scale five items intentional non-adherence 
subscale score: 20=’adherent’ <20=’non-adherent’); MARS-5 Unintent (Medication Adherence Rating Scale 
five items unintentional non-adherence subscale score: 5=’adherent’, <5=’non-adherent’). 
Attendance measures: <100% appointment attendance in last 2-3/12 months NRS (%) (Single item 
appointment attendance in last 2-3/12 months Numerical Rating Scale percentage, binary cut-offs: 
100%=adherent; <100%=non-adherent).  
Mood and functioning: PHQ-8 (Patient Health Questionnaire 8-items: 0-4 ‘No significant depressive 
symptoms’, 5-9 ‘mild depressive symptoms’, 10-14 ‘moderate depressive symptoms’, 15-19 ‘moderately severe 
depressive symptoms’, 20-24 ‘severe depressive symptoms’; GAD-7 (Generalised Anxiety Disorder 7-items: 
0-4 ‘Minimal’, 5- 9‘Mild’, 10-14 ‘Moderate’, 15-22 ‘Severe’; WSAS (Work and Social Adjustment Scale: 0-9 
‘Normal subclinical populations’, 10-19 ‘Normal subclinical populations’, 20-40 ‘moderately severe or worse 
psychopathology’). 
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT total 
(CompACT total sum score); CompACT total BA (CompACT Behavioral Awareness subscale) CompACT 
total OE (CompACT Openness to Experience subscale); CompACT total VA (CompACT Valued Action 
subscale). 
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3.2.3 Test-retest reliability of all scales 
 
Intraclass Correlation Coefficients (ICC) for baseline and three-month follow-up established 
scales data are shown in Table 12, which according to established cut-offs for 95% confidence 
intervals indicate most measures demonstrated acceptable levels of reliability (moderate to 
excellent) indicating they are stable over time (Koo & Li, 2016). However, the MARS-5 total and 
intentional dichotomised ratings at follow-up were poor to moderate. 
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Table 12: Test-retest statistics for all scales at baseline and three months 
Measure n Baseline 
Mean  
(SD) 
Follow-up 
Mean  
(SD) 
ICC  
(p-value) 
95% CI  
Adherence and attendance 
MARS-5 total 
dichotomised 
335 .86 
(.33) 
 
.85 
(.35) 
.31  
(<.01) 
.19, .47 
MARS-5 Intent 
dichotomised 
331 .65  
(.47) 
 
.62  
(.48) 
.24  
(<.01) 
.064, .39 
MARS-5 Unintent 
dichotomised 
332 .73  
(.44) 
 
.71  
(.45) 
.75 
(<.01) 
.69, .79 
Single item 
appointment 
attendance in last 2-
3 months NRS (%) 
249 .17 
(.38) 
.16 
(.37) 
.66 
(<.01) 
.56, .73 
Single item 
appointment 
attendance in last 12 
months NRS (%) 
329 .15 
(.36) 
.16 
 (.37) 
.63 
(<.01) 
.54, .70 
Functioning      
WSAS total score 336 15.98 
(11.01) 
16.08 
(10.76) 
.92 
(<.01) 
.91, .94 
Mood      
PHQ-8 total score 335 8.45 
(6.24) 
8.28 
(6.22) 
.88 
(<.01) 
.85, .90 
GAD-7 total score 335 6.1 
(5.83) 
6.04 
(5.84) 
.87 
(<.01) 
.84, .90 
Psychological Flexibility processes 
AAQ-II 335 19.78 
(10.53) 
19.69 
(10.25) 
.91 
(<.01) 
.89, .93 
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CompACT total 
score 
336 83.07 
(21.41) 
89.59 
(23.95) 
.87 
(<.01) 
.78, .91 
OE subscale 336 34.77 
(12.04) 
35.22 
(12.24) 
.87 
(<.01) 
.84, .90 
BA subscale 336 16.73 
(6.07) 
17.91 
(7.42) 
.75 
(<.01) 
.69, .80 
VA subscale 336 31.56 
(7.49) 
36.46  
(8.21) 
 .72 
(<.01) 
.32, .85 
ICC (Intraclass Correlation Coefficient using an absolute agreement definition); 95% CI (95% 
Confidence Interval). 
Adherence measures: MARS-5 (Medication Adherence Rating Scale five items total score: 
25=‘adherent’ and <25 ‘non-adherent’); MARS-5 Intent (Medication Adherence Rating Scale 
five items intentional non-adherence subscale score: 20=’adherent’ <20=’non-adherent’); 
MARS-5 Unintent (Medication Adherence Rating Scale five items unintentional non-
adherence subscale score: 5=’adherent’, <5=’non-adherent’). 
Attendance measures: <100% appointment attendance in last 2-3/12 months NRS (%) 
(Single item appointment attendance in last 2-3/12 months Numerical Rating Scale 
percentage, binary cut-offs: 100%=adherent; <100%=non-adherent).  
Mood and functioning: PHQ-8 (Patient Health Questionnaire 8-items: 0-4 ‘No significant 
depressive symptoms’, 5-9 ‘mild depressive symptoms’, 10-14 ‘moderate depressive 
symptoms’, 15-19 ‘moderately severe depressive symptoms’, 20-24 ‘severe depressive 
symptoms’; GAD-7 (Generalised Anxiety Disorder 7-items: 0-4 ‘Minimal’, 5- 9‘Mild’, 10-
14 ‘Moderate’, 15-22 ‘Severe’; WSAS (Work and Social Adjustment Scale: 0-9 ‘Normal 
subclinical populations’, 10-19 ‘Normal subclinical populations’, 20-40 ‘moderately severe 
or worse psychopathology’). 
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); 
CompACT total (CompACT total sum score); CompACT total BA (CompACT Behavioral 
Awareness subscale) CompACT total OE (CompACT Openness to Experience subscale); 
CompACT total VA (CompACT Valued Action subscale). 
 
3.2.4 Demographic and disease characteristics for adherent and non-adherent 
subgroups 
 
Consistent with the baseline total sample, 85.4% of the follow-up sample were non-adherent, 
of which 62.8% were intentionally non-adherent and 83.2% unintentionally non-adherent (Table 
13). There was still a significantly larger proportion of non-adherers from the UK compared to 
adherers. Non-adherers reported significantly worse general functioning and anxiety and 
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depression compared to adherers. However, there were no differences for any other demographic 
and disease variables. 
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Table 13: Participant characteristics at follow-up according to MARS-5 cut-offs (n=336) 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=49, 14.6%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=287, 85.4%) 
p value 
Mean age (SD) 56.65 (13.73) 56.73 (15.46) .971 
Gender (%) 
Female 
Male 
Other (“Non-binary”)  
 
33 (67.3) 
16 (32.7) 
0 
 
209 (73.1) 
76 (26.6) 
1 (0.4) 
.382 
Country (%) 
UK  
Non-UK 
 
43 (87.8) 
7 (14.0) 
 
269 (93.7) 
17 (5.9) 
.163 
White ethnicity (%)  47 (95.9) 279 (97.6) .534 
Mean education years (SD) 16.71 (2.96) 16.46 (3.63) .685 
Employment status (%) 
Full time  
Part time  
Self-employed 
Homemaker 
Retired 
Medically retired  
Unemployed 
Full/part-time student 
Other 
 
13 (26.5) 
6 (12.2) 
3 (6.1) 
0 
17 (34.7) 
4 (8.2) 
1 (2.0) 
3 (6.0) 
2 (4.0) 
 
42 (14.7) 
28 (9.8) 
16 (5.6) 
11 (3.9) 
124 (43.5) 
39 (13.7) 
5 (1.8) 
8 (2.8) 
12 (4.2) 
.026 
Relationship status (%) 
Single 
Married or civil 
partnership 
Separated or divorced 
Cohabiting 
Widowed  
 
5 (10.0) 
34 (68.0) 
 
8 (16.3) 
2 (4.1)  
0 
 
55 (19.2) 
173 (60.5) 
 
23 (8.0) 
26 (9.1) 
8 (2.8) 
.567 
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Other 0 2 (0.7) 
Mean years since diagnosis 
(SD) 
6.0 (6.71) 8.62 (10.22) .088 
More than one LTC (%) 23(46.9) 164 (57.3) .379 
Mean Depression PHQ-8 
(SD) 
6.31 (5.86) 8.81 (6.24) .0110 
Mean Anxiety GAD-7 (SD) 4.52 (5.72) 6.42 (5.82) .0311 
Functioning WSAS 12.71 (10.19) 16.6 (10.77) .0112 
Intentionally  
non-adherent MARS-5 (%) 
 
NA 
 
 
209 (73.6) 
 
 
NA 
Unintentionally non-
adherent MARS-5 (%) 
NA 238 (83.2) NA 
Single item appointment 
attendance in last 2-3 
months NRS (%) 
6 (14.3) 45 (18.3) NA 
Single item appointment 
attendance in last 12 
months NRS (%) 
2 (4.1) 54 (19.1) NA 
Adherence measures: MARS-5 (Medication Adherence Rating Scale five items total score: 
25=‘adherent’ and <25 ‘non-adherent’); MARS-5 Intent (Medication Adherence Rating Scale five 
items intentional non-adherence subscale score: 20=’adherent’ <20=’non-adherent’); MARS-5 
Unintent (Medication Adherence Rating Scale five items unintentional non-adherence subscale 
score: 5=’adherent’, <5=’non-adherent’). 
Attendance measures: <100% appointment attendance in last 2-3/12 months NRS (%) (Single item 
appointment attendance in last 2-3/12 months Numerical Rating Scale percentage, binary cut-offs: 
100%=adherent; <100%=non-adherent).  
Mood and functioning: PHQ-8 (Patient Health Questionnaire 8-items: 0-4 ‘No significant 
depressive symptoms’, 5-9 ‘mild depressive symptoms’, 10-14 ‘moderate depressive symptoms’, 15-
19 ‘moderately severe depressive symptoms’, 20-24 ‘severe depressive symptoms’; GAD-7 
(Generalised Anxiety Disorder 7-items: 0-4 ‘Minimal’, 5- 9‘Mild’, 10-14 ‘Moderate’, 15-22 
‘Severe’; WSAS (Work and Social Adjustment Scale: 0-9 ‘Normal subclinical populations’, 10-19 
‘Normal subclinical populations’, 20-40 ‘moderately severe or worse psychopathology’). 
Psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT 
total (CompACT total sum score); CompACT total BA (CompACT Behavioral Awareness subscale) 
CompACT total OE (CompACT Openness to Experience subscale); CompACT total VA (CompACT 
Valued Action subscale). 
Statistical analyses: 1t(334)=.032, p=.97, 95% CI= -4.70,4.55 two-tailed; 2Male versus female (as 
too few expected counts for “other”): (2 (1, 334)=.75, p=.38); 3Likelihood ratio (1, 336)=1.94, 
p=.16); 4White versus everything else (as too few expected counts for other groupings): Likelihood 
ratio(1, 335)=.38, p=.53); 5t(261)=.40, p=.68, 95% CI=-.97,1.49 two-tailed; 6‘Working/in education’ 
versus everything else (as too few expected counts for other categories): 2 (1, 309)=5.11, p=.02); 
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7‘In a relationship’ versus ‘not in a relationship’ (as too few expected counts for other categories): 
2(1, 336)=.34, p=.56); 8t(330)=-1.72, p=.08, 95% CI=-5.60,.36 two-tailed; 92(1, 335)=.80, p=.37); 
10t(333)=-2.59, p=.01, 95% CI= -4.40, -.60 two-tailed; 11t(333)=-2.09, p=.03, 95% CI= -3.68,-.11 
two-tailed 12t(334)=-2.38, p=<.01, 95% CI= -7.19-, -.68 two-tailed. 
 
Table 14 provides a summary of primary LTCs reported by participants from the follow-up 
sample (see Appendix K for a more detailed summary). There was no significant association 
between proportion of people with Parkinson’s disease who were adherent and non-adherent and 
all other LTCs.  
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Table 14: Primary LTC types of the follow-up sample across MARS-5 cut-offs (n=336) 
 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=49, 14.6%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=287, 85.4%) 
p value 
Parkinson’s Disease vs.  
All other LTCs (%) 
18 (36.7) 
31 (63.3) 
139 (48.6) 
147 (51.4) 
.121 
 
Type of LTC by ICD-11 disease category   
Allergies 0 2 (.07)  
Autoimmune 10 (20.4) 71 (24.7)  
Birth defect  0 1 (0.3)  
Cancers (all types) 2 (4.1) 3 (1.0)  
Cardiovascular/Circulatory 6 (12.2) 12 (4.2)  
Endocrine 1 (2.0) 7 (2.4)  
Genitourinary 0 1 (0.3)  
Hereditary 1 (2.0) 9 (3.1)  
Immunodeficiency 4 (8.2) 7 (2.4)  
Infectious 1 (2.0) 0  
Inflammatory 1 (2.0) 11 (3.8)  
Neurodegenerative 22 (44.9) 142 (49.5)  
Trauma/injury 0 2 (0.7)  
Other conditions 1 (2.0) 18 (6.3)  
LTC not reported 0 1 (.03)  
Adherence measures: ICD-11 (WHO International Classification of Diseases, 11th Revision (ICD-11) 
MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and <25 ‘non-
adherent’). 
Statistical analyses: 12 (1, 335)=2.36, p=.12. 
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3.2.5 Bivariate analyses adherence, psychological flexibility and mood and general 
functioning 
 
Consistent with baseline estimates, all biserial relationships between PF processes at baseline 
and the dichotomised adherence outcomes at 3-months follow-up were in expected directions 
(Table 15). Intentional non-adherence showed only small significant associations with PF, and 
‘openness to experience’ and ‘behavioural awareness’ subscales were unrelated. Similarly, 
unintentional non-adherence showed small or inconsistent associations with PF as measured by 
the AAQ-II, but not the CompACT. PF processes significantly predicted general functioning and 
anxiety and depression at follow-up in expected directions, showing mostly medium to large 
effects.
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Table 15: Bivariate correlations (Bca 95% CIs) between baseline psychological flexibility and adherence and appointment attendance, and mood and 
general functioning measures at follow-up (sample sizes range from n=286 to n=336) 
   MARS-5 
Intent FU 
MARS-5 
Unintent 
FU 
<100% 
App. 2-3 
mo. FU 
<100% 
App. 12 
mo. FU 
WSAS 
FU 
PHQ-8  
FU 
GAD-7 
FU 
AAQ-II 
 
CompACT 
total 
CompACT 
total OE 
CompACT 
total BA 
CompACT 
total VA 
 MARS-total 
dich FU 
 .53** 
(.46,.60) 
.64** 
(.56,.72) 
.03  
(-.07,.13) 
.15**  
(.07,.21) 
.12* 
(.01,.23) 
.17** 
(.08,.25) 
.14** 
(.05,.21) 
.16** 
(.07,.24) 
-.10* 
(-.19,-.01) 
-.08 
(-.17,.01) 
-.09 
(-.19,.01) 
-.10* 
(-.19,<-.01) 
 MARS-5 
Intent FU 
  17** 
(.06,.29) 
.01 
(-.10,.13) 
.15* 
(.04,.26) 
.19** 
(.09,.29) 
.22** 
(.11,.31) 
.18** 
(.08,.28) 
.16** 
(.06,.25) 
-.11* 
(-.21,<-.01) 
-.08 
(-.19,.01) 
-.06 
(-.16,.05) 
-.13* 
(-23,-01) 
MARS-5 
Unintent FU 
   .09 
(-.01,.18) 
.13 
(<-.01,.19) 
.10 
(-.01,.20) 
.18** 
(.08,.27) 
.13* 
(.03,.22) 
.12* 
(.02,.21) 
-.09 
(-.19,<.01) 
-.07 
(-.17,.02) 
-.08 
(-.17,.01) 
-.08 
(-.18,<.01) 
<100% App. 
2-3 mo. FU 
    .561** 
(.43,.68) 
.03 
(-.07.15) 
.09 
(-.02.21) 
.08 
(-.03,.20) 
.13* 
(.01,.24) 
-.11 
(-.23,.01) 
-.07 
(-.18,.05) 
-.02 
(-.13,.08) 
-.18** 
(-.31,-.05) 
<100% App. 
12 mo. FU 
     .19 
(.08,.31) 
.30 
(.19,.42) 
.24 
(.12,.37) 
.25 
(.14,.37) 
-.25 
(-.36,-.14) 
-.19 
(-.31,-.08) 
-.18 
(-.29,-.07) 
-.24** 
(-.36,-.12) 
WSAS FU       .64** 
(.57,.70) 
.46** 
(.37,.55) 
.52** 
(.43,.60) 
-.39** 
(-.47,-.29) 
-.31** 
(-.41,-.20) 
-.31** 
(-.40,-.20) 
-.37** 
(-.46,-.27) 
PHQ-8 FU        .79** 
(.75,.84) 
.70** 
(.62,.76) 
-.60** 
(-.66,-.52) 
-.53** 
(-.61,-.44) 
-.47** 
(-.55,-.39) 
-.46** 
(-.55,-.37) 
GAD-7 FU         .70** 
(.63,.77) 
-.62** 
(-.69,-.55) 
-.59** 
(-.66,-.51) 
-.50** 
(-.58,-.42) 
-.41** 
(-.51,-.31) 
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 Italics=point biserial Pearson’s correlations; **Correlation is significant <.01 (2-tailed); *Correlation is significant <.05 (2-tailed); Bca 95% bootstrapped CI (bias corrected 
and accelerated r value 95% confidence intervals with 1000 samples).  
Baseline psychological flexibility processes: AAQ-II (Acceptance and Action Questionnaire II); CompACT total (CompACT total sum score); CompACT total BA 
(CompACT Behavioral Awareness subscale); CompACT total OE (CompACT Openness to Experience subscale); CompACT total VA (CompACT Valued Action subscale). 
Adherence and appointment attendance measures: All measures were coded 0=’adherent’, 1=’non-adherent’. %App. 2-3 mo. FU (Single item percentage of appointment 
attendance in last 2-3 months numerical rating scale follow-up score, 100%=adherent, <100%=non-adherent”); %App. 12 mo. FU (Single item percentage of appointment 
attendance in last 12 months numerical rating scale follow-up score, 100%=adherent, <100%=non-adherent”). MARS-5 (Medication Adherence Rating Scale five items 
total score), MARS-total dich FU (MARS-5 total score at follow-up dichotomised), MARS-5 Intent FU (Medication Adherence Rating Scale five items intentional non-
adherence subscale score at follow-up: 20 coded as 0=’adherent’, <20 1= ‘non-adherent’); MARS-5 Unintent FU (Medication Adherence Rating Scale five items 
unintentional non-adherence subscale score at follow-up: 5 coded as 0=’adherent’, <5 coded as 1=’non-adherent),  
Mood and functioning: PHQ-8 total FU (Patient Health Questionnaire 8-items at follow-up), GAD-7 FU (Generalised Anxiety Disorder scale 7-items at follow-up); WSAS 
FU (Work and Social Adjustment Scale at follow-up). 
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3.2.6 Binomial regressions intentional and unintentional non-adherence 
 
A data-driven approach was taken with regards to inclusion of covariates in hierarchical 
binomial regression models, where only demographic and disease variables significantly related 
with non-adherence outcomes at the bivariate level (p<.05) at baseline were entered in the first 
step. Therefore, each model included slightly different variables. Mood measured by the PHQ-
8 (baseline M=8.45, SD=6.24; follow-up M=8.28, SD=6.22: t(334)=-8.04, p=.44, 95% CI=-
.25,60, two-tailed) and GAD-7 (baseline M=6.14, SD=5.83 follow-up M=6.04, SD=5.84: 
t(335)=.50, p=.61, 95% CI= -.30, .52, two-tailed) did not significantly change over time. 
Therefore, baseline values where relevant were entered in the first step of the regression. PF 
processes measured by the CompACT significantly improved over time (baseline M=83.07, 
SD=21.41, follow-up M=89.59, SD=23.95: t(335)=-8.37, p<.01, 95% CI=-8.05, -4.9, two-
tailed), including the BA (baseline M=16.73, SD=6.07, follow-up M=17.91, SD=7.42: t(335)=-
3.62, p<.01, 95% CI=-1.82-.54, two-tailed) and VA subscales (baseline M=31.56, SD=7.49, 
follow-up M=36.46, SD=8.21: t(335)=-14.06, p<.01, 95% CI=-5.58,-4.21, two-tailed). PF 
processes were entered in the following step to assess their predictive power on non-adherence 
after demographic and disease variables were accounted for.  
 
The first logistic regression satisfied diagnostic assumptions and tested the components of 
the PF model in predicting intentional non-adherence at 3-month follow-up controlling for 
relevant demographic and disease variables (Table 16). Demographic and disease variables 
accounted for (8.3%) (Nagelkerke R2=.083) of the variance in intentional non-adherence but 
did not significantly improve the model fit (2(9)=15.89, p=.06. Specifically, only more years 
since diagnosis (OR=1.04, 95% CI=[1.00, 1.07]) was associated with increased odds of 
intentional non-adherence. Adding PF processes did not significantly improve the model fit (Δ2 
(2)=2.59, p=.27), only explaining a further 1.4% (Nagelkerke ΔR2=.014) of the variance.  
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Table 16: Multiple binomial logistic regression to predict intentional non-adherence at 3-
months follow-up (MARS-5) 
 
Step 1: Baseline demographic and disease 
variables 
  
n=254  R2=.083 
(2(9)=15.89, p=.06 
 
-2LL=314.34 (2(8)7.5, p=.48) 
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
 
  
 
 
Gender1 -.08 -.73, .58 .91 .48, 1.73 
Age <-.01 -.03, .01 .99 .97, 1.01 
Relationship status2 -.08 -.78, .54 .92 .49, 1.73 
Years of education .01 -.06, .10 1.01 .94, 1.09 
LTC type3 -.20 -1.11, .62 .81 .37, 1.75 
More than one LTC .58 <-.01, 1.28 1.78 .98, 3.25 
Years since diagnosis .03* <.01, .08* 1.04 1.00, 1.07 
Depression (PHQ-8) .01 -.06, .09 1.01 .94, 1.08 
Anxiety (GAD-7) .02 -.06, .12 1.02 .95, 1.11 
    
Step 2: Baseline psychological flexibility 
processes  
  R
2=.097 
 Δ2 (2)=2.59, p=.27 
 
-2LL=311.74 (2(8)7.63, p=.47)  
  
 
 
b Bca 95% CI OR 
OR 95% 
CI 
Psychological inflexibility (AAQ-II) .02 -.02, .07 1.02 .97, 1.07 
Valued Action (CompACT total VA) -.02 -.07, .03 .97 .93, 1.02 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2In a 
relationship=0; 3Parkinson’s disease =0;  2 Chi-squared goodness of fit; Δ2 (Chi-squared goodness 
of fit); b= beta value; Bca 95% bootstrapped CI  (bias corrected and accelerated beta value 95% 
confidence intervals with 1000 samples); *beta is significant <.05 (2-tailed); OR (standardized odds 
ratio); OR 95% CI (standardized odds ratio 95% confidence intervals); -2LL(-2 Log Likelihood 
statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II (Acceptance and Action Questionnaire II); 
CompACT total VA (CompACT Valued Action subscale); PHQ-8 total (Patient Health 
Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items) 
 
 
The second logistic regression satisfied diagnostic assumptions and tested the components 
of the PF model in predicting unintentional non-adherence at 3-month follow-up controlling for 
relevant demographic and disease variables (Table 17). Demographic and disease variables 
were entered in the first step and PF scores in the second step. Demographic and disease 
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variables accounted for 11.7% (Nagelkerke R2=.117) of the variance in unintentional non-
adherence, significantly improving the model fit (2 (6)=26.18 (p<.01). Having LTCs other than 
Parkinson’s disease (OR=.44, 95% CI=[.23,.84]) was associated with decreased odds of 
unintentional non-adherence. Adding PF processes did not significantly improve the model fit 
(Δ2 (2)=.003 (p=.95), nor did it explain any further variance (Nagelkerke ΔR2=0).  
 
Table 17: Multiple binomial logistic regression to predict unintentional non-
adherence at 3-months follow-up (MARS-5) 
Step 1: Baseline demographic and disease 
variables 
  
n=303  R2=.117 
2 (6)=26.18 (p<.001) 
 
-2LL=344.17 (2(8)6.95, p=.54) 
  
 
 
b Bca 95% CI OR OR 95% CI 
     
Occupational status1 .26 -.40, .86 1.30 .73, 2.32 
LTC type2 -.81* -1.53, -.21* .44 .23, .84 
Years since diagnosis .01 -.01, .05 1.01 .98, 1.04 
More than one LTC .30 -.28, .93 1.36 .76, 2.42 
Depression (PHQ-8) .08* .03, .14* 1.08 1.03, 1.13 
Country of residence (UK vs. all 
other countries)3 
-.70 -1.77, .27 .49 .18, 1.29 
    
Step 2: Baseline psychological flexibility 
processes  
  R
2=.117 
 Δ2 (1)=.003(p=.95) 
 
-2LL=344.16 (2(8)4.38, p=.82)  
  
 
 
b Bca 95% CI OR OR 95% CI 
Psychological inflexibility (AAQ-II) <.01 -.03, .04 1.00 .96, 1.03 
     
Adherent=0, Non-adherent=1; 1Working=0; 2Parkinson’s disease=0; 3UK=0; 2 Chi-squared 
goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% bootstrapped CI  (bias 
corrected and accelerated beta value 95% confidence intervals with 1000 samples); *beta is 
significant <.05 (2-tailed); OR (standardized odds ratio); OR 95% CI (standardized odds ratio 95% 
confidence intervals); -2LL(-2 Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II 
(Acceptance and Action Questionnaire II); CompACT total BA (CompACT Behavioural Awareness 
subscale); PHQ-8 total (Patient Health Questionnaire 8-items). 
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3.2.7 Binomial regressions routine appointment attendance 
 
The third logistic regression did not satisfy the linearity of the logit assumption for the 
CompACT ‘behavioural awareness’ (p=.05), so should be interpreted with caution in testing 
baseline validated PF measures in predicting nonattendance to related health care appointments 
in the last 2-3 months (i.e. anything less than 100%) at 3-month follow-up controlling for 
relevant demographic and disease variables (Table 18). Demographic and disease variables 
accounted for 3.9% (Nagelkerke R2=.039) of the variance in nonattendance in the last 2-3 
months but did not significantly improve the model fit (2(3)=6.85, p=.077). Having more than 
one LTC (OR=1.99, 95% CI=[1.01, 3.94]) was associated with increased odds of 
nonattendance. Adding PF processes did not significantly improve the model fit (Δ2(4)=8.41 
(p=.07, 2LL= 249.82), explaining a further 4.7% (Nagelkerke ΔR2=.047) of the variance. 
However, consistent with baseline analyses, engaging in valued action (OR=.93, 95% 
CI=[.89,.98]) was associated with decreased odds of non-attendance. 
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Table 18: Multiple binomial logistic regression to predict appointment nonattendance in the 
last 2-3 months at 3-month follow-up. 
 
Step 1: Baseline demographic and disease 
variables 
  
n=286  R2=.039 
2 (3) = 6.85 (p=.07) 
 
-2LL = 246.90 (2(8)11.96, p=.15) 
  
 
 
b Bca 95% CI OR OR 95% CI 
More than one LTC .69* .052, 1.50* 1.99 1.01, 3.94 
Depression (PHQ-8) <.01 -.07, .08 1.00 .92, 1.08 
Anxiety (GAD-7) .02 -.05, .10 1.02 .94, 1.11 
    
Step 2: Baseline psychological flexibility 
processes  
  R
2=.086 
 Δ2 (4) = 8.41 (p=.07) 
 
-2LL=249.82 (2(8)14.95, p=.06)  
  
 
 
b Bca 95% CI OR OR 95% CI 
Psychological inflexibility (AAQ-II) .02 -.03, .08 1.02 .97, 1.08 
Openness to Experience subscale 
(CompACT total OE) 
.01 -.03, .06 1.01 .97, 1.06 
Behavioural awareness (CompACT 
total BA) 
.01 -.05, .08 1.01 .95, 1.08 
Valued Action (CompACT total VA) -.06* -.12, -.01* .93 .89, .98 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2White=0; 2 Chi-squared 
goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% bootstrapped CI  (bias 
corrected and accelerated beta value 95% confidence intervals with 1000 samples); *beta is 
significant <.05 (2-tailed); OR (standardized odds ratio); OR 95% CI (standardized odds ratio 95% 
confidence intervals); -2LL(-2 Log Likelihood statistic); R2 (Nagelkerke R2 / pseudo R2); AAQ-II 
(Acceptance and Action Questionnaire II); CompACT total BA (CompACT Behavioral Awareness 
subscale); CompACT total OE (CompACT Openness to Experience subscale); CompACT total VA 
(CompACT Valued Action subscale; PHQ-8 total (Patient Health Questionnaire 8-items), GAD-7 
(Generalised Anxiety Disorder scale 7-items) 
 
 
The final logistic regression satisfied diagnostic assumptions and tested the components of 
the PF model in predicting nonattendance to related health care appointments in the last 12 
months (i.e. anything less than 100%) controlling for relevant demographic and disease 
variables (Table 19). Demographic and disease variables accounted for 19.0% (Nagelkerke 
R2=.190) of the variance in nonattendance in the last 12 months, significantly improving the 
model fit (2(7)=38.18 (p<.01). Being older (OR=.96, 95% CI=[.94,.99]) was associated with 
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decreased odds of nonattendance. Adding PF processes did not significantly improve the model 
fit (Δ2(4)=7.12, p=.13, 2LL= 239.77), explaining a further 3.3% (Nagelkerke ΔR2=.033) of the 
variance and none of the processes were related.  
 
Table 19: Multiple binomial logistic regression to predict appointment nonattendance in the 
last 12 months at 3-month follow-up. 
Step 1: Baseline demographic and disease 
variables 
  
n=323  R2=.190 
2 (7) = 38.18 (p<.01) 
 
-2LL = 246.90 (2(8)4.22, p=.83) 
  
 
 
b 
Bca 95% 
CI 
OR OR 95% CI 
Age -.03* -.06, <-.01* .96 .94, .99 
Gender1 -.22 -1.39, .66 .80 .33, 1.94 
More than one LTC .76 -.02, 1.67 2.15 .98, 4.69 
LTC type2 .09 -1.05, 1.20 1.09 .40, 2.98 
Years since diagnosis <-.01 -.04, .03 .99 .96, 1.03 
Depression (PHQ-8) .02 -.07, .09 1.02 .94, 1.10 
Anxiety (GAD-7) .07 <-.01,.17 1.07 .99, 1.16 
    
Step 2: Baseline psychological flexibility 
processes  
  R
2=.223 
 Δ2 (4) =7.12 (p=.13) 
 
-2LL = 239.77 (2(8)46.44, p=.59)  
  
 
 
b 
Bca 95% 
CI 
OR OR 95% CI 
Psychological inflexibility (AAQ-II) -.02 -.08, .03 .97 .92, 1.03 
Openness to Experience subscale 
(CompACT total OE) 
.01 -.04, .06 1.01 .96, 1.05 
Behavioural awareness (CompACT 
total BA) 
-.03 -.12, .04 .97 .90, 1.04 
Valued Action (CompACT total VA) -.06 -.13, <.01 .93 .88, .98 
     
Adherent=0, Non-adherent=1; 1Female=0 with “other” case excluded; 2Parkinson’s Disease=0; 2 
Chi-squared goodness of fit; Δ2 (Chi-squared goodness of fit); b= beta value; Bca 95% 
bootstrapped CI  (bias corrected and accelerated beta value 95% confidence intervals with 1000 
samples);; *beta is significant <.05 (2-tailed); OR (standardized odds ratio); OR 95% CI 
(standardized odds ratio 95% confidence intervals); -2LL(-2 Log Likelihood statistic); R2 
(Nagelkerke R2 / pseudo R2); AAQ-II (Acceptance and Action Questionnaire II); CompACT total 
BA (CompACT Behavioral Awareness subscale); CompACT total OE (CompACT Openness to 
Experience subscale); CompACT total VA (CompACT Valued Action subscale; PHQ-8 total 
(Patient Health Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items) 
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Chapter 4: Discussion 
 
This final chapter will first provide a brief summary of the main findings from the literature 
review and empirical study. Novel contributions of the project will then be highlighted. This 
will be followed by a discussion of the theoretical utility and implications of the PF model in 
conceptualising and treating non-adherence in people with LTCs in relation to previous 
literature. Potential limitations of the thesis will then be discussed. Finally, possible avenues for 
future research and clinical practice to improve our understanding and treatment of non-
adherence are provided. 
 
4.1 Summary of main findings 
 
The current thesis aimed to apply and evaluate the utility of a new conceptual model – 
psychological flexibility – to understand treatment non-adherence in people with LTCs and 
inform the development of novel intervention targets to improve adherence in the future. 
Chapter 1 began by introducing treatment non-adherence as a multifaceted problem, 
highlighting important challenges with operationalising this complex construct. It also provided 
a critical summary of the evidence for several different psychological approaches aiming to 
conceptualise and improve non-adherence, including the theory of planned behaviour, common 
sense model of illness perceptions and necessity concerns framework. However, the overall 
explanatory power of these models were shown to be modest and interventions stemming from 
them demonstrated limited efficacy. The review also illustrated that no single theory provided 
a comprehensive explanation of adherence that fully integrates all potentially important 
psychosocial variables in the literature. The broadly applicable and potentially modifiable 
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processes within ACT’s PF model were identified as an alternative way of integrating existing 
variables to conceptualise non-adherence in people with LTCs but had received less research 
attention to date. Further longitudinal investigation and the development of new momentary 
measurements of PF, adherence and emotional functioning was warranted. 
 
The large longitudinal study presented in Chapter 2 tested key elements of the PF model. 
Adherence and attendance outcomes showed poor convergence overall and unintentional non-
adherence was more common than intentional non-adherence. Findings identified mostly small, 
significant bivariate cross-sectional relationships between PF and self-reported adherence and 
routine appointment attendance outcomes, emotional and general functioning. Specifically, as 
predicted, greater psychological inflexibility was associated with lower levels of adherence and 
appointment attendance and poorer functioning in people with LTCs. PF processes were more 
related to intentional than unintentional non-adherence, where only the CompACT and its 
behavioural awareness subscale (i.e. ‘aware’ sub-process) were significantly related to 
unintentional non-adherence. Furthermore, PF was not significantly associated with adherence 
outcomes and appointment attendance at baseline after controlling for demographic and disease 
variables, indicating few differences between non-adherence subtypes.  
 
Longitudinal bivariate relationships between PF at baseline and adherence and appointment 
attendance outcomes at three months were largely consistent with baseline analyses. However, 
the magnitude of these relationships were generally smaller and not all reached statistical 
significance. Specifically, the AAQ-II was significantly related to unintentional non-adherence 
at three months but unrelated at baseline, while the opposite was true for the CompACT. Only 
bivariate relationships between PF measured using the AAQ-II and valued action subscale of 
the CompACT (i.e. ‘engaged’ sub-process) adherence and appointment attendance in the last 
two-three months remained significant. However, only the valued action subscale retained 
significance in relation to appointment attendance within the last twelve months. Overall, the 
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AAQ-II showed slightly larger associations with adherence and attendance, and mood, 
outcomes compared to the CompACT. While it has been argued that the AAQ-II may reflect a 
measure of generalised emotional distress (Wolgast, 2014) and might artificially enhance its 
explanatory power, the magnitude of correlations with key outcome variables were consistently 
smaller than the PHQ-8 and the GAD-7. An unexpected finding was that PF processes measured 
using the CompACT (i.e. behavioural awareness and valued action subscales) significantly 
improved over the three-month period, despite mood and other outcomes remaining unchanged. 
However, this might reflect measurement error or a characteristic of self-selected participants 
within the follow-up sample. 
 
Baseline self-reports of PF did not significantly predict adherence and appointment 
attendance outcomes at three months follow-up, indicating few differences between non-
adherence subtypes, after controlling for demographic and disease variables. Taken together, 
PF processes only accounted for a very small non-significant proportion of the variance. 
Consistent with a previous cross-sectional study investigating PF in relation to antiretroviral 
therapy non-adherence in people with HIV (Harrison et al., 2019, unpublished) and studies 
examining the application of social cognitive models to understand non-adherence behaviour 
(Brandes & Mullan, 2014; Rob Horne et al., 2013; Rich et al., 2015), current findings indicate 
PF processes (as measured here) have limited explanatory power in understanding non-
adherence in people with LTCs. One possible reason for this finding is that the AAQ-II and 
CompACT are not LTC or adherence specific, but rather measure more general patterns of 
behaviour, and therefore may be less sensitive for, or understandable to, people living in these 
different contexts. Relatedly, the sample included a wide range of conditions that come with 
different adherence behaviour demands. Specifically, some adherence behaviours may be 
considered minimal, whilst others considerably more intrusive, perhaps depending on the 
type/stage of disease. In addition, some adherence behaviours are required to halt progression 
of a disease, whilst others target symptom relief. Arguably, different LTCs will be associated 
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with different numbers of appointments, where some people may be seen more frequently than 
others, potentially adding significant variability in regression analyses. 
 
The study identified a range of demographic and disease factors related to adherence and 
appointment attendance at the bivariate level. However, subsequent regression analyses 
revealed there were more potent demographic and disease predictors of adherence outcomes 
cross-sectionally and longitudinally. Specifically, more years since diagnosis was significantly 
associated with greater likelihood of intentional non-adherence, whilst having Parkinson’s 
disease and higher levels of depression were associated with an increased likelihood of 
unintentional non-adherence. In addition, being older was a significant predictor of poor 
attendance to routine clinical appointments over the last twelve months at three months follow-
up, but cross-sectional relationships were not consistent with this finding. Low mood at baseline 
was significantly associated with greater likelihood of poor appointment attendance outcomes 
cross-sectionally but was not a significant predictor at follow-up. This difference is unlikely to 
be attributable to improvements in mood, which appeared stable over time. These findings 
emphasise the potential importance of contextual factors and need for context-specific measures 
of PF to improve prediction. However, significant relationships between increased age and 
having Parkinson’s disease with unintentional non-adherence, might also support the idea that 
being more forgetful is more likely to be a cause than a form of experiential avoidance (i.e. 
being ‘closed’) per se.  
 
4.2 Contributions to the literature 
 
The current thesis makes a distinct contribution to the literature. This is the first study 
investigating the potentially important role of PF processes in predicting self-reported 
intentional and unintentional non-adherence and routine health care appointment attendance in 
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people with a range of LTCs. Therefore, it improves on previous cross-sectional studies in the 
area (e.g., Harrison et al., 2019, unpublished), providing insight into the potential role of PF in 
predicting adherence and attendance outcomes over time. The survey showed that self-reported 
PF was a relatively weak predictor of self-reported adherence and appointment attendance 
outcomes and certain demographic and disease factors have a potentially significant role to play 
in predicting non-adherence.  
 
4.3 Theoretical implications 
4.3.1 Theoretical implications of our understanding of PF and ACT 
 
The introduction outlined the potential applicability of the PF model as a way to 
conceptualise and treat non-adherence in LTCs. The longitudinal survey findings show PF 
processes have some, albeit limited, explanatory power in understanding self-reported non-
adherence (intentional r=.11-.16; unintentional r=.09-.12) and appointment attendance 
outcomes (2 to 3 months r=.11-.13; 12 months r=.25) at the bivariate level. These findings were 
largely consistent with other psychological models in the literature, including the self-regulation 
model (r=.02-0.12), necessity-concerns framework (OR=.50-1.74) and theory of planned 
behaviour (r=.30). Therefore, at present there is no clear indication that elements drawn from 
any single candidate theory are necessarily more important.  
 
This study found only small relationships between self-reported non-adherence, appointment 
attendance and emotional and general functioning, contrasting with the expectation that non-
adherence triggers low mood and reduces functioning or vice-a-versa. However, consistent with 
the LTC literature (Graham et al., 2016; Kashdan & Rottenberg, 2010; Veehof, Trompetter, 
Bohlmeijer, & Schreurs, 2016) the finding that PF processes share significant medium to large 
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bivariate relationships with emotional functioning suggests the model has some transdiagnostic 
utility in predicting other important domains of functioning and helping people with LTCs better 
manage their distress to increase values-based activity. Many trials in these reviews show that 
PF is a clinically relevant change process, such that increased PF leads to improvements in 
mood (Graham et al., 2016). Given that distress predicts non-adherence and PF correlates 
strongly with mood in the current study, it could be that increasing PF leads to improvements 
in mood, which in turn may reduce non-adherence behaviour. This might explain why ACT 
shows promising preliminary outcomes in adherence in people with LTCs (Moitra et al., 2011; 
Nelson et al., 2014) and psychosis (Spidel et al., 2018), but currently it remains unclear whether 
these improvements are achieved through targeting mood rather than adherence directly. 
 
There are potential theoretical gaps in the PF model and/or measures used here that may 
have accounted for the limited explanatory power in predicting adherence and attendance 
outcomes. First, PF is based on RFT, which provides a universal explanation of how naturally 
occurring human verbal behaviour processes interact with arbitrary language conventions in the 
social context, which can come to dominate our private experience (Torneke, 2010). RFT argues 
this learning can potentially influence our behaviour, including whether people with LTCs 
adhere or not. However, RFT’s operant explanation is less specific about how an individual’s 
established pattern of behaviour might be influenced by, or coincide with, ideas from other 
psychological models, such as personality, pre-existing vulnerabilities, critical life events and 
trauma, and acquired or developmental neurocognitive impairments. Unlike CBT, ACT also de-
emphasises the importance of collaboratively developing a tailored conceptual model to help 
understand the client’s past experience and/or schema to contextualise their present strengths 
and difficulties as a basis for further intervention. However, it has been argued that the same 
verbal processes in RFT will also influence the way clinicians and researchers come to talk 
about, create and evaluate psychological constructs. This can often occur in absence of any 
underlying ontological and epistemological assumptions or overarching basic level theory, or 
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without evaluating the constructs’ validity and utility at an applied level (McCracken & Morley, 
2014). For instance, to date there is still limited evidence testing whether sharing a detailed 
conceptual model incorporating precipitating/vulnerability and other psychological factors 
correlates with better treatment outcomes (Bieling & Kuyken, 2003; Johnstone, 2018).  
 
Relatedly, current findings might also suggest that PF processes as measured in the current 
study are too ‘broad brush’ to predict more discreet non-adherence and appointment attendance 
behaviours, reflecting only some among many other valued actions or goals of an individual. 
Currently, PF measures remain intra-personal and trait-based. As mentioned previously, 
researchers could either try to develop more context-sensitive idiographic and/or momentary 
measures, which would fit with PF/ACT’s focus on behaviours in context. Alternatively, efforts 
could focus on adopting a COM-B approach by looking at PF’s relationship to non-adherence 
in combination with a range of other psychological variables drawn from other candidate 
models, such as specific beliefs about illness or treatments (Karekla, Karademas, & Gloster, 
2018). This ‘lumping’ approach might artificially improve the predictive power of models, but 
equally risk contradicting underlying theoretical assumptions (Harrison et al., 2017). 
Additionally, over-focusing on narrower cognitive treatment targets could also potentially 
overlook broader contextual factors/life circumstances that might be influencing a person’s non-
adherence behaviour (e.g. loss/bereavement, family or relationship problems, access to health 
care). However, recent evidence of merging more theoretically consistent 
approaches/techniques, such as ACT and MI, show promising outcomes in other areas (Ehman 
& Gross, 2019). 
 
Second, bivariate correlations in the baseline analysis indicated certain socio-demographic 
contextual factors were related to non-adherence, including being in a relationship. This finding 
contrasted with a recent study examining similar relationships in people with HIV indicating 
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being single was a potent predictor of non-adherence to anti-retroviral therapy (Harrison et al., 
2019). It is also unclear contextually how or why being ‘in a relationship’ or ‘not’ might exert 
influence on a person’s non-adherence behaviour, and if and how social processes specifically 
contribute to poor adherence through the lens of PF. The current sample was older and therefore 
being in a relationship incorporated people who have experienced death of spouse or divorce, 
as well as being single. Although ACT is fundamentally a relational therapy that seeks to 
understand the person’s broader life context, it is usually confined to the client-therapist 
relationship (Harris, 2009; Hayes et al., 1999). Unlike systemic and family-based approaches 
(Carr, 2000; Dallos & Stedmon, 2006), the PF model and the overly intra-personal PF measures 
are less explicit about how to understand complex social-contextual processes that may 
influence non-adherence and how we might intervene at a broader systems level.  
 
ACT attempts to contextualise a person’s behavioural patterns as either “workable” or 
“unworkable”, which could potentially inform values-based goals about socialising or 
connecting more with others. For instance, taking one’s medication may in some cases be 
required in order to achieve such goals, and yet the same treatments may trigger unpleasant side 
effects that act as barriers to action. However, social-oriented values-based goals or actions in 
ACT are typically individually-derived and attempts to achieve them may not necessarily be 
met with positively reinforcing responses, understanding or reciprocation from others. This 
might explain why some researchers highlight the importance of perceived or actual stigma as 
being bigger drivers of non-adherence than general psychological factors in certain LTCs 
(Fekete, Williams, & Skinta, 2018; Rachlis, Mills, & Cole, 2011). Therefore, only assessing an 
individual’s intra-personal PF processes (as measured here) and targeting these in ACT in 
isolation may be too insensitive to identify or address workable or unworkable contextual-
relational patterns (and, e.g., stigma) and exert a limited impact clinically. Future theoretical 
and intervention developments incorporating social processes (e.g. shared values-based goals 
and experiential avoidance) may enhance the utility of PF in adherence. Family based ACT 
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interventions have been argued to be more applicable particularly in young people who are non-
adherent to medications (Hadlandsmyth et al., 2013). Such developments could potentially 
involve obtaining outcomes of the individual’s family, carer, or friends. However, this may be 
particularly problematic if the individual experiences unchangeable complex social 
circumstances and/or social dynamics in the home or work contexts (e.g. an unsupportive, or 
overly solicitous, partner/carer, colleague or health care provider). Unfortunately, the current 
study did not successfully recruit adolescents with LTCs as initially planned, therefore the 
applicability of PF to understand non-adherence in this subgroup remains unclear.  
 
Third, the sample included people with a range of LTCs who are likely to be prescribed a 
variety of different treatments, indicating that more years since diagnosis and LTC type were 
consistent predictors over time. However, potential distinctions between biomedical factors in 
the PF model also remain unclear. Despite being promoted as a transdiagnostic approach, which 
is largely supported by a recent study including only people with HIV (Harrison et al., 2019, 
unpublished), the varied and complex nature of treatment regimens and their biological impact 
on the body cannot easily be explained by PF. Future studies could explore potential differences 
between specific LTCs, co-morbidity (Williams et al., 2008) and treatments in conjunction with 
PF processes to identify at risk groups. For example, the over-use of pain relief medications 
observed in chronic pain are also a form of non-adherence behaviour that will likely differ to 
other LTCs (Harrison, Graham, & McCracken, 2017). It might also be helpful to explore 
potential differences within LTCs, for example testing stage of disease progression, use of 
polypharmacy and whether there are short and long-term psychological consequences of 
following regimens that range in complexity and method of administration (e.g., painful 
injectables like disease modifying treatments in MS: Remington, Rodriguez, Logan, 
Williamson, & Treadaway, 2013).  
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Fourth, it could be argued that PF, as measured in the current broad LTC sample, does not 
incorporate enough disease-specific biological processes to explore the interaction between 
aspects of all three elements in the broader “biopsychosocial” framework (Engel, 1977). As 
newer adherence technologies emerge to support more objective ways of measuring adherence, 
aspects of biological processes may be more easily incorporated in PF and adherence studies. 
However, theoretically PF prioritises behavioural processes that have broad applicability in 
measuring with precision, predicting and influencing outcomes (Hayes, Pistorello, & Levin, 
2012), and whilst it acknowledges neuro- and physiological processes are important, it does not 
deem these variables as directly modifiable through treatments like ACT. To date, no studies 
have examined the relationship between PF processes, adherence and neurophysiological or 
physiological variables in LTCs. Therefore, investigating relationships between PF and 
physiology processes may be an interesting avenue for future research. 
 
A related point is that Parkinson’s disease and higher levels of depression were significant 
predictors of unintentional non-adherence (i.e. forgetting) in the sample. Acute or chronic 
neurocognitive changes are common in these and other LTC groups and often associated with 
non-adherence (Lovejoy & Suhr, 2009). A recent HIV sample reported significant medium 
sized relationships between perceived cognitive problems and unintentional non-adherence 
(Harrison et al., 2019, unpublished). However, no studies have explored potential moderating 
relationships between actual neurocognitive impairments in the context of PF and adherence 
relationships and whether they are modifiable as part of an ACT intervention, or whether an 
adjunctive neurorehabilitation component focussing on remedial and compensatory strategies 
may be optimal. 
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4.3.1 Theoretical implications of our understanding of adherence 
 
Eighty-eight percent of the baseline sample were estimated to be non-adherent, according to 
the binary cut-offs of the MARS-5, whilst 84.6% reported they attend 100% of their medical 
appointments. The high percentage of non-adherers according the MARS-5 is almost double 
the proportion of estimates recorded in previous studies in the LTC literature, which range from 
25% to 50% (Coleman et al., 2012; DiMatteo, 2004b; DiMatteo, Giordani, Lepper, & Croghan, 
2002; Haynes, 2001; Osterberg & Blaschke, 2005). Aside from possible self-selection bias and 
poor stability of the binary cut-offs score over time, one possible reason for this could be that 
the sample was predominantly comprised of older people with Parkinson’s disease, who might 
experience challenges with memory and increased use of polypharmacy at this later life stage. 
However, a related issue could also be that the items used within the MARS-5 significantly 
contributed to variability in the data when applied to such a diverse sample of people with 
different LTCs and corresponding treatment regimens. For instance, a person with 
comorbidities and multiple treatment regimens at timepoint one may have answered items at 
timepoint two with a different condition and medications in mind. Additionally, participant’s 
interpretation and response of items on the MARS-5, such as “I adjust the dosage of my 
medication”, may also have captured either a person’s tendency to alter their medication use 
against (or in line with) their doctor’s advice, depending on the specific treatment or condition 
they are referring to.      
 
Despite the relatively small relationships between self-reported adherence and general 
functioning, there is also an implicit assumption in most adherence, concordance or compliance 
research that non-adherence and symptom exacerbation, or illness deterioration, will equate to 
reduced engagement in meaningful activities and QoL. This prevailing view is perhaps 
unsurprising from a ‘common sense’ point of view, but also given that historically a significant 
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proportion of adherence research has been funded by pharmaceutical companies. However, the 
PF and ACT literature indicates that people can live valued lives despite the presence and 
progression of difficult symptoms and prognoses, especially when adaptations to valued-
activity are modified to account for such changes (Graham et al., 2016). Typically, adherence 
is the goal, but it may be that unpleasant side-effects and poor prognosis influence a person’s 
informed and valued choice to not adhere, whilst at the same time continuing to pursue other 
valued activities. For example, taking breast cancer hormone therapies that reduce the chance 
of cancer recurrence may for some people cause extreme side effects that adversely affect their 
QoL (e.g. significant pain, sexual dysfunction etc.) Therefore, it could be at times more in line 
with the person’s values to be non-adherent and accept they have a slightly increased chance of 
disease recurrence in order to have a better QoL, rather than a greater chance of quantity of life. 
This would suggest that greater PF may not necessarily relate 100% to higher rates of adherence. 
Ultimately, PF and ACT may still potentially be a useful approach to support people in 
developing an awareness of the consistency (or lack of consistency) between their values and 
behaviour, rather than specifically targeting PF with the sole aim of improving adherence. 
 
4.4 Limitations 
 
The current study has several limitations, which are outlined in the following section.  
 
First, longitudinal studies are useful to quantify temporal relationships between self-reported 
PF, adherence and attendance, and general and emotional functioning. However, causation 
cannot strictly be inferred, since changes in other exogeneous factors or contextual processes 
may have exerted influence on participants reporting of PF and adherence behaviour during the 
three-month period (Cole & Maxwell, 2003). However, evidence from ACT-based 
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interventions targeting adherence offer preliminary support for the idea that PF processes could 
be modified to improve adherence in the context of LTCs (Moitra & Gaudiano, 2016; Nelson 
et al., 2014). 
 
Second, the importance of non-significant PF predictors may also be underestimated due to 
common-method variance and conceptual overlap with other psychological/emotional 
processes in some regression models. However, sensitivity analyses were conducted with 
anxiety and depression removed from these analyses, revealing only modest change in effect 
sizes. Relatedly, CFAs tested the validity of proposed factor structures in all PF, adherence and 
emotional and general functioning variables, but standard hierarchical regression analyses were 
used to assess predictive relationships, which do not account for measurement structure overlap 
or error accrued by scale items (MacKenzie & Podsakoff, 2012). Another issue was that the 
data-driven, rather than strictly theoretically-driven, approach informing the inclusion of 
covariates and predictors within the regression models meant they were not directly comparable, 
and the differing number of variables may have inadvertently advantaged or disadvantaged 
particular models. 
 
Third, the use of two timepoints over a three-month period reflected a compromise between 
the primary and secondary aims. However, this relatively short timescale precludes clear 
interpretation of relationships over a longer follow-up period. Another issue is that two 
timepoints have been described as insufficient to be a robust longitudinal design for two reasons. 
First, any change reflects “only an increment of difference between the two times and does not 
evaluate if change was steady or delayed, or whether it plateaued and then changed again” 
(Ployhart & Vandenberg, 2010, p.97). Second, true change and measurement error may be 
confounded, such that true change is assumed when in fact measurement error suppresses scores 
at baseline and increases them at follow-up (Ployhart & Vandenberg, 2010). Relatedly, Ployhart 
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et al. (Ployhart & Vandenberg, 2010) also suggest at least three timepoints is optimal for 
increasing precision of reliability estimates and temporal ordering of variables for mediational 
analyses. However, as this study was exploratory in nature no mediational hypotheses were 
tested. 
 
4.4.1 Sampling 
 
The online study was successful in recruiting people with LTCs with a range of demographic 
and disease characteristics from a range of voluntary sector organisations, but none were 
recruited via the National Health Service (NHS). Therefore, the health status and diagnosis of 
participants in the sample could not be confirmed by a medical professional and self-selection 
bias is likely. Another challenge with self-selection bias in online adherence research 
specifically is that participants may be inherently more responsive and adherent, representing 
only a small proportion of the larger LTC population who may be harder to reach.  
 
Relatedly, the sample was unusual in that 41.0% percent of participants were diagnosed with 
Parkinson’s disease, in their mid-fifties, and predominantly English-speaking UK residents. 
However, no sensitivity analyses were conducted to directly compare adherence, and the 
relationship between PF and adherence, of people with Parkinson’s Disease with other LTCs. 
The sample was therefore less representative of people with other LTCs and adolescents, despite 
efforts to recruit for an adolescent version of the survey, and the fact that UK has a different 
health care access context compared to other countries. Additionally, the study did not explore 
polypharmacy, which is more common in older people with LTCs (Marcum & Gellad, 2012). 
This may have contributed significant variability to the regression analyses data since 
participants may have responded to the MARS-5 quite differently, where for example, they 
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defer to an average rating for all regimens or for one only, and/or provide ratings for different 
treatments at the two time points. 
 
Although the initial sample size for the study was large and cross-sectional and longitudinal 
analyses were arguably sufficiently powered (Faul et al., 2009), the attrition rate was relatively 
high (48.0%) and there was no way of enumerating response rates, which may limit 
generalisability of findings. The study was hypothesis-driven using pre-registration to avoid 
data fishing. However, the number of correlations explored in combination with the initially 
large sample size may have resulted in detecting spurious or artificially inflated effects. Another 
issue is that the range of LTCs and reduced sample size at follow-up meant that prediction 
models precluded potential moderation and subgroup effects, where combining all LTCs into 
one group may lose potentially important distinctions. However, the study was exploratory in 
nature and no specific hypotheses about subgroups were identified a priori. 
 
4.4.2 Self-report of adherence, attendance and disease characteristics 
 
In addition to theoretical limitations of PF outlined, there may be other possible reasons why 
PF processes showed small correlations with self-reported non-adherence and appointment 
attendance outcomes in this study related to measurement error.  
 
First, the online survey format precluded the use of more objective measures of adherence 
and self-reporting biases commonly highlighted in the adherence literature (Horne, 2006) would 
likely have significantly under- or possibly over-estimated the rate of actual rates of non-
adherence. Responses on the appointment attendance scales may not necessarily reflect a 
person’s choice, since more severely disabled participants may want to attend face-to-face 
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medical appointments but may struggle to do so. Additionally, the longitudinal analyses meant 
that the retrospective twelve months attendance outcome reflected behaviours that pre-dated the 
baseline score. 
 
Second, the ‘near perfect’ categorical anchors of adherence used for the MARS-5 will have 
likely reduced precision, having indicated that 88.5% of sample were unintentionally non-
adherent, which potentially reflects a gross overestimate compared to previous adherence 
studies. Therefore, it follows that cut-offs applied to intentional and unintentional non-
adherence will likely have impacted on the precision and accuracy of ‘caseness’ within the 
regression models and predictive accuracy of PF and other variables.  
 
Third, poor convergence between self-reported adherence on the MARS-5 and new 
attendance outcomes raises the question of whether either were adequately measuring adherence 
and health utilisation in the current sample. This was supported by confirmatory factor and test-
re-test analyses, which indicated the MARS-5 may not be accurately measuring what it intends 
to measure in this sample, nor is it optimally reliable over time. In contrast, the single-item 
attendance outcomes could not be factor-analysed, were skewed and therefore categorised into 
binary cut-offs similar to the MARS-5 but showed moderate levels of stability over time. The 
near perfect cut-offs used for both measures might therefore not have sufficiently captured 
variability in PF or emotional and general functioning. However, the new attendance scales 
were designed to reduce participant burden and the MARS-5 was used to capture pragmatic 
adherence subcategories, where other scales did not differentiate between intentional and 
unintentional non-adherence and/or were too costly (Morisky et al., 1986). Despite these 
limitations, the MARS-5 and appointment attendance scales offered a universal, albeit with 
potentially debatable validity, way of quantifying adherence across LTCs. Support for both 
measures were that relationships with key variables mostly fell in expected directions and 
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potential lack of measurement precision might suggest the magnitude of these effects were 
underestimated. 
  
Fourth, the MARS-5 adherence did not specify a time-frame. It is therefore plausible that 
participants provided an average rating over a self-selected timeframe. Arguably, problems with 
retrospective bias can also arise with measures that specify historical timeframes (Moskowitz 
& Young, 2006). 
 
A further limitation was that the study used non-validated self-report questions about 
participant’s LTCs that did not distinguish between disease severity and/or disease-specific 
functioning using validated measures. In addition, disease variables (e.g. disease duration and 
number of LTCs) may also have been susceptible to either exaggeration or under-reporting by 
participants. However, obtaining confirmation by medical professionals about participant’s 
disease subtype or severity, relapse status and treatment regimens (and related allergies or 
adverse reactions to them) on entry to the study would have provided greater accuracy. 
However, obtaining this information would also have been costly and time consuming, 
potentially increasing participant burden and adding increasing complexity to statistical 
analyses.  
 
4.4.3 Self-report psychometric instruments 
 
A final limitation relates to the self-reported questionnaires used to assess PF, mood and 
general functioning constructs in the longitudinal study. Most scales included in the adult 
sample have been used in other LTC samples, but few of them have been properly validated. 
Attempting to validate new momentary measures against established measures that have yet to 
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be fully validated in LTC samples may undermine convergent, criterion and predictive validity. 
However, efforts were made to confirm the validity of all scales using CFA methods. These 
suggested it was unclear if the underlying constructs identified in a previous validation sample 
for the CompACT were indicated based on more established fit indices, though the goodness of 
fit criteria designed to test ordinal data was acceptable (Francis et al., 2016).  
 
Despite this, all psychological scales showed acceptable internal consistencies and test-re-
test reliabilities, although significant life events that might explain reliable change over the 
three-month period could not be ruled-out. Additionally, all scales produced correlations with 
adherence and appointment attendance outcomes and emotional and general functioning in 
hypothesised directions, consistent with previous PF correlational (Cheung & Mak, 2016; 
Kamody et al., 2017) and ACT-based intervention literature (Moitra & Gaudiano, 2016; Nelson 
et al., 2014) supporting criterion and predictive validity. Discriminant validity of established 
scales was not examined in the current study, but the varied magnitude of correlations between 
mood and PF with adherence and attendance outcomes provided some preliminary support for 
the idea that measures tapped overlapping but distinct constructs. 
 
As mentioned previously, PF measures may have been too ‘broad brush’ to capture 
variability in more discreet adherence behaviours. Therefore, an important challenge for 
measurement development in PF and adherence research is deciding whether to use more 
established generic intra-personal PF measures or develop LTC and/or non-adherence-specific 
PF scales that is sufficiently sensitive to context, but equally does not inadvertently overlap with 
behavioural descriptions in self-reported adherence instruments.  
 
A further limitation is that other than self-reported anxiety and depression, the questionnaire 
did not ask participants about other emotions, such as anger, or ask about other mental health 
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difficulties using a valid and reliable self-report instruments (e.g., Zimmerman & Mattia, 2001) 
or clinician diagnostic interviews (e.g., First, Gibbon, Spitzer, Benjamin, & Williams, 1997). 
Therefore, other mental health difficulties were not controlled for statistically or by exclusion, 
which may also contribute to non-adherence.   
 
4.5 Future directions and clinical implications  
 
The previous section highlights several methodological issues that future research should 
attempt to address. With these in mind, the current thesis identifies several important avenues 
for future research summarised in the following section. 
 
Future studies examining temporal relationships between PF and adherence and appointment 
attendance outcomes may benefit from the following: 
 
First, sufficiently powered temporal designs should either incorporate three or preferably 
more timepoints to capture true change over time (Ployhart & Vandenberg, 2010) to further 
examine theoretically-informed interrelationships (i.e. mediation) between PF, general and 
emotional functioning with more objective valid and reliable adherence measures. 
Alternatively, temporal designs could also include sufficiently powered EMA studies or RCTs. 
The secondary aim of the current study incorporated feedback from experts by experience and 
preliminarily validated the new ultra-brief momentary/state scales of PF, mood and adherence 
for people with LTCs with some success. Relatedly, when assessing test-re-test reliability future 
research could also explore responsiveness, by asking participants questions about key life 
events over the study period (e.g. disease activity/relapse, change in medication, uptake of 
psychological or psychiatric treatments) that might provide some understanding of why changes 
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might have occurred. Conducting sensitivity analysis with only those people who are stable over 
time may also be informative. 
 
Second, given the possible variance between and within LTC groups, and their respective 
treatments and use of polypharmacy, it might also be helpful to limit samples to specific LTCs 
to ensure they are sufficiently representative. Efforts should also be made to conduct future 
studies with adolescents and adults separately as there are likely to be important distinctions.  
 
Third, using structural equation modelling procedures (Anderson & Gerbing, 1988) to first 
factor-analyse observed variables and then use these models to estimate temporal relationships 
between more objective adherence and healthcare utilisation outcomes in conjunction with 
emotional, physical and social-role functioning outcomes might tell us more about these 
interrelationships. SEM methods could also determine the unique contribution of separate 
models to directly compare them head-to-head or in combination. Such analyses could also 
incorporate theoretically informed mediation, moderation, subgroup and/or sensitivity analyses 
to test if key demographic and disease variables identified in the current study (i.e. age, 
depression, perceived or actual neurocognitive impairments, LTC type and perhaps country of 
residence) differentially influence these relationships to identify at risk groups. Equally, latent 
class analysis may be useful in this regard (Tyndall et al., 2018). 
 
Fourth, valid and more objective measures of adherence and health care utilisation, such as 
nebuliser microchips used in cystic fibrosis (Latchford et al., 2009), MEMS® and others 
obtained via existing medical records (e.g. actual health care appointment attendance and 
relevant biomarkers), could be triangulated with self-report instruments. Self-reported 
adherence measures should be validated for specific LTCs with established non-adherence cut-
offs and ideally specify a specific timeframe to improve precision to an extent. For example, 
specific number of doses skipped in HIV may be more important in relation to CD4+ counts and 
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functioning than anchors used in the MARS-5. The current study suggests using adherence 
instruments that distinguish intentional and unintentional non-adherence may be less important 
in relation to PF. However, better validated measures incorporating these constructs might be 
clinically meaningful and help to clarify differences in PF-adherence and health care utilisation 
relationships across demographic and disease variables, such as age, years since diagnosis, LTC 
type and depression.  
 
Given that self-report adherence data is commonly negatively skewed and often results in 
the use of relatively arbitrary categories of adherence and non-adherence by researchers (see 
email communication from Professor Rob Horne Appendix L), one alternative approach might 
be to conduct receiver operating characteristic (ROC) analyses (Hajian-Tilaki, 2013) as part of 
a self-reported adherence measure’s validation study, which could involve setting it against 
more objective measures of adherence to determine more meaningful cut-offs to improve 
convergent validity. 
 
Fifth, it may be useful to include more than one overall measure of PF in a given study to 
further clarify the factor structure of scales like the CompACT in LTCs. Alternatively, other 
scales specific to each aspect of the six-process model are also available to use showing good 
psychometric properties (e.g., Cardaciotto, Herbert, Forman, Moitra, & Farrow, 2008; 
Gillanders et al., 2014; Trompetter et al., 2013; Zettle et al., 2018). 
 
Sixth, one way to overcome measurement problems and aggregation bias (Johnston & 
Johnston, 2013) might be to use more objective ecological momentary assessments of adherence 
in conjunction with preliminarily validated momentary measures of PF and mood that were 
developed as part of the current study’s secondary aim. Briefly, two new 3-item daily and hourly 
PF scales showed acceptable psychometric properties for potential use in EMA designs. 
Alternatively, other momentary measures informed more directly by general RFT processes are 
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also available (Levin, Krafft, Pierce, & Potts, 2018; Pierce & Levin, 2019) and possible 
alternatives to self-report have been recently proposed (Newsome, Newsome, Fuller, & Meyer, 
2018). Other ACT researchers have also highlighted how EMA could potentially capture 
dynamic changes over time and across contexts (e.g. using emerging smartphone application 
technologies), including potential effects of periodic and cumulative non-adherence in the 
context mental health (Moitra & Gaudiano, 2016) and LTCs. EMA methods also examine 
within-individual and group-level relationships between variables in conjunction with relevant 
events or changes in routine (Hektner et al., 2007). An important step in developing the 3-item 
PF momentary scales as part of the secondary aim of the current project has been consulting 
with people with LTCs when co-constructing ultra-brief momentary measures for people with 
LTCs to ensure measure content is understandable3.1However, using additional methods, such 
as Delphi and/or think aloud approaches, might be helpful to capture patient and clinicians 
lived-experience or views of the scales in greater depth to further inform the measure 
development process. 
 
Finally, depending on the outcome of these preclinical studies, it might be more 
economically viable to develop and evaluate briefer ACT-based interventions for people with 
LTCs to address non-adherence. These could potentially be delivered via minimal face-to-face 
or telephone and/or email support by clinical psychologists and/or other HCPs. Specifically, 
Focused ACT (FACT) works on the assumption that the modal frequency of psychological 
sessions is one, and therefore FACT is specifically designed to shift PF processes in the context 
of brief health care consultations (Strosahl, Robinson, & Gustavsson, 2012). However, arguably 
it may also be important to evaluate the feasibility and efficacy of standard-length ACT 
interventions for adherence in specific LTCs prior to embarking on this work. 
 
                                            
31While outside the scope of this thesis, these findings will be published at a later date. 
 127 
 
Such an intervention could potentially be supplemented by a guided self-help web-based 
platform to improve access that is informed by a more reliable clinical assessment process. The 
current study findings indicate that it may be important to screen service-users for other 
potentially important contextual factors, such as age, duration of illness, depression 
neurocognitive impairments, LTC type and relationship status. Individuals with these 
characteristics may require a simpler approach, more time to complete sessions, remedial or 
compensatory strategies (e.g. simple smartphone reminders) to support homework completion 
and promote adherence (Alfonsson, Englund, & Parling, 2019) and/or a higher intensity 
intervention. Interventions such as FACT may have useful applications in adherence but need 
to be preliminarily evaluated in case-series studies, and feasibility and definitive RCTs to ensure 
they acceptable to people with LTCs and cost-effective. Orienting HCPs to ACT ideas via a 
brief clinician training may also improve delivery and facilitation of informed-consent and 
collaborative decision-making processes in consultation with people with LTCs (Conn et al., 
2015; Levin, Herbert, & Forman, 2017). Competency assessment and regular supervision 
ideally provided by a clinical health psychologist may further support therapist’s fidelity to the 
model. 
 
4.6 Conclusions  
 
This initial investigation found limited evidence for a contribution of PF model to 
explanations of non-adherence in LTCs. The two classifications of adherence did not appear to 
have any clear differential psychological responses associated with them. Given that ACT seeks 
directly to improve PF, the present study does not suggest that ACT is more suitable than 
existing behaviour change approaches informed by social cognitive models. However, this 
study is the first longitudinal evaluation of PF and further research with more sensitive 
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adherence and context-sensitive PF measurements and methodologies may give more precise 
evaluations on which to base future trials or clinical practice. 
 
The study identifies significant methodological problems. However, whilst adherence 
appears to be multifactorial in nature, findings suggest that ACT may have a small role in 
helping improve non-adherence in LTCs, but that contextual factors, such as being older, in a 
relationship, having a longer disease duration, depression and cognitive impairments, should 
first be considered within an intervention. However, in the current study relationships between 
mood and PF were medium to strong, consistent with established evidence showing 
interventions targeting PF can improve mood in the wider LTC and mental health literature. 
Therefore, ACT’s efficacy could reduce non-adherence via improvements in mood. 
 
Less research has been conducted to support the idea that ACT-based approaches may 
improve adherence outcomes as compared to general and emotional functioning, which might 
be transferrable to a range of treatments. Currently, studies focusing specifically on adherence 
are mostly small, uncontrolled and have not measured PF processes as part of mediation 
analyses. Assessment of key therapeutic mechanisms in larger trials after EMA investigations 
could further clarify the idiographic and group-level utility of PF model. Moderation analyses 
will help determine who may benefit and identify at risk groups. In practice, such approaches 
aim to assist people in opening-up to thoughts and feelings related to non-adherence to pursue 
valued actions or goals. It might be that designing and evaluating either separate or integrated 
theories, and corresponding treatment approaches, may lead to more effective psychological 
interventions for adherence in LTCs in the future. 
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Appendix A 
Search strategy for literature review 
 
Databases: Medline, PsychInfo, EMBASE December 2017 and April 2019. 
 
1. Adherence/ OR 
2. Medication adherence.mp. OR 
3. Adherence.mp. OR 
4. Non$adherence.mp. OR 
5. Compliance/ OR 
6. Compliance.mp. OR 
7. Concordance/ OR 
8. Concordance.mp.  
 
9. Psychotherapy/ OR 
10. Psycho*.mp. OR 
11. Social cognitive.mp. OR 
12. Behavio$r change.mp. OR 
13. Acceptance and Commitment Therapy/  
 
14. Chronic health conditions/ OR 
15. Chronic illness/ OR 
16. Long-term health conditons.mp. 
 
17. 1 to 8 AND 9 to 12 AND 13 to 15 
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INFORMATION SHEET FOR PARTICIPANTS 
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Medication Adherence in Physical health conditions (MAP) study 
We would like to invite you to take part in a research study conducted by Leeds University. The study 
will investigate people’s experiences of taking medication for physical health conditions. Before you 
decide whether you want to take part, it is important for you to understand why the research is being 
done and what your participation will involve. Please take time to read the following information carefully 
and discuss it with family members or friends if you wish. Please contact the research team if anything 
is unclear or if you would like more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
Who is conducting, organising and funding the study?   
This project is being conducted by Dr. Anthony Harrison (Principal Investigator), Psychologist in Clinical 
Training at the University of Leeds. The study is being conducted as part of Anthony’s doctoral studies 
along with his supervisors, Dr. Christopher Graham and Dr. Gary Latchford (Chief Investigator). It is an 
unfunded study, forming part of Anthony’s Doctorate in Clinical Psychology at Leeds University. 
What is the purpose of the study?  
Previous research has shown that people living with illness may not always take prescribed medication 
to manage their condition. How people think and feel is related to whether they take medication or not, 
where most studies have focused on people’s mood or beliefs about their medication or illness 
specifically. However, little research has explored how people relate to their thinking, and how certain 
types of behaviour might also impact on how they take their medication. We are interested in how people 
with chronic health conditions respond to taking their medication, how much it affects them, and how 
they deal with it on the day-to-day. Better understanding how people with chronic health conditions relate 
to their thinking about medication, and how they behave, will help researchers develop new treatments 
aiming to support people living with illness. 
Why have I been chosen?  
You have been approached about this study because you are 16 years old or older and have a physical 
health condition and have been prescribed medication to manage it. We have invited people with a 
variety of conditions to take part in the project. 
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Do I have to take part?  
No. It is up to you to decide whether to take part or not. If you are interested in taking part, we will ask 
you to tick a box conforming your consent prior to completing the survey. You are free to change your 
mind and to withdraw at any time. This will not in any way affect your standard of care. 
What will happen to me if I take part?  
If you agree to take part after reading this information sheet you can access the online questionnaire 
directly by continuing with this survey.  
The survey will ask you questions about your health condition and how it affects your life, experiences 
of taking medication, and how you relate to your thoughts, feelings and behaviours, and should take 
around twenty minutes to complete. You can save a partially completed questionnaire and complete it 
later if you wish. If you submit a partially completed questionnaire, where possible your information will 
still be used in our data analysis, unless you request contact us to withdraw your data. 
We will ask you to tell us if you wish to complete the questionnaire again at three months. This will allow 
us to see if and how your experience changes over time. We will ask for your email address at the end 
of the questionnaire so we can send you the second questionnaire link via email. You can withdraw your 
data for either the first or second questionnaire up until the final analysis date (01.03.2019) and it will not 
be used in the final analysis. You will need to contact us directly to request this using the same email 
address you entered at the start of either questionnaire. If you do not provide us with your email address 
at the start of either questionnaire your data cannot be withdrawn once submitted because it will be 
unidentifiable, and we will be unable to link your first questionnaire to your second questionnaire. It is optional 
to provide your name and email address. Please be aware that if you decide to provide your name and/or 
email address to receive the follow-up questionnaire and/or results of the study, your questionnaire will not 
be anonymous.  
Will You Compensate Me for My Time? 
Unfortunately, this is unfunded study therefore we cannot compensate you for your time. While we very 
much appreciate your help, and you may find the experience useful, you will not benefit financially from 
the project. However, at the conclusion of the study, we will send a summary of the results online so you 
can view the main findings. 
Are there any costs? 
The questionnaire will take between 20-30 minutes of your time, so other than your time and effort there 
are no other costs to you associated with the project. 
What are the possible disadvantages and risks of taking part?  
The risks involved in participating are minimal. It is possible that you might find it distressing to reflect 
on questions in relation to your own lived experiences of your illness and taking medication. If you get 
upset, you can skip questions, take a break or decide not to continue with the survey. Should you become 
unduly distressed during or after completion of the questionnaire and continue to feel this way, we 
suggest you access sources of support, including your doctor, but also a family member or friend. For 
any other queries about completing the survey please contact Anthony directly at umamh@leeds.ac.uk, 
Clinical Psychology Training Programme, Institute of Health Sciences School of Medicine, Level 10 
Worsley Building, Clarendon Way, Leeds LS2 9N. 
What are the possible benefits of taking part?  
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There will be no direct benefits to you for taking part in this study. However, the answers that you give 
will provide the researchers with more information about medication use for people with health 
conditions. This information may help to improve the treatment of people with illness in the future. In 
addition, some people may find it helpful or interesting to reflect on how their health condition and 
medication use affects them. On completing the project, we can send you a summary of our findings if 
you prefer.  
If this study has harmed you in any way…  
In the unlikely event that you are unhappy with the way that the project is conducted complaint 
mechanisms are available to you. In the first instance please contact Dr. Gary Latchford 
g.latchford@leeds.ac.uk. If you are not satisfied with this process, we advise you contact Clare Skinner, 
Head of Research Integrity and Governance c.e.skinner@leeds.ac.uk  
Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study will be kept confidential in accordance with the 
Data General Data Protection Regulations 2018. The completed questionnaire data will be downloaded 
onto a secure university computer. Only the researchers will have access to the computer, which will 
have a password to protect all confidential files. 
Any personal details or identifiable information will be removed and contact details will be stored 
separately on another password protected file Your information will only be available to members of the 
research team and will only be used for the purposes of the current study. The data will be kept securely 
at Leeds University. It will be destroyed three years after the research has finished, and your contact 
details will be destroyed once results are sent to you should you opt-in for this.  
What will happen if I don’t want to carry on with the study?  
You are free to withdraw from the study at any time without having to give a reason even if you decide 
to take part initially. However, your data cannot be withdrawn once the results have been analysed and 
written up (01.035.2019). 
What will happen to the results of the study?  
The results of this study may be published in scientific journals and at medical and psychological 
academic conferences. You will not be identified in any report or publication. A lay summary of our 
findings can be emailed to you if you prefer. 
Who has reviewed the study?  
The study has been reviewed by the University of Leeds School of Medical Research Ethics 
Subcommittee (SoMREC) (Ref: MREC17-068) 
 
I understand that by that by ticking “I agree” and completing and 
submitting this questionnaire I am consenting to participate in the study 
  
I agree 
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C.2 Parental participant information sheet on Online Surveys 
 
 
INFORMATION SHEET FOR PARENTS OF ADOLESCENT PARTICIPANTS 
YOU CAN PRINT A COPY OF THIS INFORMATION SHEET OR YOU CAN REQUEST THAT WE SEND 
YOU A VERSION TO YOUR EMAIL 
Medication Adherence in Physical health conditions (MAP) study 
We would like to invite your child to take part in a research study conducted by Leeds University. The 
study will investigate young people’s experiences of taking medication for physical health conditions. 
Before you decide whether you want your child to take part, it is important for you to understand why the 
research is being done and what their participation will involve. Please take time to read the following 
information carefully and discuss it with family members or friends if you wish. Please contact the 
research team if anything is unclear or if you would like more information. Take time to decide whether 
or not you wish for your child to take part. Thank you for reading this. 
Who is conducting, organising and funding the study?  
This project is being conducted by Dr. Anthony Harrison (Principal Investigator), Psychologist in Clinical 
Training at the University of Leeds. The study is being conducted as part of Anthony’s doctoral studies 
along with his supervisors, Dr. Christopher Graham and Dr. Gary Latchford (Chief Investigator). It is an 
unfunded study, forming part of Anthony’s Doctorate in Clinical Psychology at Leeds University. 
What is the purpose of the study?  
Previous research has shown that young people living with illness may not always take prescribed 
medication to manage their condition. How young people think and feel is related to whether they take 
medication or not, where most studies have focused on their mood or beliefs about their medication or 
illness specifically. However, little research has explored how people relate to their thinking, and how 
certain types of behaviour might also impact on how they take their medication. We are interested in 
how young people with chronic health conditions respond to taking their medication, how much it affects 
them, and how they deal with it on the day-to-day. Better understanding how young people with chronic 
health conditions relate to their thinking about medication, and how they behave, will help researchers 
develop new treatments aiming to support them living with illness. 
Why has my child been chosen?  
You have been approached about this study because your child has a physical health condition and has 
been prescribed medication to manage it. We have invited young people with a variety of conditions to 
take part in the project. 
Does my child have to take part?  
No. It is up to you and your child to decide whether to take part or not. If you are interested in your child 
taking part, we will ask you to tick a box conforming your consent prior to getting their consent before 
they complete the survey. You are both free to change your mind and to withdraw at any time. This will 
not in any way affect your child’s standard of care. 
What will happen to my child if they take part?  
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If you agree for your child to take part after reading this information sheet and reviewing the questionnaire 
in the following pages you will be asked to submit a consent form and provide an electronic signature at 
the end. At which point, your child can then access the online questionnaire directly by following a 
weblink provided. It may be helpful to discuss participation in the study with your child/children prior to 
them agreeing to participate.  
The survey will ask your child questions about their health condition and how it affects their life, 
experiences of taking medication, and how it relates to their thoughts, feelings and behaviours. It should 
take around twenty minutes to complete. Your child can save a partially completed questionnaire and 
complete it later if they wish. If your child submits a partially completed questionnaire, where possible 
their information will still be used in our data analysis, unless you or they contact us to request we 
withdraw their data. 
We will ask your child if they wish to complete the questionnaire again at three months. This will allow 
us to see if and how their experience, changes over time. We will ask for their email address at the end 
of the questionnaire so we can send the second questionnaire link to them via email. You or your child 
can withdraw their data for either the first or second questionnaire up until the final analysis date 
(01.03.2019) and it will not be used in the final analysis. They or you will need to contact us directly to 
request this using the same email address they or you entered at the start of both questionnaires. If your 
child or you do not provide us with your email address at the start of either questionnaire their data cannot 
be withdrawn once submitted because it will be unidentifiable, and we will be unable to link your child’s first 
questionnaire to their second questionnaire. It is optional to provide your name and email address. Please 
be aware that if you decide to provide your name and/or email address to receive the follow-up questionnaire 
and/or results of the study, your questionnaire will not be anonymous. 
Will you compensate me or my child for our time? 
Unfortunately, this is unfunded study therefore we cannot compensate for you or your child’s time. While 
we very much appreciate your help, and your child may find the experience useful, your child will not 
benefit financially from the project. However, at the conclusion of the study, we can send a summary of 
the results to you via email so you can view the main findings. 
Are there any costs? 
The questionnaire will take between 20-30 minutes of your child’s time, so other than their time and effort 
there are no other costs to you associated with the project. 
What are the possible disadvantages and risks of taking part?  
The risks involved in participating are minimal. It is possible that you and your child might find it 
distressing to reflect on questions in relation to your own lived experiences of your illness and taking 
medication. If your child gets upset, they can skip questions, take a break or decide not to continue with 
the survey. Should you or your child become unduly distressed during or after viewing or completing the 
questionnaire and continue to feel this way, we suggest you access sources of support, including your 
GP or current NHS clinician/s, NHS 111 (Tel: 111), or other organisations, such as The Samaritans (Tel: 
116 123). For any other queries about completing the survey please contact Anthony directly at 
umamh@leeds.ac.uk, Clinical Psychology Training Programme, Institute of Health Sciences School of 
Medicine, Level 10 Worsley Building, Clarendon Way, Leeds LS2 9N. 
What are the possible benefits of taking part?  
There will be no direct benefits to your child for taking part in this study. However, the answers that they 
give will provide the researchers with more information about medication use for young people with 
health conditions. This information may help to improve the treatment of young people with illness in the 
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future. In addition, some young people may find it helpful or interesting to reflect on how their health 
condition and medication use affects them. On completing the project, we can send you a summary of 
our findings if you prefer.  
If this study has harmed your child in any way…  
In the unlikely event that you are unhappy with the way that the project is conducted complaint 
mechanisms are available to you. In the first instance please contact Dr. Gary Latchford 
g.latchford@leeds.ac.uk. If you are not satisfied with this process, we advise you contact Clare Skinner, 
Head of Research Integrity and Governance c.e.skinner@leeds.ac.uk  
Will my child’s data be kept confidential?  
Yes. All information about your child’s participation in this study will be kept confidential in accordance 
with the General Data Protection Regulations 2018. The completed questionnaire data will be 
downloaded onto a secure university computer. Only the researchers will have access to the computer, 
which will have a password to protect all confidential files. 
Any personal details or identifiable information will be removed and contact details will be stored 
separately on another password protected file. Your child’s information will only be available to members 
of the research team and will only be used for the purposes of the current study. The data will be kept 
securely at Leeds University. It will be destroyed three years after the research has finished, and your 
contact details will be destroyed once results are sent to you should you opt-in for this. 
What will happen if I don’t want to carry on with the study?  
You and your child are free to withdraw from the study at any time without having to give a reason even 
if you decide to take part initially. However, your child’s data cannot be withdrawn once the results have 
been analysed and written up (01.03.2019). 
What will happen to the results of the study?  
The results of this study may be published in scientific journals and at medical and psychological 
academic conferences. Your child will not be identified in any report or publication. A lay summary of our 
findings can be emailed to you if you prefer. 
Who has reviewed the study?  
The study has been reviewed by the University of Leeds School of Medical Research Ethics 
Subcommittee (SoMREC) (Ref: MREC17-068).  
Please now review the questionnaire in the following pages using the "Back" 
and "Next" function at the bottom of each page. At the end of the questionnaire 
you will be asked to submit a consent form and provide an electronic signature. 
At which point your child can then access the online questionnaire directly by 
following the weblink provided. 
[After survey review] 
 
I understand that by ticking “I agree” and submitting this form I am 
consenting to my child’s/children’s participation in the study 
 
  
I agree 
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Providing your contact email is optional. However, providing your email will mean we can 
withdraw your child’s and your data before the final analysis date if you wish 
(01.03.2019). We could also send you the results of this study and news about related 
future studies. 
IMPORTANT: If your child does not provide your (or their own) email address in their 
second questionnaire in 3 months, we will be unable to link it up with their data from the 
first questionnaire. 
Your email address: 
Your child’s full name: 
On submitting your parental consent, please advise your child that they 
can now complete their consent form and survey on their own: [Link to 
adolescent version of survey]  
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C.3 Adolescent (aged 13-15) participant information sheet on Online 
Surveys  
 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
YOU CAN PRINT A COPY OF THIS INFORMATION SHEET OR YOU CAN REQUEST THAT WE SEND 
YOU A VERSION TO YOUR EMAIL 
Medication Adherence in Physical health conditions (MAP) study 
Hi! My name is Dr. Anthony Harrison. I’m a researcher and psychologist doing my clinical training at Leeds 
University. Right now, I’m trying to learn more about how young people take their medications for their illness. 
I would like to ask you to help me by being in a study, but before I do, I want to explain what will happen if 
you decide to help me. So please take time to read the below information and discuss it with family members 
or friends if helpful. Thank you for reading this! 
If you want to take part, you can go ahead and complete the questionnaire after reading this page, which will 
ask you about how you think and feel about taking medications for your health condition, and how deal with 
it from day-to-day. There are no right or wrong answers! It should take about 20 to 30 minutes to finish. 
You can save a nearly finished questionnaire and complete it later if you want. If you submit a half-
completed questionnaire, your information will probably still be used in our data analysis, unless you tell 
us to take it out. We will send a reminder to your email asking you to complete the same questionnaire 
again in three months to help us to see if things change over time for you. You can take out your data 
up until 01.03.2019 and it will not be used in the final analysis. If you want to take it out, you will need to 
contact me using your same email address you enter below. If you do not share your email address with 
me your data cannot be taken out once you submit this questionnaire because I won’t know who you 
are! You don’t have to provide your name and email address. Please be aware that if you decide to 
share your name and/or email address to get the follow-up questionnaire and/or results of the study, 
your questionnaire will not be anonymous. 
There are no costs to taking part, other than your time and effort. By being in the study, you will help me 
understand why young people take or don’t take medication for their physical health condition. 
You might find thinking about some of the questions upsetting. If you get upset, you can skip questions, take 
a break or decide not to carry on with the questionnaire. Should you become really upset during or after 
completing the questionnaire, and continue to feel this way, we suggest you ask you or your parent / guardian 
to contact your doctor, or NHS 111 (Telephone: 111), or other services like The Samaritans (Telephone: 116 
123). If you have any other questions about the survey please contact me directly at umamh@leeds.ac.uk or 
Clinical Psychology Training Programme, Institute of Health Sciences School of Medicine, Level 10 Worsley 
Building, Clarendon Way, Leeds LS2 9N. 
There will be no direct benefits for you taking part in this study (e.g. we can’t give you any money), but the 
answers that you give will give me with more information about medication use for young people with health 
conditions. This information may help to make treatments for young people better in the future. Also, some 
young people may find it helpful or interesting to think about how their health condition and medication use 
makes them think, feel and behave. We can also send you a summary of our findings if you like. 
Your parents/guardian will not know what you have said in the questionnaire. When I tell other people about 
my study, I will not use your name, and no one will be able to tell who I’m talking about.  Your questionnaire 
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data will be downloaded onto a secure Leeds University computer. Only me and my team will get onto the 
computer, and we will use a password-protected files. All your information will be deleted after 3 years. Your 
contact details will be destroyed as soon as the once results are sent to you should you want them. 
Your parent / guardian has said it’s okay for you to be in my study. But if you don’t want to be in the study, 
you don’t have to be. What you decide won’t make any difference to the care you receive for your health 
condition. I won’t be upset, and no one else will be upset, if you don’t want to be in the study. If you want to 
be in the study now but change your mind later, that’s okay. You can stop at any time.  If there is anything 
you don't understand you should tell me so I can explain it to you. 
The results of this study may be written-up in scientific journals and at medical and psychological 
conferences. You will not be identified in any report or publication. We can send you a copy of our findings if 
you like. 
The questionnaire has been seen by the University of Leeds University Ethics Committee who said they 
thought it was fine (Reference number: MREC17-068). 
You can ask me questions about the study.  If you have a question later that you don’t think of now, you can 
email me or ask your parents to call me or send me an email.     
Do you have any questions for me now? If so please email me: umamh@leeds.ac.uk 
Would you like to be in my study and answer some questions about your how you take your medication? 
I understand that by that by ticking “I agree” and completing and 
submitting this questionnaire I am consenting to participate in the study 
  
I agree 
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Appendix D 
Final Online Survey questionnaire for Adults (18+) version 
Demographic and illness information 
 
Please feel free to take a break at any point. You can save your progress at the bottom of each page 
using the 'Finish Later' button on each questions page of the survey. 
 
Questions About Your Illness: 
What physical health condition do you have that you need to take medication for? If 
you have more than one, please indicate which you consider to be your primary 
illness. (This was a drop-down menu of all physical health conditions, including an 
“other” option) 
Do you have more than one physical health conditions listed? Please 
tick 
Yes  
No   
When was your long-term health condition diagnosed? (DD/MM/YY): 
Are you prescribed medications for your illness?  
 
Please 
tick 
Yes  
No (please do not continue with this survey)  
 
Questions About You: 
What is your age (years):  
                     
How do you identify your gender? 
 
Please 
tick 
Female   
Male   
Other gender identity (please specify):  
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What is your ethnicity? 
 White - English /  
      Welsh / Scottish /  
      Northern Irish /            
      British / Irish  
      /Gypsy or Irish  
     Traveller /  
     Any Other  
    White background 
 Mixed / Multiple ethnic  
group - White and Black 
Caribbean / White and 
Black African / White and 
Asian / Any Other Mixed / 
multiple ethnic 
background 
 
 Asian / Asian 
British  
– Indian / Asian  
British   
– Pakistani / Asian 
British      
– Bangladeshi / Asian 
British  
– Chinese / Asian 
British - Any other  
Asian background 
 Black / African / 
Caribbean / Black 
British – African / 
Black British – 
Caribbean / Black 
British – Any other 
Black 
   Other ethnic 
group  
 – Arab Other ethnic 
group  
– Any other ethnic 
group 
 Not known / not 
provided 
 
 
In what country do you currently live?  
(This was a drop-down menu of all countries) 
 
 
What is your present relationship status? 
 
Please 
tick 
Single   
Married / Civil partnership    
Widowed  
Separated / Divorced        
Co-habiting / Living together  
Other (please state):  
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How many years of education have you completed:  ___________ (Years) 
 
Which of the following best describes your current occupational 
status? 
 
Please tick 
Employed outside the home, full-time  
Employed outside the home, part-time  
Self-employed  
Homemaker  
Retired        
Medically retired  
Unemployed      
Full / part-time student   
Other (please state):  
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Work and Social Adjustment Scale (WSAS)  
(Mundt, Marks, Shear, & Greist, 2002) 
 
Questions about your illness: 
Physical health conditions sometimes affect people’s ability to do certain day-to-day tasks. To rate 
problems related to your illness please look at each statement below and use the scale provided to 
indicate how much your illness impairs your ability to carry out the activity. 
Because of my illness my ability to work/study is impaired. ‘0’ means ‘not at all impaired’ and ‘8’ means very 
severely impaired to the point I can't work. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness my home management (cleaning, tidying, shopping, cooking, looking after home or 
children, paying bills) is impaired. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness my social leisure activities (with other people e.g. parties, bars, clubs, outings, visits, 
dating, home entertaining) are impaired. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness, my private leisure activities (done alone, such as reading, gardening, collecting, 
sewing, walking alone) are impaired. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness, my ability to form and maintain close relationships with others, including those I live 
with, is impaired. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
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Medication Adherence Report Scale 5-items (MARS-5)  
(Horne, Hankins, & Jenkins, 2001). 
 
Questions about your medication for your illness: 
Many people find a way of using their medicines which suits them. This may differ from the 
instructions on the label or from what their doctor had said. Here are some ways in which people 
have said they use their medicines. For each statement, please tick the box which best 
applies to you.  
 Never Seldom Sometimes Often Always 
I forget to take my medication 
 
     
I adjust the dosage of my medication  
 
     
I stop using my medication for a while  
 
     
I decide to skip my medication doses 
 
     
I take fewer tablets than prescribed to me 
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New non-validated single-item daily momentary numerical rating scale for self-
reported adherence  
 
In your view, how good have you been at taking your medications for your illness on time 
and as prescribed Today. Please rate on a scale of 0 (not good at all) to 10 (extremely good): 
0 1 2 3 4 5 6 7 8 9 10 
 
Please indicate if not applicable:  
 
New non-validated single-item hourly momentary numerical rating scale for self-
reported adherence  
 
Over the past hour, in your view how good have you been at taking your medications for 
your illness on time and as prescribed. Please rate on a scale of 0 (not good at all) to 10 
(extremely good): 
0 1 2 3 4 5 6 7 8 9 10 
 
Please indicate if not applicable:  
 
New non-validated scales exploring health care utilisation as a proxy of adherence 
 
In the last two to three months, what percentage of routine appointments for your illness 
have you attended?  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
Please indicate if not applicable:  
 
In the last year, what percentage of routine appointments for your illness have you attended?  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
Please indicate if not applicable:  
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Acceptance and Action Questionnaire (AAQ-II)  
(Bond et al., 2011) 
 
Questions about your thinking and how you’re feeling more generally: 
Below you will find a list of statements. Please indicate how true each statement is for you by 
selecting the relevant box.  
 
 
 
 
Never 
 true 
Very 
seldom 
true 
Seldom  
true 
Sometimes  
true 
Frequently  
true 
Almost 
always 
true 
Always  
true 
1. My painful 
experiences and 
memories make 
it difficult for me 
to live a life that I 
would value. 
1 2 3 4 5 6 7 
2. I’m afraid of my 
feelings. 1 2 3 4 5 6 7 
3. I worry about not 
being able to 
control my 
worries and 
feelings. 
1 2 3 4 5 6 7 
4. My painful 
memories 
prevent me from 
having a fulfilling 
life. 
1 2 3 4 5 6 7 
5. Emotions cause 
problems in my 
life. 
1 2 3 4 5 6 7 
6. It seems like 
most people are 
handling their 
lives better than I 
am. 
1 2 3 4 5 6 7 
7. Worries get in 
the way of my 
success. 
1 2 3 4 5 6 7 
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Comprehensive assessment of Acceptance and Commitment Therapy processes 
(CompACT)  
(Francis, Dawson and Golijani-Moghaddam, 2016) 
 
Please rate the following 23 statements using the scale below: 
 
 
 
 
 
Strongly 
disagree 
Moderately 
disagree 
Slightly 
disagree 
Neither 
agree 
nor 
disagree 
Slightly 
agree 
Moderately 
agree 
Strongly 
agree 
1. I can identify 
the things that 
really matter to 
me in life and 
pursue them 
0 1 2 3 4 5 6 
2. One of my big 
goals is to be 
free from 
painful 
emotions  
0 1 2 3 4 5 6 
3. I rush through 
meaningful 
activities 
without being 
really attentive 
to them 
0 1 2 3 4 5 6 
4. I try to stay 
busy to keep 
thoughts or 
feelings from 
coming 
0 1 2 3 4 5 6 
5. I act in ways 
that are 
consistent with 
how I wish to 
live my life 
0 1 2 3 4 5 6 
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6. I get so caught 
up in my 
thoughts that I 
am unable to 
do the things 
that I most 
want to do 
0 1 2 3 4 5 6 
7. I make choices 
based on what 
is important to 
me, even if it is 
stressful 
0 1 2 3 4 5 6 
8. I tell myself 
that I shouldn’t 
have certain 
thoughts 
0 1 2 3 4 5 6 
9. I find it difficult 
to stay focused 
on what’s 
happening in 
the present 
0 1 2 3 4 5 6 
10. I behave in line 
with my 
personal 
values 
0 1 2 3 4 5 6 
11. I go out of my 
way to avoid 
situations that 
might bring 
difficult 
thoughts, 
feelings, or 
sensations  
0 1 2 3 4 5 6 
12. Even when 
doing the 
things that 
matter to me, I 
find myself 
doing them 
without paying 
attention 
0 1 2 3 4 5 6 
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13. I am willing to 
fully 
experience 
whatever 
thoughts, 
feelings and 
sensations 
come up for 
me, without 
trying to 
change or 
defend against 
them 
0 1 2 3 4 5 6 
14. I undertake 
things that are 
meaningful to 
me, even when 
I find it hard to 
do so 
0 1 2 3 4 5 6 
15. I work hard to 
keep out 
upsetting 
feelings 
0 1 2 3 4 5 6 
16. I do jobs or 
tasks 
automatically, 
without being 
aware of what 
I'm doing 
0 1 2 3 4 5 6 
17. I am able to 
follow my long 
terms plans 
including times 
when progress 
is slow 
0 1 2 3 4 5 6 
18. Even when 
something is 
important to 
me, I’ll rarely 
do it if there is 
a chance it will 
upset me  
0 1 2 3 4 5 6 
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19. It seems I am 
"running on 
automatic" 
without much 
awareness of 
what I'm doing 
0 1 2 3 4 5 6 
20. Thoughts are 
just thoughts – 
they don’t 
control what I 
do 
0 1 2 3 4 5 6 
21. My values are 
really reflected 
in my 
behaviour 
0 1 2 3 4 5 6 
22. I can take 
thoughts and 
feelings as 
they come, 
without 
attempting to 
control or 
avoid them 
0 1 2 3 4 5 6 
23. I can keep 
going with 
something 
when it’s 
important to 
me 
0 1 2 3 4 5 6 
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New 9-item daily momentary Psychological Flexibility scale of “Open, Aware, 
Engaged” to be statistically reduced to 3 items.  
 
Below you will find a list of statements. Please indicate how true each statement is for you by 
selecting the relevant number. 
Today: 
 
 
 
 
Not 
at all 
 
 
 
  
Some-
what 
    
Very 
much 
1. I struggled to 
control my 
thoughts or 
feelings 
0 1 2 3 4 5 6 7 8 9 10 
2. I put a lot of effort 
into making my 
thoughts or 
feelings stop or 
go away* 
0 1 2 3 4 5 6 7 8 9 10 
3. I got upset with 
myself for having 
certain thoughts 
or feelings. 
0 1 2 3 4 5 6 7 8 9 10 
4. I thought about 
things that 
happened in the 
past or worried 
about the future, 
instead of what 
was happening at 
the time. 
0 1 2 3 4 5 6 7 8 9 10 
5. I found it difficult 
to stay focused 
on what was 
happening in the 
present 
0 1 2 3 4 5 6 7 8 9 10 
6. I did jobs or tasks 
automatically, 
without being 
aware of what I 
was doing 
0 1 2 3 4 5 6 7 8 9 10 
7. I stopped doing 
things that were 
important to me 
when I felt bad. 
0 1 2 3 4 5 6 7 8 9 10 
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8. My worries and 
fears got in the 
way of doing the 
things that 
mattered to me.  
0 1 2 3 4 5 6 7 8 9 10 
9. I got so wrapped 
up in what I was 
thinking or feeling 
that I couldn’t do 
the things that 
mattered to me. 
0 1 2 3 4 5 6 7 8 9 10 
 
New 9-item hourly momentary Psychological Flexibility scale of “Open, Aware, 
Engaged” to be statistically reduced to 3 items. 
 
Within the last hour or so: 
 
 
 
 
Not 
at all 
 
 
 
  
Some-
what 
    
Very 
much 
1. I struggled to 
control my 
thoughts or 
feelings 
0 1 2 3 4 5 6 7 8 9 10 
2. I put a lot of effort 
into making my 
thoughts or 
feelings stop or 
go away* 
0 1 2 3 4 5 6 7 8 9 10 
3. I got upset with 
myself for having 
certain thoughts 
or feelings. 
0 1 2 3 4 5 6 7 8 9 10 
4. I thought about 
things that 
happened in the 
past or worried 
about the future, 
instead of what 
was happening at 
the time. 
0 1 2 3 4 5 6 7 8 9 10 
5. I found it difficult 
to stay focused 
on what was 
happening in the 
present 
0 1 2 3 4 5 6 7 8 9 10 
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6. I did jobs or tasks 
automatically, 
without being 
aware of what I 
was doing 
0 1 2 3 4 5 6 7 8 9 10 
7. I stopped doing 
things that were 
important to me 
when I felt bad. 
0 1 2 3 4 5 6 7 8 9 10 
8. My worries and 
fears got in the 
way of doing the 
things that 
mattered to me.  
0 1 2 3 4 5 6 7 8 9 10 
9. I got so wrapped 
up in what I was 
thinking or feeling 
that I couldn’t do 
the things that 
mattered to me. 
0 1 2 3 4 5 6 7 8 9 10 
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Patient Health Questionnaire 8-items (PHQ-8)  
(Kroenke, et al. 2009; Johnson, 2002) 
 
  Over the last 2 weeks, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
Several 
days 
More than 
half the 
days 
Nearly 
every 
day 
        1.  Little interest or pleasure in doing things 0 1 2 3 
        2.  Feeling down, depressed, or hopeless 0 1 2 3 
        3.  Trouble falling asleep or sleeping too much 0 1 2 3 
        4.  Feeling tired or having little energy 0 1 2 3 
        5.  Poor appetite and overeating  0 1 2 3 
6.  Feeling bad about yourself – or that you’re a 
failure and let yourself or your family down 
0 1 2 3 
7. Trouble concentrating on things, such as 
reading a newspaper or watching television   
0 1 2 3 
8. Moving or speaking so slowly that other 
people could have noticed.  
 
Or the opposite – being also fidgety or 
restless that you have been moving around a 
lot more than usual. 
0 1 2 3 
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Generalised Anxiety Disorder Scale 7 items (GAD-7)  
(Spitzer, Kroenke, Williams, & Löwe, 2006; Mossman et al, 2017). 
 
  Over the last 2 weeks, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
Several 
days 
More than 
half the 
days 
Nearly 
every 
day 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
        3.  Worrying too much about different things 0 1 2 3 
        4.  Trouble relaxing 0 1 2 3 
        5.  Being so restless that it is hard to sit still 0 1 2 3 
6. Becoming easily annoyed or irritable 0 1 2 3 
7. Feeling afraid as if something awful might 
happen? 
0 1 2 3 
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Modified daily version of the Patient Health Questionnaire 2 items (PHQ-2)  
(Kroenke, Spitzer, & Williams, 2003) 
 
  How often have you been bothered by the following    
  problems today? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Little interest or pleasure in doing things 0 1 2 3 
        2.  Feeling down, depressed, or hopeless 0 1 2 3 
 
Modified hourly version of the Patient Health Questionnaire 2 items (PHQ-2) 
(Kroenke, Spitzer, & Williams, 2003) 
 
  Over the last hour or so, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Little interest or pleasure in doing things 0 1 2 3 
        2.  Feeling down, depressed, or hopeless 0 1 2 3 
 
Modified daily version of the Generalised Anxiety Disorder (GAD-2) scale 
(Skapinakis, 2007) 
 
  How often have you been bothered by the following  
  problems today? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
 
Modified hourly version of the Generalised Anxiety Disorder (GAD-2) scale 
(Skapinakis, 2007) 
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  Over the last hour or so, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
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Appendix E 
Final Online Survey questionnaire for Adolescent (13-17) version 
Demographic and illness information 
 
Please feel free to take a break at any point. You can save your progress at the bottom of each page 
using the 'Finish Later' button on each questions page of the survey. 
 
Questions About Your Illness: 
What physical health condition do you have that you need to take medication for? If 
you have more than one, please indicate which you consider to be your primary 
illness. (This was a drop-down menu of all physical health conditions, including an 
“other” option) 
Do you have more than one physical health conditions listed? Please 
tick 
Yes 
 
 
No  
 
When was your physical health condition diagnosed? (DD/MM/YY):  
Are you prescribed medications for your illness?  
 
Please 
tick 
Yes 
 
 
No (please do not continue with this survey) 
 
 
 
Questions About You: 
What is your age (years):  
                     
How do you identify your gender? 
 
Please 
tick 
Female  
 
 
Male  
 
Other gender identity (please specify): 
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What is your ethnicity? 
 White - English /  
      Welsh / Scottish /  
      Northern Irish /            
      British / Irish  
      /Gypsy or Irish  
     Traveller /  
     Any Other  
    White background 
 Mixed / Multiple ethnic  
group - White and Black 
Caribbean / White and 
Black African / White and 
Asian / Any Other Mixed / 
multiple ethnic 
background 
 
 Asian / Asian 
British  
– Indian / Asian  
British   
– Pakistani / Asian 
British      
– Bangladeshi / Asian 
British  
– Chinese / Asian 
British - Any other  
Asian background 
 Black / 
African / 
Caribbean / 
Black British – 
African / Black 
British – 
Caribbean / 
Black British – 
Any other Black 
   Other ethnic 
group  
 – Arab Other ethnic 
group  
– Any other ethnic 
group 
 
 Not known / 
not provided 
 
 
In what country do you currently live?  
(This will be a drop-down menu of all countries) 
 
 
What is your present relationship status? 
 
Please 
tick 
Single  
 
In a relationship   
 
Other (please state): 
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How many years of education have you completed:  ___________ (Years) 
 
Which of the following best describes your current education status? 
 
Please 
tick 
Full-time student  
 
Part-time student 
 
Homeschooled 
 
Other (please state): 
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New modified version of the Work and Social Adjustment Scale for adolescents (WSAS)  
(Mundt, Marks, Shear, & Greist, 2002) 
Questions about your illness: 
Illnesses sometimes affect people’s ability to do certain day-to-day tasks. To rate problems related 
to your illness please look at each statement below and use the scale provided to indicate how 
much your illness affects your ability to carry out the activity. 
Because of my illness my ability to study is badly affected. ‘0’ means ‘not at all a problem’ and ‘8’ means 
“very severely” affected to the point I can't study. 
 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness my attention to home tasks (e.g. cleaning tidying my room) is badly affected. 
 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness my social leisure activities (with other people e.g. parties, outings, visits, dating, 
having people over) are badly affected. 
 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness, my private leisure activities (done alone, such as reading, playing, walking alone) 
are badly affected. 
 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
Because of my illness, my ability to form and keep close relationships with others, including those I live with, 
is badly affected. 
0  
Not at 
all 
1 
 
2 
Slightly 
3  
 
4 
Definitely 
5 
 
6  
Markedly 
7 
 
8 
Very 
Severely 
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Medication Adherence Report Scale 5-items (MARS-5)  
(Horne, Hankins, & Jenkins, 2001). 
 
Questions about your medication for your illness: 
Many people find a way of using their medicines which suits them. This may differ from the 
instructions on the label or from what their doctor had said. Here are some ways in which people 
have said they use their medicines. For each statement, please select the box which best 
applies to you.  
 
 Never Seldom Sometimes Often Always 
I forget to take my medication 
 
     
I adjust the dosage of my medication  
 
     
I stop using my medication for a while  
 
     
I decide to skip my medication doses 
 
     
I take fewer tablets than prescribed to me 
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New non-validated single-item daily momentary numerical rating scale for self-
reported adherence  
 
In your view, how good have you been at taking your medications for your illness on time 
and as prescribed Today. Please rate on a scale of 0 (not good at all) to 10 (extremely good): 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Please indicate if not applicable:  
 
 
New non-validated single-item hourly momentary numerical rating scale for self-
reported adherence  
 
Over the past hour, in your view how good have you been at taking your medications for 
your illness on time and as prescribed. Please rate on a scale of 0 (not good at all) to 10 
(extremely good): 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Please indicate if not applicable:  
 
In the last two to three months, roughly what percentage of routine appointments for your 
illness have you attended?  
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
Please indicate if not applicable:  
 
New non-validated scales exploring health care utilisation as a proxy of adherence 
 
In the last year, roughly what percentage of routine appointments for your illness have you 
attended?  
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
 
Please indicate if not applicable:  
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Avoidance and Fusion Questionnaire for Youth 8-items (AFQ-Y-8)  
(Greco, Lambert, & Baer, 2008) 
 
We want to know more about what you think, how you feel, and what you do. Read each sentence. 
Then, select a number between 0-4 that tells how true each sentence is for you. 
 
 
Not at all True A little True Pretty True True Very True 
 
1. My life won’t be good until I feel 
happy. 
 
0 1 2 3 4 
 
2. My thoughts and feelings mess 
up my life. 
 
0 1 2 3 4 
 
3. The bad things I think about 
myself must be true. 
 
0 1 2 3 4 
 
4. If my heart beats fast, there 
must be something wrong with 
me. 
 
0 1 2 3 4 
5. I stop doing things that are 
important to me whenever I feel 
bad.  
0 1 2 3 4 
 
6. I do worse in school when I 
have thoughts that make me 
feel sad. 
 
0 1 2 3 4 
 
7. I am afraid of my feelings. 
 
0 1 2 3 4 
 
8. I can’t be a good friend when I 
feel upset. 
 
0 1 2 3 4 
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Child and Adolescent Mindfulness Measure (CAMM)  
(Greco, Baer, & Smith, 2011) 
 
We want to know more about what you think, how you feel, and what you do. Read each sentence. 
Then, select the number that tells how often each sentence is true for you. 
 
 
Never 
True 
Rarely 
True 
Some-
times 
True 
Often 
True 
Always 
True 
1. I get upset with myself for having feelings that don’t make 
sense. 
0 1 2 3 4 
2. At school, I walk from class to class without noticing what 
I’m doing. 
0 1 2 3 
 
4 
 
3. I keep myself busy so I don’t notice my thoughts or feelings. 0 1 2 3 4 
4. I tell myself that I shouldn’t feel the way I’m feeling. 0 1 2 3 4 
5. I push away thoughts that I don’t like. 0 1 2 3 
 
4 
 
6. It’s hard for me to pay attention to only one thing at a time. 0 1 2 3 
 
4 
 
7. I get upset with myself for having certain thoughts. 0 1 2 3 4 
8. I think about things that have happened in the past instead 
of thinking about things that are happening right now. 
 
 
0 1 2 3 4 
9. I think that some of my feelings are bad and that I shouldn’t 
have them. 
0 1 2 3 4 
10. I stop myself from having feelings that I don’t like. 0 1 2 3 4 
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New 9-item daily momentary Psychological Flexibility scale of “Open, Aware, 
Engaged” to be statistically reduced to 3 items.  
 
Below you will find a list of statements. Please indicate how true each statement is for you 
by selecting the relevant number. 
Today: 
 
 
 
 
Not 
at all 
 
 
 
  
Some-
what 
    
Very 
much 
1. I struggled to 
control my 
thoughts or 
feelings 
0 1 2 3 4 5 6 7 8 9 10 
2. I put a lot of effort 
into making my 
thoughts or 
feelings stop or 
go away* 
0 1 2 3 4 5 6 7 8 9 10 
3. I got upset with 
myself for having 
certain thoughts 
or feelings. 
0 1 2 3 4 5 6 7 8 9 10 
4. I thought about 
things that 
happened in the 
past or worried 
about the future, 
instead of what 
was happening at 
the time. 
0 1 2 3 4 5 6 7 8 9 10 
5. I found it difficult 
to stay focused 
on what was 
happening in the 
present 
0 1 2 3 4 5 6 7 8 9 10 
6. I did jobs or tasks 
automatically, 
without being 
aware of what I 
was doing 
0 1 2 3 4 5 6 7 8 9 10 
7. I stopped doing 
things that were 
important to me 
when I felt bad. 
0 1 2 3 4 5 6 7 8 9 10 
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8. My worries and 
fears got in the 
way of doing the 
things that 
mattered to me.  
0 1 2 3 4 5 6 7 8 9 10 
9. I got so wrapped 
up in what I was 
thinking or feeling 
that I couldn’t do 
the things that 
mattered to me. 
0 1 2 3 4 5 6 7 8 9 10 
 
 
New 9-item hourly momentary Psychological Flexibility scale of “Open, Aware, 
Engaged” to be statistically reduced to 3 items. 
 
Within the last hour or so: 
 
 
 
 
Not 
at all 
 
 
 
  
Some-
what 
    
Very 
much 
1. I struggled to control 
my thoughts or feelings 
0 1 2 3 4 5 6 7 8 9 10 
2. I put a lot of effort into 
making my thoughts or 
feelings stop or go 
away* 
0 1 2 3 4 5 6 7 8 9 10 
3. I got upset with myself 
for having certain 
thoughts or feelings. 
0 1 2 3 4 5 6 7 8 9 10 
4. I thought about things 
that happened in the 
past or worried about 
the future, instead of 
what was happening at 
the time. 
0 1 2 3 4 5 6 7 8 9 10 
5. I found it difficult to stay 
focused on what was 
happening in the 
present 
0 1 2 3 4 5 6 7 8 9 10 
6. I did jobs or tasks 
automatically, without 
being aware of what I 
was doing 
0 1 2 3 4 5 6 7 8 9 10 
7. I stopped doing things 
that were important to 
me when I felt bad. 
0 1 2 3 4 5 6 7 8 9 10 
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8. My worries and fears 
got in the way of doing 
the things that mattered 
to me.  
0 1 2 3 4 5 6 7 8 9 10 
9. I got so wrapped up in 
what I was thinking or 
feeling that I couldn’t do 
the things that mattered 
to me. 
0 1 2 3 4 5 6 7 8 9 10 
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Patient Health Questionnaire 8-items Adolescent version taken from the 9 item 
(PHQ-A)  
(Johnson, 2002) 
Instructions: How often have you been bothered by each of the following symptoms during the 
past two weeks? For each symptom put an “X” in the box beneath the answer that best describes 
how you have been feeling. 
    (Please indicate your answer) 
Not  
at all 
Several 
days 
More than 
half the 
days 
Nearly 
every 
day 
        1.  Feeling down, depressed, irritable or hopeless?  0 1 2 3 
        2.  Little interest or pleasure in doing things? 0 1 2 3 
        3.  Trouble falling asleep, staying asleep, or  
             sleeping too much? 
0 1 2 3 
        4.  Poor appetite, weight loss, or overeating? 0 1 2 3 
        5.  Feeling tired, or having little energy? 0 1 2 3 
6. Feeling bad about yourself – or feeling that you 
are a failure and let yourself or your family 
down? 
0 1 2 3 
7. Trouble concentrating on things like school 
work, reading, or watching TV 0 1 2 3 
8. Moving or speaking so slowly that other people 
could have noticed.  
 
Or the opposite – being also fidgety or restless 
that you have been moving around a lot more 
than usual. 
0 1 2 3 
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Generalised Anxiety Disorder Scale 7 items (GAD-7)  
(Spitzer, Kroenke, Williams, & Löwe, 2006; Mossman et al, 2017). 
 
  Over the last 2 weeks, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
Several 
days 
More than 
half the 
days 
Nearly 
every 
day 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
        3.  Worrying too much about different things 0 1 2 3 
        4.  Trouble relaxing 0 1 2 3 
        5.  Being so restless that it is hard to sit still 0 1 2 3 
6. Becoming easily annoyed or irritable 
0 1 2 3 
7. Feeling afraid as if something awful might 
happen? 0 1 2 3 
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Modified daily version of the Patient Health Questionnaire 2 items (PHQ-2)  
(Kroenke, Spitzer, & Williams, 2003) 
 
  How often have you been bothered by the following     
  problems today? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Little interest or pleasure in doing things 0 1 2 3 
        2.  Feeling down, depressed, or hopeless 0 1 2 3 
 
Modified hourly version of the Patient Health Questionnaire 2 items 
(PHQ-2) (Kroenke, Spitzer, & Williams, 2003) 
 
  Over the last hour or so, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Little interest or pleasure in doing things 0 1 2 3 
        2.  Feeling down, depressed, or hopeless 0 1 2 3 
 
Modified daily version of the Generalised Anxiety Disorder (GAD-2) scale 
(Skapinakis, 2007) 
 
  How often have you been bothered by the following   
  problems today? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
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Modified hourly version of the Generalised Anxiety Disorder (GAD-2) scale 
(Skapinakis, 2007) 
 
  Over the last hour or so, how often have you  
  been bothered by the following problems? 
  (Please indicate your answer) 
Not  
at all 
  
Very  
much 
        1.  Feeling nervous, anxious or on edge 0 1 2 3 
        2.  Not being able to stop or control worrying 0 1 2 3 
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Appendix F 
Email communication from Doctor Nima Moghaddam regarding 
sample descriptive data for CompACT total and subscale scores 
with only 20.0% scale item missing 
Nima Moghaddam <NMoghaddam@lincoln.ac.uk> 
  
  
Reply all 
Mon 07/01, 15:49 
Anthony Harrison  
Research Project 
Flag for follow up. Completed on 30 January 2019. 
You replied on 07/01/2019 21:59. 
Hi Anthony, 
  
There’s a collaborative European project that is handling missing CompACT data in a way 
that resembles your second approach: Allowing for 25% missing item-level data and using 
mean (versus total) scores – they’re using the Mean function in SPSS syntax, which will 
automatically divide by the number of valid values (adjusting the item-count for items with 
missing data). 
  
It would be possible to empirically test a few imputation methods (within a sub-set of 
complete data: comparing methods to see which provides the best approximation of 
values obtained with the complete data [as a benchmark]) but we think the mean-scoring 
approach would be defensible. For reference, here are the descriptive stats for the 
CompACT when mean-scored (0-6 scale) in our original (general population) sample (N = 
352): 
Openness to Experience: Mean = 3.18; SD = 1.30 
Behavioural Awareness: Mean = 3.40; SD = 1.37 
Valued Action: Mean = 4.76; SD = 0.88 
CompACT Total (Psych Flex): Mean = 3.78; SD = 0.91 
  
Best wishes, 
  
Nima 
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Appendix G 
Initial 22-items for new momentary Psychological Flexibility “Open, 
Aware, Engaged” questionnaire (daily/hourly versions were 
identical) 
Below you will find a list of statements. Please indicate how true each statement is for you by selecting 
the relevant number. 
Today / Within n the last hour or so: 
 
 
 
 
Not 
at all 
 
 
 
  
Some-
what 
    
Very 
much 
OPEN / CLOSED 
1. I tried to distract 
myself from 
thinking about 
upsetting things 
0 1 2 3 4 5 6 7 8 9 10 
2. I kept myself busy 
so I didn’t notice my 
thoughts or 
feelings. 
0 1 2 3 4 5 6 7 8 9 10 
3. I struggled to 
control my thoughts 
or feelings 
0 1 2 3 4 5 6 7 8 9 10 
4. I put a lot of effort 
into making my 
thoughts or feelings 
stop or go away* 
0 1 2 3 4 5 6 7 8 9 10 
5. I worked hard to 
stop upsetting 
feelings 
0 1 2 3 4 5 6 7 8 9 10 
6. I pushed away 
thoughts and 
feelings that I didn’t 
like. 
0 1 2 3 4 5 6 7 8 9 10 
7. I got upset with 
myself for having 
certain thoughts or 
feelings. 
0 1 2 3 4 5 6 7 8 9 10 
8. I got upset and 
bothered by my 
feelings or thoughts 
0 1 2 3 4 5 6 7 8 9 10 
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9. I thought that some 
of my feelings are 
bad and that I 
shouldn’t have 
them. 
0 1 2 3 4 5 6 7 8 9 10 
10. I told myself that I 
shouldn’t have 
certain thoughts or 
feelings 
0 1 2 3 4 5 6 7 8 9 10 
11. I stopped myself 
from having 
feelings that I didn’t 
like. 
0 1 2 3 4 5 6 7 8 9 10 
12. I went out of my 
way to avoid 
situations that 
might bring difficult 
thoughts, feelings, 
or sensations in my 
body 
           
AWARE / UNAWARE 
13. I thought about 
things that 
happened in the 
past or worried 
about the future, 
instead of what was 
happening at the 
time. 
0 1 2 3 4 5 6 7 8 9 10 
14. I rushed through 
activities that I care 
about without really 
paying attention to 
them 
0 1 2 3 4 5 6 7 8 9 10 
15. Even when doing 
things that mattered 
to me, I found 
myself doing them 
without paying 
attention 
0 1 2 3 4 5 6 7 8 9 10 
16. I found it difficult to 
stay focused on 
what was 
happening in the 
present 
0 1 2 3 4 5 6 7 8 9 10 
17. I did jobs or tasks 
automatically, 
without being aware 
of what I was doing 
0 1 2 3 4 5 6 7 8 9 10 
ENGAGED / DISENGAGED 
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18. I stopped doing 
things that were 
important to me 
when I felt bad. 
0 1 2 3 4 5 6 7 8 9 10 
19. My worries and 
fears got in the way 
of doing the things 
that mattered to me.  
0 1 2 3 4 5 6 7 8 9 10 
20. I got so wrapped up 
in what I was 
thinking or feeling 
that I couldn’t do 
the things that 
mattered to me. 
0 1 2 3 4 5 6 7 8 9 10 
21. I didn’t act in ways 
that fit with how I 
want to live my life 
0 1 2 3 4 5 6 7 8 9 10 
22. Even when an 
activity was 
important to me, I 
didn’t do it because 
I thought it would 
upset me 
0 1 2 3 4 5 6 7 8 9 10 
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Appendix H 
Feedback from adult and adolescent participants regarding the 
initial  22-items for the new momentary Psychological Flexibility 
“Open, Aware, Engaged” questionnaire (face validity) 
Person 
(LTC; adult 
or 
adolescent) 
 
 
 
Ranking of 
items 
Rachel 
Sawyer 
(Inflammatory 
Bowel 
Disease; 
adult) 
Alison 
Potts (TBI 
and carer 
for mother 
with 
psychosis; 
adult) 
Sarah 
Bittlestone 
(Multiple 
Sclerosis; 
adult) 
 
Maisie 
Stewart 
(Endocrine 
disorder; 
adolescent) 
Elom 
Nyonator 
(Chronic 
constipation; 
adolescent) 
1 (most 
important) 
21 3 4 18 3 
2 15 16 16 12 7 
3 20 7 17 22 12 
4 16 13 18 20 10 
5 14 17 20 19 16 
6 19 19 21 17 17 
7 17 1 1 15 18 
8 18 10 6 3 21 
9 22 12 7 4 15 
10 13 19 
(repeat) 
19 6 13 
11 7 4 3 14 14 
12 3 9 8 8 22 
13 8 15 10 7 1 
14 12 22 11 10 2 
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15 9 18 12 13 19 
16 6 14 13 11 20 
17 5 11 14 5 4 
18 4 8 22 9 6 
19 11 20 15 2 5 
20 1 5 9 16 8 
21 10 6 2 21 9 
22 (least 
important) 
2 21 5 1 11 
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Appendix I 
Confirmatory Factor Analyses Results for  
Established Measures at Baseline 
 
Measure Estimator n Number of 
factors tested 
Item STDY 
Estimate 
SE R2 SE Absolute model fit indices  
(goodness of fit value cut-offs) 
         RMSEA 
(<.06) 
TLI  
(>.95) 
CFI 
(>.95) 
SRMR 
(<.08) 
WRMR 
(>1) 
MARS-5 MLR 545 1: Adherence 1 .42 .04 .17 .04 .11 .85 .92 .04* NA 
    2 .50 .04 .25 .05      
    3 .78 .03 .61 .05      
    4 .82 .03 .68 .05      
    5 .74 .03 .55 .05      
AAQ-II WLSMV 555 1: PF 1 .82 .01 .68       .02 .20 .96* .97* NA 1.57* 
    2 .90 <.01 .81       .01      
    3 .90 <.01 .81       .01        
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    4 .88 .01 .78       .02      
    5 .87 .01 .76       .01      
    6 .85 .01 .72       .02      
    7 .87 .01 .75       .02      
CompACT WLSMV 478 1: OE 2 .46      .03 .21       .03 .15 .72 .75 NA 2.75* 
    4 .54       .03 .29       .03      
    6 .79       .02 .63       .03      
    8 .56       .03 .31       .03      
    11 .77       .02 .59       .03      
    13 .67       .02 .45       .03      
    15 .50        .03 .25       .03      
    18 .71       .02 .51       .03      
    20 .63       .02 .40       .03      
    22  .72       .02   .52       .03      
   2: BA 3 .68       .02   .46       .03      
    9 .83       .02   .69       .03      
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    12 .80       .02 .65       .03      
    16 .65       .02 .42       .03      
    19 .65       .02 .42       .03      
   3: VA 1 .73       .02 .54       .04      
    5 .72       .02 .52       .03      
    7 .57       .03 .33       .03        
    10 .36       .04 .13       .02      
    14 .52       .03 .27       .03      
    17 .79       .02 .62       .03      
    21 .50       .03 .25       .03      
    23 -.18       .03 .03       .01      
CompACT WLSMV 478 1: PF 2 .44       .03 .20       .03 .16 .68 .71 NA 2.96* 
    4 .52       .03 .27       .03      
    6 .77 .02 .60       .03      
    8 .54       .03 .30       .03      
    11 .75       .02 .56       .03      
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    13 .65       .02 .42       .03      
    15 .49       .03 .24       .03      
    18 .69       .02 .48       .03      
    20 .61       .02 .38       .03      
    22 .70       .02 .49       .03      
    3 .62       .02 .38       .03      
    9 .74       .02 .55       .03      
    12 .74       .02 .53       .03      
    16 .58       .02 .34       .03      
    19 .59       .02 .34       .03      
    1 .65       .02  .42       .03      
    5 .62       .02   .39       .03      
    7 .49       .03 .24       .03      
    10 .28       .03   .07       .02      
    14 .44       .03 .19       .02      
    17 .68       .02 .47       .03      
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    21 .43       .03 .18       .03      
    23 -.21       .03 .04       .01      
WSAS WLSMV 551 1: Functioning 1   .86       .01 .73       .01 .15 .99* .96* NA .62 
    2 .92 <.01 .85       .01      
    3 .92 <.01   .85       .01      
    4 .90 <.01 .81       .01      
    5 .82 .01 .67       .02      
PHQ-8 WLSMV 543 1: Depression 1 .85      .01 .72       .02 .11 .95* .97* NA 1.33* 
    2 .81       .02 .66       .03      
    3 .68       .02 .46       .03      
    4 .79       .02 .62       .03      
    5 .80       .02 .64       .03      
    6 .83       .02 .70       .03      
    7 .68       .02 .46       .04      
    8 .59       .03 .35       .04      
GAD-7 WLSMV 555 1: Anxiety 1 .89       .01 .80       .020 .12 .98* .99* NA 1.08* 
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    2 .96      <.01 .93       .013      
    3 .94       <.01 .90       .014      
    4 .83       .01 .69       .028      
    5 .67      .03 .45       .040      
    6 .76      .02 .58       .034      
    7 .83       .01 .69       .032      
STDY estimate (Mplus standardises estimates using the variances of observed outcome and latent variables only). 
Good fit indices: CFI (Comparative Fit Index); RMSEA (Root Mean Square Error of Approximation); SRMR (Standardized Root Mean Square Residual) ; TLI (Tucker 
Lewis Index); WRMR (Weighted Root Mean Square Residual). 
Established measures: AAQ-II (Acceptance and Action Questionnaire II); CompACT (Comprehensive assessment of Acceptance and Commitment Therapy processes); BA 
(CompACT Behavioral Awareness subscale); OE (CompACT Openness to Experience subscale); VA (CompACT Valued Action subscale); PHQ-8 total (Patient Health 
Questionnaire 8-items), GAD-7 (Generalised Anxiety Disorder scale 7-items); WSAS (Work and Social Adjustment Scale). 
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Appendix J 
Primary LTC types of the baseline sample across MARS-5 cut-offs 
(n=695) 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=80, 11.5%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=617, 88.5%) 
p value 
Parkinson’s Disease vs.  
All other LTCs (%) 
36 (45.0) 
44 (55.0) 
250 (40.6) 
366 (59.4) 
.451 
 
Type of LTC by ICD-11 disease category   
Allergies 
(incl. vasculitis) 
1 (1.3) 3 (0.5) 
 
 
Autoimmune 20 (25.0) 157 (25.4)  
Ankylosing spondylitis* 0 1 (0.2)  
Arthritis 0 4 (0.6)  
Autoimmune 
polyendocrine syndromes 
0 
 
2 (0.3)  
Coeliac disease 0 1 (0.2)  
Hashimoto's thyroiditis 5 (6.3) 13 (2.1)  
Inflammatory bowel 
disease 
0 1 (0.2)  
Lupus erythematosus 2 (2.5) 45 (7.3)  
Microscopic Colitis 0 1 (0.2)  
Mucous membrane 
pemphigoid 
0 1 (0.2)  
Rheumatoid arthritis, other 
inflammatory 
polyarthropathies and 
systematic connective 
tissue 
1 (1.3) 47 (7.6)  
Thyroid disease 8 (10.0) 29 (4.7)  
Ulcerative colitis 1 (1.3) 8 (1.3)  
*Also, disease of the musculoskeletal system and connective tissue 
Birth defect  0 2 (0.3)  
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Spina bifida 0 1 (0.2)  
Williams syndrome 0 1 (0.2)  
Cancers (all types) 3 (3.8) 9 (1.5)  
Cardiovascular/Circulatory 7 (8.8) 39 (6.3)  
Atrial fibrillation 1 (1.3) 0  
Coronary heart disease 0 3 (0.5)  
Heart failure 1 (1.3) 1 (0.2)  
Hypertension 2 (2.5) 3 (0.5)  
Postural orthostatic 
tachycardia syndrome 
2 (2.5) 32 (5.2)  
Sick sinus syndrome 1 (1.3) 0  
Endocrine 0 18 (2.9)  
Addison's disease 0 1 (0.2)  
Diabetes Type I* 0 15 (2.4)  
Diabetes Type II* 0 2 (0.3)  
*Also, metabolic    
Genitourinary 
Endometriosis 
 
0 
 
2 (.03) 
 
Hereditary 0 29 (4.7)  
Charcot-Marie-Tooth 
disease* 
0 4 (0.7)  
Cystic fibrosis 0 1 (0.2)  
Ehlers–Danlos** 
syndrome (various types) 
0 20 (2.9)  
Eczema 0 2 (0.3)  
Myotonia congenita 0 1 (0.2)  
Panhypopituitarism*** 0 1 (0.2)  
*Also, degenerative; **metabolic; ***endocrine 
Immunodeficiency 6 (7.5) 11 (1.8)  
Common variable 
immunodeficiency 
0 1 (0.2)  
HIV/AIDS 6 (7.5) 10 (1.6)  
Infectious 
Bronchiectasis 
 
0 
 
2 (.03) 
 
Inflammatory 1(1.3) 18 (2.9)  
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Antiphospholipid 
syndrome 
0 1 (0.2)  
Asthma 0 8 (1.3)  
Behçet's disease 0 2 (0.3)  
Chronic obstructive 
pulmonary disease 
1 (1.3) 1 (0.2)  
Myositis (polymyositis and 
dermatomyositis) 
0 1 (0.2)  
Periodontal disease 0 1 (0.2)  
Psoriasis 0 3 (0.5)  
Ulcers 0 1 (0.2)  
Neurodegenerative 41 (51.3) 263 (42.6)  
Epilepsy 1 (1.3) 7 (1.1)  
Multiple sclerosis* 4 (5.0) 6 (1.0)  
Parkinson’s disease 36 (45.0) 250 (40.5)  
*Also, autoimmune and inflammatory 
Neurology other 
Myoclonus Dystonia 
0 
 
1 (0.2) 
 
 
Trauma/injury 0 6 (0.9)  
Brain injury 0 3 (.05)  
Cerebral palsy 0 2 (.3)  
Progressive supranuclear 
palsy 
0 1 (0.2)  
Other conditions 1 (1.3) 55 (8.9)  
Bile acid diarrhea 0 1 (0.2)  
Chronic fatigue 
syndrome/Myalgic 
encephalomyelitis 
0 7 (1.1)  
Chronic pain 0 3 (0.5)  
Fibromyalgia 0 9 (1.5)  
Gastroesophageal Reflux 
Disease 
0 
 
1 (0.2)  
Kidney disease 1 (1.3) 1 (0.2)  
Migraine 0 32 (5.2)  
Peripheral neuropathy 0 1 (0.2)  
Bile acid diarrhea 0 1 (0.2)  
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LTC not reported 0 2 (.3)  
Adherence measures: ICD-11 (WHO International Classification of Diseases, 11th Revision (ICD-11) 
MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and <25 ‘non-
adherent’). 
Statistical analyses: 12 (1)=.57, p=45 
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Appendix K 
Primary LTC types of the follow-up sample across MARS-5 cut-offs 
(n=336) 
 
 
Adherent 
(according to 
MARS-5 cut-off) 
(n=50, 14.9%) 
Non-adherent 
(according to MARS-5 
cut-off) 
(n=285, 81.5%) 
p value 
Parkinson’s Disease vs.  
All other LTCs (%) 
19 (38.0) 
31 (62.0) 
138 (48.4) 
147 (51.6) 
.171 
 
Type of LTC by ICD-11 disease category   
Allergies 
Vasculitis 
0 2 (.07)  
Autoimmune 10 (20.4) 71 (24.7)  
Arthritis 0 1 (.03)  
Autoimmune 
polyendocrine syndromes 
0 1 (0.3)  
Coeliac disease 0 1 (0.3)  
Hashimoto's thyroiditis 3 (6.1) 10 (3.5)  
Inflammatory bowel 
disease 
1 (2.0) 3 (1.0)  
Lupus erythematosus 3 (6.1) 20 (7.0)  
Rheumatoid arthritis, other 
inflammatory 
polyarthropathies and 
systematic connective 
tissue 
0 20 (7.0)  
Thyroid disease 2 (4.1) 12 (4.2)  
Ulcerative colitis 1 (2.0) 3 (1.0)  
*Also, disease of the musculoskeletal system and connective tissue 
Birth defect  0 1 (0.3)  
Spina bifida    
Cancers (all types) 2 (4.1) 3 (1.0)  
Cardiovascular/Circulatory 6 (12.2) 12 (4.2)  
Atrial fibrillation 1 (2.0) 0  
Coronary heart disease 0 1 (0.3)  
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Heart failure 0 2 (0.7)  
Hypertension 3 (6.1) 0  
Postural orthostatic 
tachycardia syndrome 
1 (2.0) 9 (3.1)  
Sick sinus syndrome 1 (2.0) 0  
Endocrine 1 (2.0) 7 (2.4)  
Addison's disease 0 1 (0.3)  
Diabetes Type I* 1 (2.0) 5 (1.7)  
Diabetes Type II* 0 1 (0.3)  
*Also, metabolic    
Genitourinary 
Endometriosis 
0 1 (0.3)  
Hereditary 1 (2.0) 9 (3.1)  
Charcot-Marie-Tooth 
disease* 
1 (2.0) 2 (0.7)  
Ehlers–Danlos** 
syndrome (various types) 
0 6 (2.1)  
Panhypopituitarism*** 0 1 (0.3)  
*Also, degenerative; **metabolic; ***endocrine 
Immunodeficiency 4 (8.2) 7 (2.4)  
Common variable 
immunodeficiency 
0 1 (0.3)  
HIV/AIDS 4 (8.2) 6 (2.1)  
Infectious 
Bronchiectasis 
1 (2.0) 0  
Inflammatory 1 (2.0) 11 (3.8)  
Asthma 0 5 (1.7)  
Behçet's disease 0 1 (0.3)  
Chronic obstructive 
pulmonary disease 
1 (2.0) 1 (0.3)  
Periodontal disease 0 1 (0.3)  
Psoriasis 0 2 (0.7)  
Ulcers 0 1 (0.3)  
Neurodegenerative 22 (44.9) 142 (49.5)  
Epilepsy 1 (2.0) 0  
Multiple sclerosis* 3 (6.1) 3 (1.0)  
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Parkinson’s disease 18 (36.7) 139 (48.4)  
*Also, autoimmune and inflammatory 
Trauma/injury 0 2 (0.7)  
Brain injury 0 2 (0.7)  
Other conditions 1 (2.0) 18 (6.3)  
Chronic fatigue 
syndrome/Myalgic 
encephalomyelitis 
0 1 (0.3)  
Chronic pain 0 1 (0.3)  
Fibromyalgia 0 3 (1.0)  
Gastroesophageal Reflux 
Disease 
0 1 (0.3)  
Kidney disease 1 (2.0) 0  
Migraine 0  11 (3.8)  
Peripheral neuropathy 0 1 (0.3)  
LTC not reported 0 1 (.03)  
Adherence measures: ICD-11 (WHO International Classification of Diseases, 11th Revision (ICD-11) 
MARS-5 (Medication Adherence Rating Scale five items total score: 25=‘adherent’ and <25 ‘non-
adherent’). 
Statistical analyses: 12 (1)=.62, p=.17 
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Appendix L 
Email communication from Professor Rob Horne regarding 
distribution of MAR-S 5 data 
 
Hi Anthony, 
 
Sorry for the radio licence my end 
I have been meaning to contact you and to support your work with MARS. 
I disagree with Durand et al on this point. The argument for using continuous data above 
dichotomised is a good general principle  as dichotomising loses information.  However, in 
the case of self-report adherence scores I think we. need to take a more pragmatic 
approach. The data is typically highly negatively skewed and transformations do not solve 
the problem. From a pragmatic point of view, we are often interested in separating 
samples into high vs low adherence and can do this on the basis of frequency distribution 
of scale scores within that sample. 
  
Of course its better if we don’t have to do this as a continuous measure of degrees of 
adherence is better. BUT and it’s a big one, self-repots are flawed and do not provide the 
degree of accuracy and reliability to justify such a ‘purist’ approach. 
  
Would it be helpful to arrange a telcon to discusses your data and these issues in more 
detail? 
  
With best wishes 
Rob 
Rob Horne 
Professor of Behavioural Medicine  
  
Director, Centre for Behavioural Medicine 
UCL School of Pharmacy, University College London 
http://www.ucl.ac.uk  
  
UCL Academic Lead  
Centre for Advancement of Sustainable Medical Innovation (CASMI) 
http://www.casmi.org.uk 
  
Research administration (temp): KAREN LINDSAY 
Tel: +44 (0)20 7874 1281 Fax:+ 44 (0)20 7387 5693 
Email: karen.lindsay@ucl.ac.uk  
  
Follow CBM on Twitter https://twitter.com/CBM_UCLSoP 
 
 
 
 
 
